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ABSTRACT

DESIGNING A CALIBRATION SET IN SPECTRAL SPACE FOR EFFICIENT
DEVELOPMENT OF AN NIR METHOD FOR TABLET ANALYSIS

By
Md Anik Alam
May 2018

Dissertation supervised by Carl A. Anderson
Designing a calibration set is the first step in developing a spectroscopic calibration
method for quantitative analysis of pharmaceutical tablets. This step is critical because
successful model development depends on the suitability of the calibration data. For
spectroscopic-based methods, traditional concentration based techniques for designing
calibration sets are prone to have redundant information while simultaneously lacking
necessary information for a successful calibration model. The traditional method also
follows the same design approach for different spectroscopic techniques and different
formulations, thereby lacks the optimizing capability to be technique and formulation
specific.
A method for designing a calibration set in the Near Infrared (NIR) spectral space was
developed for quantitative analysis of tablets. The pure component NIR spectra of a tablet
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formulation were used to define the spectral space of that formulation. This method
minimizes sample requirements to provide an efficient means for developing multivariate
spectroscopic calibration.
Multiple comparative studies were conducted between commonly employed experimental
design approaches to calibration development and the newly developed spectral space
based technique. The comparisons were conducted on single API (Active Pharmaceutical
Ingredient) and multiple API formulation to quantify model drugs using NIR
spectroscopy. Partial least squares (PLS) models were developed from respective
calibration designs. Model performance was comprehensively assessed based on the
ability to predict API concentrations in independent prediction sets. Similar prediction
performance was achieved using the smaller calibration set designed in spectral space,
compared to the traditionally designed large calibration sets. An improved prediction
performance was observed for the spectrally designed calibration sets compared to the
traditionally designed calibration sets of equal sizes. Spectral space was also used to
incorporate physico-chemical information into the calibration design to provide an
efficient means of developing robust calibration model. Robust calibration model is
critical to ensure consistent model performance during model lifecycle. A weight
coefficient based technique was developed for selecting loading vector in PLS model to
aid in building robust calibration model.
It was also demonstrated that the optimal structures of calibration sets are different
between NIR and Raman spectroscopy for the same tablet formulation. The optimum
calibration structures are also different between two APIs for the same spectroscopic
technique, indicating the criticality of the calibration design to be formulation and
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technique specific. This study demonstrates that a calibration set designed in spectral
space provides an efficient means of developing spectroscopic multivariate calibration for
tablet analysis. This study also provides opportunity to design formulation and technique
specific calibration sets to optimize calibration capability.
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Chapter 1: Introduction

1.1 Statement of the Problem
NIR spectroscopy (NIRS) is a well-established analytical tool in the pharmaceutical
industry for quantitative analysis of tablets [1-5]. NIRS offers substantial advantages in
terms of time and cost compared to the wet chemical methods. However, successful
application of this technology depends on an appropriate calibration method, and an
appropriate calibration method is built upon appropriate calibration sample design.
Typical steps to develop a NIR quantitative calibration method for pharmaceutical tablets
are: calibration design, sample set preparation, spectral data collection, reference
analysis, and model development [2]. Defining the calibration sample set is the first step
for calibration model development. There are a number of requirements for an
appropriate calibration set for tablet analysis; examples include spanning the
concentration range for an active pharmaceutical ingredient (API) and excipients,
multiple lots of raw materials, different processing conditions, mutually independent
samples, etc [6]. A proper calibration set is a pre-requisite for generating appropriate
spectral data and achieving desirable predictive performance from NIRS. Therefore, the
size and direction of the calibration spectral subspace is of critical importance for
successful quantitative model development [7].
Other elements of NIR method development have been the subject of many
comprehensive reviews and continuous advancements (e.g. pretreatment techniques,
regression methods). Yet, analysis of calibration set design and its effect on model
performance has received far less attention in the literature and regulatory guidelines.
There is no standardized reference method for developing spectroscopic calibration sets
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for quantitative analysis of tablets. Practical approaches used for designing calibration
sets include experimental design entirely in concentration space (e.g. full-factorial design,
central composite design) [8-11], calibration sample selection form large data set based
on a selection algorithm [12-16], preparation of sample set that spans target
concentrations and anticipated variance (including physical sources of variance) over the
product lifecycle [17-21]. The objective of these techniques is to generate an appropriate
calibration set that contains ‘sufficient’ information about the system to develop a
successful quantitative model. As sufficient information is challenging to define, the
general idea is to incorporate as much variance as possible in an effort to ensure that all
future variance is captured in the calibration set [22]. This idea often leads to the creation
of a large calibration set. The reported numbers of calibration samples for NIR
quantitative methods are typically large for pharmaceutical tablets, such as 500 [23], 450
[24], 414 [25], 297 [26] and 276 [27]. Preparation of such large calibration sets is costly,
especially in the product development phase when API is expensive. It is also very time
consuming to perform the reference analysis (typically HPLC) of such large calibration
sets. A small calibration set with desired predictive performance would be helpful to save
time and cost associated calibration method development for tablet analysis using NIRS.
Ironically, the traditionally developed large and expensive calibration sets typically
contain redundant information. Redundant information is not necessary for developing a
successful quantitative model. However, samples containing redundant information are
typically identified in posterior analysis from their spectral responses. An analysist often
ends up preparing and analyzing samples that are unnecessary for the intended purpose.
Currently, there is no published technique to identify the redundant samples at the outset
2

of calibration development. Such a technique would be helpful to reduce the efforts in
preparing redundant calibration samples and save considerable time and cost associated
with calibration development.
It is also possible to miss the critical samples in the large calibration sets leading to a lack
of robustness of the method despite specific efforts to the contrary. A calibration set may
simultaneously contain redundant spectral information and lack the necessary
information to provide model robustness. Current approaches for calibration development
do not provide opportunity to identify the most critical calibration samples at the outset of
calibration development. Such a technique is useful to identify the smallest possible
calibration set with desired predictive performance.
Information about critical sample requirements of a calibration set is most useful at the
outset of method development to design a small and efficient NIR calibration set for
tablet analysis. This requirement is formulation specific and is dependent on the spectral
response of the individual constituent. Current strategies for designing NIR calibration
sets do not account for variations in pharmaceutical formulations and their spectral
responses. Regulatory guidelines and general rules of thumb are usually followed for all
types of formulations resulting in similar concentration ranges, levels and number of
samples for all types of calibration sets. However, an optimal calibration design for one
formulation can be sub-optimal for a different formulation. Different NIR responses
produced by different formulations should be considered during the selection of
calibration range, size, concentration levels and variance information. Variation of the
spectrally similar components might give redundant information and need not to be
varied simultaneously in the calibration set. Concentration of a component with relatively
3

weak spectral response might not need to be varied extensively whereas the component
with dominant spectral features might require wide variation in the calibration set to
develop a successful calibration model. Non-linearity between the concentration and
spectral response can be highly dependent on the formulation and analytical technique of
interest. The same calibration designs of different formulations can be mapped differently
into the spectral space of an analytical technique, generating redundant information for
one formulation while lacking necessary information for the other. A formulation specific
calibration strategy should be developed to best utilize NIR capability for quantitative
analysis of tablets.
A calibration set should also be specific to analytical technique. Currently, little or no
differences are usually found between NIRS and other spectroscopic calibration designs.
The same calibration design of the same formulation can perform differently depending
on the analytical technique. Practically, there is no best calibration design that works for
all purposes. A great deal depends on the method requirements and resource availability
[28]. The traditional practices for developing calibration sets are inefficient in utilizing
the available resources and minimizing redundant information. The calibration strategies
are also too generalized to account for formulation variability and variation in spectral
responses. A formulation and technique specific calibration strategy is required to make
the calibration process efficient and optimize the calibration performance.
This dissertation demonstrates a strategy for designing a calibration set in spectral space
for quantitative analysis of tablets using NIRS. This strategy requires fewer calibration
samples to achieve desired prediction performance of the calibration model. This strategy
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also offers a formulation and technique specific calibration experiments for calibration
method development.

1.2 Hypothesis and Objectives
The central hypothesis of this dissertation is that designing experiments in spectral space
provides a more efficient means compared to current practices for developing
spectroscopic calibrations for quantitative analysis of pharmaceutical tablets.
Given the central hypothesis, the objectives of this dissertation work were,
1. Develop a strategy to design NIR calibration sets in spectral space for
pharmaceutical tablets
a. Calibration design for a model drug product containing one API.
b. Calibration design for a model drug product containing multiple API.
2. Evaluate calibration performance between spectral calibration sets and traditional
calibration sets for quantitative analysis of tablets using NIR
a. Comparative studies between calibration strategies for single API.
b. Comparative studies between calibration strategies for multiple API.
3. Develop a strategy to incorporate physical information into the spectral design of
NIR calibration set
a. Develop strategy to incorporate physical information into the spectral
space
b. Evaluate calibration model robustness between spectral calibration sets
and traditional calibration sets
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4. Compare optimized calibration sets of NIR and Raman spectroscopy for
quantitative analysis of pharmaceutical tablets

1.3 Literature Survey
The first calibration set development and quantitative analysis of pharmaceutical
components using NIRS was reported in 1961 [29]. A series of reports followed later on
the quantification of amine salts (first application in a solid system) [30],
allylisopropylacetureide and phenacetin [31], meprobamate [32], carisoprodol [33] and
water content [34] in pharmaceutical compounds using NIRS 1. Since then, application of
this technology has been exponentially expanding due to advancements in computational
power, multivariate statistics and also information contained in the spectral range [35].
The pharmaceutical industry has adapted NIRS due to its potential to offer fast, easy and,
most importantly, non-invasive and non-destructive analysis technique. However, an
appropriate calibration set is required to deal with complex and overlapping features of
NIR spectra and non-specificity inherent to the technique [36]. An appropriate calibration
set is also critical to ensure consistent calibration performance during product life cycle.
Any change in the formulations, physical properties of the components or manufacturing
unit operations may cause the validated NIR method to become unusable [37].
Current strategies for developing calibration sets suffer from the redundancy of
unnecessary information and the inadequacy of critical information in the calibration
design. Redundancy of the calibration set and appropriateness of the calibration designs
are critical factors that need to be considered during NIR calibration development. Bondi
et al. demonstrated improved accuracy of full factorial and I-optimal designs over other
1

Calibration development for these reported methods used a univariate approach
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types of factorial and optimal designs for NIR calibration development [9]. Although the
I-optimal design was a subset of the full factorial design, the difference in predictive
performance was statistically insignificant. This work suggests the presence of redundant
information in the full factorial calibration design. Xiang et al. analyzed the effect of
correlated design on the selectivity and robustness of the calibration models [38]. They
demonstrated that the model selectivity and robustness of a randomized design was
superior to that of a correlated design. Low correlation in the randomized design was
critical to avoid fitting of the partial least squares (PLS) model to the non-selective
correlation between spectra and excipient concentration. Naes et al. compared five
mixture designs for developing calibration models and concluded that similar variation
was required between the calibration and the prediction sets for successful model
development [9, 39]. The same author also demonstrated the tendency of traditional
calibration methods to contain redundant information in a subsequent paper; similar
prediction performance was achieved with 20 samples out of 114 samples from the
calibration set [40]. All of these examples demonstrate that a calibration set may
simultaneously contain redundant spectral information and lack the necessary
information to provide calibration model robustness. However, this information is
available only in retrospective analyses, after considerable time and effort has been spent
on the calibration development.
The current strategies for developing NIR calibration set need significant improvement to
make the calibration process efficient and optimize calibration performance.
Optimization of the calibration strategy requires an in-depth understanding about the
requirements of an appropriate calibration set and the effects of calibration structure on
7

calibration model performance. This understanding can be helpful to identify the
necessary information for a calibration set and challenge the current philosophy of
incorporating all possible variances into the calibration set. The current recommendation
of a large calibration set can be replaced by an efficient strategy for developing NIR
calibration set to quantitatively analyze pharmaceutical tablets.
This chapter is aimed at reviewing the general requirements for an NIR calibration set
designed to quantitatively analyze pharmaceutical formulations, current strategies for
developing calibration sets and their effects on calibration model performances based on
the published literature and regulatory guidelines. This discussion is particularly focused
on the calibration sets designed to use inverse least squares regression techniques (partial
least squares, principal component regression), considering their wide applicability and
most frequent usage for quantitative analysis of pharmaceutical formulation.
1.3.1 Calibration set requirements
There are several requirements for an appropriate NIR calibration set. Blanco et al.
indicated wide concentration variation and physico-chemical variability as critical
requirements [41]. Mutual independence of samples was added to this list by other groups
[6, 38]. Naes et al. discussed these requirements in terms of calibration spectral space and
associated eigenvectors due to inherent collinearity of the NIR spectra [39]. Presence of
all relevant eigenvectors, wide spanning of the eigenvector’s directions and even spread
of the spectral space over the eigenvector subspace were considered necessary parameters
for NIR calibration set. However, calibration set requirements can be further discussed in
terms of range and level of concentration, number of samples and variance information.
8

1.3.1.1

Range and levels of concentration

An appropriate concentration range and variability in calibration set is necessary to
ensure NIR method robustness [42]. The concentration range must be selected
appropriately to cover the anticipated concentration range in the routine samples. An
extrapolation due to inappropriate calibration range is detrimental to calibration model
performance. The effect of extrapolation is more critical to multivariate NIRS method
compared to univariate counterpart [43]. Although a wide concentration range is
encouraged, there are limitations in terms of time and resources available to develop a
large calibration set. The typical production samples do not cover wide concentration
range as the Pharmacopoeias often allow 5% deviation of the nominal content for the API
[42]. Synthetic samples are often prepared in lab to extend the concentration range.
International Conference on Harmonisation (ICH) suggests a range of ±20% of the
nominal content of API for the assays method and ±30% for the content uniformity
method [44]. The concentration range can be further extended by the inclusion of pure
component (100%) or placebo tablets (0%) [45]. However, extreme points have high
leverage during calibration development. High leverage samples can significantly change
model direction and affect prediction performance in the concentration range of interest.
Although a wide concentration range is considered to increase model robustness, it can
introduce non-linearity. Good fit is almost guaranteed for a small set with narrow region.
However, the predictions outside this small range are of little value considering the
samples being outside of the validated range of the method [46]. Multiple ranges of a
single calibration set are also used for different prediction samples [47]. A prediction
sample at the calibration center is predicted by a narrow calibration range samples (local
9

calibration) whereas, prediction samples at the edge are predicted by a broad calibration
range samples (global calibration). This technique is known as bracketing. Bracketing
can also be performed by selecting an optimal subset from global calibration set [48].
Optimal subset can be changed each time a new test sample encountered.
There is no guideline reported for excipient concentration range in the calibration set.
Scheibelhofer et al. considered the variation of API more critical than the small deviation
of the excipients from the target [49]. However, all possible variations in excipient
concentrations were recommended to be included into the calibration set [49].
Components having common spectral features were emphasized in this aspect. A
regulatory guideline for excipient variation would be helpful in designing an appropriate
calibration set with desired predictive performance.
The concentration levels of a calibration set are also critical to develop appropriate
calibration model. Uniform distribution of the concentration levels is favored over
Gaussian or normal distribution [50, 51]. High leverage samples in the normal
distribution are considered undesirable during model development. The ICH Guideline
recommends at least five concentration steps to prove linearity [44]. Several samples
should be available per source of variance in NIR calibration set [47, 51]. The link
between API concentration range and clinical performance has not been discussed either
in literature or in guidelines. The calibration range is selected primarily based on
acceptable API range in the final dosage forms. A risk-based approach for defining the
range would be advantageous to bridge the gap between acceptable API range,
calibration range and clinical performance [52].
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1.3.1.2

Number of samples

Appropriate number of calibration samples is critical to calibration model performance
[53]. ‘Appropriate number’ has been defined as the number providing sufficient chemical
and physical variability resulting in appropriate spectral variability [54]. The number is
formulation, method and technique dependent and usually decided based on experience.
A set of 20–30 calibration points was considered sufficient for model accuracy by several
groups [47, 55, 56]. Agelet et al. recommended 100 samples for a robust NIR calibration
[50]. This requirement can be smaller for homogeneous samples. ASTM recommends
multiplying the number of principal component (PC) by a factor of 6 to determine
appropriate sample number [57]. However, a priori data set is a prerequisite to calculate
the PCs. Mathematical approaches have been reported to determine the number of
calibration samples [49]. For a mixture system having “P” levels for each chemical
component, the appropriate number of calibration sample ‘N’ can be calculated as,
𝑁𝑁 =

1
∗ 𝑝𝑝 ∗ (𝑝𝑝 + 1)
2

(1.1)

Li et al. used full factorial approach to determine the number of calibration samples for a
system containing “C” chemical components, each at “P” level, using following equation
[58].
𝑁𝑁 = 𝑃𝑃𝐶𝐶−1

(1.2)

A degree of freedom is lost due to the mixture constraint. Such approaches give general
direction for calibration sample number. However, these strategies require each varying
component to have same number of levels, which may not always be feasible.
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The appropriate numbers of calibration samples are also determined by splitting the
available data into calibration and test set. Alvarenga et al. suggested that, the calibration
should not be smaller than the 2/3 of the data set [59]. A smaller set is preferred to save
time and cost, however, a minimum number must set to meet the statistical requirement.
A two-points (extreme) calibration set was also reported during NIRS method
development [60], for which statistical validity was questionable.

1.3.1.3

Variance information

The information content of the calibration set and quality of the calibration samples are
considered to be more important than the number of calibration samples [22, 61]. A large
variation in all directions at the region of interest is a critical requirement for an
appropriate calibration set [59]. The information should include variation due to
concentrations as well as physical properties, moisture contents [51, 62] of the samples
and other factors that are bound to influence NIR spectra [63]. The calibration samples
should have a wider range of variation than the production samples to ensure model
robustness [19]. The wider range samples can be prepared at the laboratory scale or by
spiking (under-dosing/over-dosing) the production samples with appropriate amount of
API and/or excipients. However, lab-engineered samples were criticized due to its
potential to introduce greater than nominal variances and increase prediction errors [62].
A calibration model has the potential to fail during the prediction of future samples
having different interference information such as temperature effects, season to season
variation, different tablet for the same active component, and batch effects in industrial
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production processes [64-67]. The structure and information content of the calibration set
are critical for achieving appropriate representation of the future samples [46].
Several requirements are reported and they provide a general guideline for NIR
calibration set development. However, many of the calibration requirements can be
method specific and can vary depending on method requirements. Instead of a general
calibration design guideline, a standard method specific protocol is essential to meet the
calibration requirements. It is also critical to establish appropriate metrics to ensure the
fulfillment of calibration set requirements.
1.3.2 Strategies for developing calibration set
The main objective of developing a NIR calibration set is to represent routine production
samples and aid in developing a successful predictive model. Routine samples should not
be used alone to develop calibration set as these samples contain API and excipients in
amounts very close to the target composition, which precludes spanning a wide enough
concentration range for calibration set [41, 63, 68]. Several strategies are used to develop
calibration sets. Sarraguca et al. reported four strategies [63] for developing calibration
set using:
1) Production samples with a wide concentration range [24, 69, 70]
2) Production samples spiked with API/excipients [71-73]
3) Designed laboratory samples [73, 74]
4) Combined set of production and laboratory samples [42]
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Blanco et al. discussed similar strategies and recommended a combined approach [75].
The author also demonstrated a strategy using laboratory samples with a calculated
process spectrum to explain the spectral difference between laboratory and production
samples [41]. Spiking production samples and designing laboratory samples are the two
most common strategies. These strategies were found to be similar in terms of model
performance [63, 72, 73, 75]. Spiked samples usually match with the routine production
samples in terms of physical properties offering additional advantages [73]. However, a
high correlation between component’s concentrations in spiked samples can lead to poor
model specificity. Experimental design of the laboratory samples can be used to reduce
the correlation between component concentrations [42]. Another widely used strategy
involves the selection of calibrations set samples from a large data using different
selection techniques [74]. In this report, strategies are classified into three major
categories based on the techniques used for developing NIR calibration set:
A. Use of design of experiment to prepare a calibration set
B. Use of sample selection techniques to select a calibration set
C. Under dosing/over dosing (spiking) production samples to prepare a calibration
set

1.3.2.1

Use of design of experiment to prepare calibration set

Design of experiments (DoE) is a statistical tool to design a controlled and limited
number of experiments to gain in-depth understanding about the relationship between
factors and responses of an underlying system. In the field of multivariate calibration
(MVC), DoE is used to design calibration samples to define the relationship between
14

concentration and spectral response. The implementation of DoE is challenging in MVC
due to the inconsistency between the theory and practical application. In the calibration
design, the concentrations are considered as factors and spectra are considered as
response. In contrast, in the model system (regression) the concentration and spectral
response act as response and factors, respectively. Although this inconsistency has been
previously addressed [76], a practical solution is yet to be introduced. There are several
types of experimental designs employed to develop NIR calibration set.

1.3.2.1.1

Full Factorial Design

During spectroscopic calibration development, a full factorial design is used to prepare
calibration set using all possible combinations of the varying components. The details of
full factorial design can be found elsewhere [77]. Although this design is intended to
provide orthogonality, it is not possible to attain complete orthogonality in calibration
design of a pharmaceutical system due to the mixture constrain (total is 100%), especially
in solid samples. Therefore, the orthogonality between API and major excipients are
emphasized over the minor excipients. Complete orthogonality can be achieved using
sample solutions. A full factorial orthogonal design was created to build NIR calibration
dataset for predicting human serum albumin, gamma-globulin and glucose in control
serum and phosphate buffer solution [78, 79]. However, the calibration set was developed
by randomly selected 80 samples out of 125. Thus, the orthogonality of the design was
not maintained in the calibration set. The effect of randomized selection on calibration
model performance was not analyzed.
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Selection of design factors and levels are critical during calibration development. In most
cases, the API and major excipients are considered as the factors of the design, because
the primary objective of the calibration design is to develop mathematical relationship
between API concentration and spectral response. The variations in the major excipients
are required to train the calibration model against non-specific variation in the spectral
response. Other excipients usually act as fillers to fulfill the constraint. For multiple API,
only the APIs can act as factors [80]. A component ratio can also act as a factor of the
calibration design. Using a ratio as factor helps to reduce the number of design points
while maintaining wide range of concentration. Igne et al. considered API concentration
and major excipient’s ratios as two factors of the design during the development of a
calibration set for blend monitoring [81, 82]. The first calibration set contained spectra
from different time points of blending runs whereas the second set contained spectra at
the end of the blending runs assuming that the blend reached homogeneity.
Aside from the compositions, external factors such as moisture content, batch, day,
operator and collection temperature can also be included in the design to introduce
external variance into the calibration set [83]. Inclusion of the external factors usually
leads to a robust calibration model. However, it can also affect model accuracy due to
spectral sensitivity to the external factors. Kamran et al. included the API concentration,
particle size distributions (PSD) and compression pressures as the design factors during
the quantification of ibuprofen in tablets [84]. The calibration performance was found to
be sensitive to PSD variation. The model performance was improved by developing the
calibration set on uniform PSD of API and filler. In this study, the sample set was
randomly split into calibration and validation set. An independent validation set should
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have been used to retain the orthogonality of the design in calibration set. Such validation
set was used to assess calibration performance during the quantification of red iron oxide
in tablets [85]. The calibration model was found to be sensitive to the thickness variation
built into the calibration design. A uniform distribution of the tablet thicknesses in
calibration set would be helpful to make the model robust against thickness variation.
Full factorial design can be combined with a fractional factorial design during calibration
set development. Cogdill et al. used a combination of full factorial (in production scale)
and fractional factorial design (in lab scale) during API quantification in tablets [23]. The
common design factors were the source of API and Magnesium stearate, granules’
moisture content and compression force. Additionally, in the fractional factorial design,
API content was varied at ±30% of the nominal content. The use of a fractional design
helped to reduce the number of design points. The calibration model was demonstrated to
be robust against source, time, and compaction pressure variation. Another calibration set
was developed for predicting Radial Tensile Strength (RTS) of the tablet. Compression
force was varied in the calibration set to produce tablets with different RTSs.

1.3.2.1.2

D-Optimal Design

D-optimal design is widely used for developing calibration set with optimum number of
samples when the classical symmetrical designs cannot be used because of the large
number of design points or the irregular shape of the experimental region [86]. This
technique is used to maximize the information content of a design by maximizing the
determinant (D) of the information matrix (X’X). The details of the design can be found
elsewhere [87].
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Karande et al. used a D-optimal design to develop a NIR calibration set for blend
monitoring [88]. A set of 24 design points was created by D-optimal design strategy out
of which, 3 design points were removed for the test set leaving 21 design points for the
calibration development. These 21 design points might not be the optimum set of 21
points that had maximum determinant. It would be ideal to create a separate design for
the test set to maintain optimality of the calibration set. In this study, the calibration range
was 2-6 % and the resulting calibration model was used for predicting a full blend run
where API concentration outside the range was expected to be encountered during the
blending process. Prediction outside the calibration range should have been considered
with limited confidence. D-optimal design was also used to create a calibration set for
monitoring a five component blending run [89].
Tomuta et al. used D-optimal design strategy to develop a calibration set for quantitative
analysis of API and excipients in meloxicam tablets [90]. The ranges of variation were
kept ± 20% from the target composition for all components and levels of variation were
different for different components. The calibration model was able to predict meloxicam
and isomalt concentration accurately, but unable to predict sodium starch glycolate and
magnesium stearate due to low concentration. However, meloxicam and sodium starch
glycolate had similar concentrations (6.25% and 5%) but different levels of variation in
the calibration design. The effect of level variations on prediction performance was not
analyzed. In another study, D-optimal design was used to prepare a set of placebo
samples during the determination of ibuprofen content in production granules, tablet
cores and coated tablets [91]. The calibration samples were prepared by mixing different
levels of API with randomly selected placebo matrix and compressing them at different
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pressures. The randomization of the placebo mixture helped to mitigate the possibility of
compositional correlation in the calibration design.
D-optimal design was also used to create a calibration set during flow property analysis
of pharmaceutical powder [92]. A sample set with compositional variations was designed
to cause variation in flow properties e.g., angle of repose, compressibility index and
hausner ratio. A similar approach was taken to analyze the PSD of a pharmaceutical
powder system [93]. Compositional variation was designed and assumed to create
variation in the PSD of the final formulation. The use of a D-optimal design ensured
maximum concentration variation with given number of design points. However, it did
not ensure maximum variation in the PSD with the given design points. D-optimal design
was also used to prepare a calibration set during the determination of simvastatin and
excipients in lyposomes [94], diacetylmorphine, Caffeine and Acetaminophen [95] and
cetirizine dihydrochloride in powder samples [96].

1.3.2.1.3

Binary Design

In the statistical literature, binary design refers to a certain type of block design [97]. In
this report, binary design is defined as a “design having high correlation between
concentrations of two/multiple components in the calibration set”. The correlation is
termed as chance correlation in the literature [38]. Although there is poor model
specificity associated with this design due to the presence of correlation, it is the most
widely used design in multivariate calibration development.

19

Patel et al. used binary design to create a NIR calibration set for sulfamethoxazole (SMZ)
form I prediction in binary polymorphic mixtures and multi-component mixtures [98].
Because of the concentration correlation between two forms of SMZ, model predictive
performance for SMZ form I was depended on signals from both forms of SMZ, leading
to poor model specificity. Although sample mass has been reported to affect NIR baseline
[47], sample mass variation between the binary samples (300mg) and multicomponent
samples (330 to 6000mg) were not considered during the assessment of model
performance. In the multicomponent mixtures, the diluent concentration was kept
constant. A mixture design would be appropriate to allow different levels of the diluent
concentrations with same number of design points. Binary design was used to prepare a
calibration set for predicting two polymorphs of carbamazepine in bilayer tablets [99].
A

B

Figure 1-1. TNIR spectra of double-layered tablet consisting of various ratios of
forms I and III CBZ (A) and Model regression vector (B) [100]

20

The calibration set was prepared by varying the ratio of two polymorphs. The spectral
changes were highly correlated between two polymorphs due to their perfectly correlated
concentrations as shown in Figure 1-1.
A positive regression co-efficient explained the appearance of form I (also disappearance
of form III) and negative regression co-efficient explained the opposite scenario. A
similar approach was taken to vary crystalline and amorphous cephalexin in a calibration
set for pharmaceutical powder [101]. Although these studies reported acceptable model
performance, the effect of chance correlation on model specificity was overlooked in the
analysis. If the amount of one form were changed while keeping the concentration of the
other form constant or vice versa, the model would fail in predicting any of the forms
accurately. An appropriate calibration design without correlation could be helpful to
overcome this limitation.
Binary design was used during the comparison between reflectance and transmission
mode of NIRS based on the ability to predict Theophylline anhydrous concentration in
tablets [102]. This design was also used to prepare the calibration sets for determining
meloxicam [103], bromazepam and clonazepam [104] and riboflavin [18] content in
pharmaceutical preparations. In these studies, several factors such as non-uniform
distribution of API, tablet weight variation should have been investigated besides the
chance correlation due to their potentials to affect NIR calibration performance.
Introducing a small amount of random variation using replication in the design can
reduce the effect of correlation on model specificity. Varying the excipient mixtures
instead of an excipient as one factor can also minimize this effect. The correlation
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between API and excipient mixtures can be less detrimental to model specificity due to
relatively small changes in a particular component concentration. Replication and
excipient mixture method was used during a calibration set development for NIR content
uniformity method [105]. Model specificity can also be improved by selecting
wavelengths that are unique to the analyte of interest [106]. However, this technique can
affect model accuracy. In the binary design, full wavelength selection usually provides
improved accuracy due to all types of correlated signals. Specificity is an important
figures of merit and should always be assessed since it is the underlying chemistry basis
for the method [105].
Binary design was also used to prepare a calibration set for quantitative analysis of
mixtures containing components of similar or different PSD [60]. Only the two extreme
point calibration samples were demonstrated to be sufficient for quantitative analysis of
components having similar PSD. However, statistical validity of the two-point calibration
is questionable. A larger sample set was required for components with different PSD.
Lack of specificity was observed which might be the result of binary calibration design.
A similar calibration approach was undertaken to monitor powder mixing between two
components of different PSD [107]. Binary design can be less detrimental to a mixing
analysis compared to the quantitative analysis of a single component. For a mixing
analysis, it is desired for the method to be sensitive to all components of the system
whereas for quantitative analysis it should be sensitive to the analyte of interest only.
A calibration set can also contain compositional correlation due to the processing of the
calibration samples. For instance, a NIR method was developed to quantify drug content
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during a continuous blending process of API, granules and lubricant [108]. Concentration
of the API was varied by varying the API flow rates whereas flow rates for the granules
and lubricant were kept constant. However, their concentrations must have been changed
in the volume of sample scanned by the spectrometer. This change might be directly
correlated with the API concentration thus introduced binary structure in the calibration
set.

1.3.2.1.4

Mixture Design

Mixture design is also widely used to develop calibration set for NIR method. Mixture
design reduces the number of calibration samples while applying constraint on mixture
composition using an optimality criterion. The details of the design can be found
elsewhere [109].
A mixture design was used to prepare a calibration set during simultaneous determination
of chondroitin, glucosamine and ascorbic acid in capsule powder [110] and
acetylsalicylic acid, ascorbic acid and Caffeine monohydrate in powder mixtures [96].
Shi et el. used a mixture design to develop a calibration and prediction sets while
quantifying Theophylline, MCC and Lactose in tablets [111]. A ternary diagram was used
to generate six design points as shown in Figure 1-2. The three outmost points were not
included in the calibration because of their lack of leverage for other components. As the
same calibration set was used for all components, this led to extrapolated prediction
outside the calibration range for MCC and Lactose. Component specific calibration set
would be helpful to avoid extrapolation of prediction range.
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Figure 1-2. Tablet chemical composition. Squares were the calibration data points,
and circles were the prediction data points [111]
Short et el. also used mixture design to develop a calibration set for quantifying
Theophylline in tablets [11]. A set of 29 calibration sample was designed to cover all
concentration ranges of a four-component system. The same design was used during the
prediction of crushing strength and density of tablets using NIR reflectance [112] and
imaging[113]. Ozdemir et al. used mixture design to develop a calibration set for
quantitative analysis of a complex mixture [114]. A set of 21 design points was created
and three sets of samples were prepared at the same composition resulted a total of 63
samples. Two calibration sets were developed, one using the first set of 21 samples (set
A) and the other using the first and second set of 21 samples (total 42 samples in set B),
both predicting the third set of 21 samples (set C). Better model accuracy was observed
from set A compared to set B. This was contra-indicatory to the statement that more
number of calibration samples helps to minimize model prediction error [48, 115].
Calibration performance does not solely depend on the sample size.
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Alexandrino et al. used a combined approach of a mixture and D-optimal designs to
develop a calibration set for quantitative analysis of polymer thin films [116]. An
experimental domain of polymer mixture was generated by a mixture design with
constraints on concentration range. Subsequently a D-optimal design was used to
generate a set of 17 design points inside the domain. Different amounts of API were
randomly assigned to each design point. Subsequent splitting of the design points into
calibration and test was performed. This procedure might not generate the optimum
calibration set with appropriate variance. A straightforward approach would be to use a
D-optimal design with concentration range constraint. This would allow systematic
variance of API along with the excipients.

1.3.2.1.5

Correlation Design

Correlation design is used to assess the correlation between different variables. Although
the objective of calibration design is far from finding the correlation between API and
excipient concentrations, the correlation between component concentrations is critical to
the specificity of the calibration model. Calibration sets have been designed to reduce
correlation between component concentrations in NIR calibration set. In this report, such
designs are termed as correlation designs. Khan et al. used a correlation design to develop
a calibration set for on line monitoring of pharmaceutical blends [117]. The formulation
contained API with three major excipients resulted six pairs correlation statistics. A set of
21 design points was selected from 10,000 simulations based on the minimization of the
sum of square of six pair correlations. Equal flexibility was given to each component in
terms of allowable concentration variation. The resulting ranges of concentration
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variations were different for different components, API being the third in descending
order. As API concentration variation is more critical than the excipients concentration
variation [49], large variation in the API concentration and small variation in the
excipients concentration would be advantageous. In another study, the ranges of
concentration variations were set higher (70-130%) for the API compared to the
excipients (90-110%) [118]. The API and excipients were varied such that all correlation
coefficients were below 0.5. The ranges of variation can also be set according to the
target concentrations. Correlation design was also used to develop a calibration set for
monitoring powder blend [17]. The blend contained 7 chemical components including
two APIs. In the design, concentration variations for the most and least concentrated
components were ±10% and ±80%, respectively. However, the effect of these range
variations on NIR model performance was not discussed in any of the studies.

1.3.2.1.6

Other Designs

Several other designs have been used to prepare calibration sets for NIR method. Ito et al.
used a central composite design to develop an NIR calibration set while predicting
Acetaminophen and Caffeine concentrations in bi-layer tablets [26]. Shi et al. used a
Placket-Burman design to develop a calibration set for quantitative analysis of powder
mixture [119] and for blend monitoring [120]. Blend monitoring was also performed
using an extreme vertices design [121] and a simplex lattice design [122]. A simplex
lattice design of 5 degree and 21 mixture points was used to generate a set of 126
calibration samples varying each component at 6 levels. The same design (excluding mg
stearate) was carried out for determining chlorpheniramine concentration in tablets [123].
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Alcala et al. used a multivariate design approach for developing a calibration set during
API prediction in tablets [124]. The main difference between multivariate design and
other conventional designs lies in the data structure and subsequent chemometric analysis
(3-way vs 2-way, respectively). The multivariate designs are analyzed through extended
modeling techniques (multiway PLS), whereas conventional designs are analyzed
through traditional PLS. Osorio et al. used a science based calibration technique where a
small calibration set was demonstrated to be sufficient for monitoring a powder blending
process [125]. Although a high correlation between component concentrations was
present in the calibration design, specificity was assured by selecting unique peak of API
and developing an univariate prediction model.

1.3.2.2

Use of sample selection techniques to select calibration set

Calibration sets for a NIR method can also be developed by selecting samples with or
without constraints from a given dataset. A random selection process without constraint
was performed during the determination of ginsenosides in pharmaceutical tablets [126].
A set of 93 production samples was randomly selected from the manufacturing site for
method development. Subsequent randomization was performed to split the data into
calibration and test set. Calibration set selection without constraints usually have limited
applications. Certain constraints are usually applied during the selection process to ensure
regulatory compliance, appropriate concentration range, widespread variance and
sufficient representability of the future dataset.
Moffat et al. used a random selection method with constraints to prepare a calibration set
for Acetaminophen tablets [74]. The calibration set was selected from fifteen production
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and five development batches to include scale variations as well as concentration
variation into the calibration model. A similar randomized approach was used to prepare
calibration set ranging 80-120% of the nominal API content [21]. Meza et al. prepared a
calibration set by randomly selecting samples from specific concentration levels of
ibuprofen during tablet quantitation [127]. A randomized approach was also used for
splitting compositionally varying dataset into calibration and test set during the
quantification of propranolol hydrochloride in powder mixture [128].
The random selection method can be combined with an experimental design to develop a
calibration set. Ferreira et al. selected a set of calibration samples randomly from a
designed sample set of powder mixtures during hydrochlorothiazide (HCTZ)
quantification in powder mixtures and tablets [129]. Certain constraints were applied
during the selection step to ensure homogenous distribution of HCTZ in the calibration
set. The developed model was used to predict three sets of pharmaceutical samples:
powder samples before compression, intact tablets and powder samples obtained by
grinding tablets. Tablet prediction had the least accuracy among three sample sets due to
the density difference between tablet and powder mixture (calibration samples). This
study indicated the criticality of the physico-chemical properties of the calibration
samples. However, high correlation (r2~0.99) between HCTZ and MCC concentrations
was overlooked during specificity analysis. A similar method was used to prepare two
calibration sets for the quantification of multiple API and tablet RTS [130]. Certain
constraints were applied to ensure uniform distribution of APIs and tablet RTS.
The calibration samples can also be selected via different selection algorithms. The
Kennard-Stone algorithm was used to select a set of representative calibration samples
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for determining amoxicillin content in suspension [131]. Kennard stone algorithm is a
widely-used technique for selecting a representative subset from a large dataset. The
selection algorithm provides uniform coverage over the dataset by selecting the most
separated samples at successive iterations. The algorithm provides unique solution,
thereby results in the same representative set for all iterations. The details of the Kennard
stone algorithm can be found elsewhere [132]. Li et al. used this algorithm to select the
calibration set during azithromycin quantification in tablets of different colors and shapes
prepared by different manufacturers [133]. Four different calibration sets were selected
from four data sets containing spectra of coated tablets, powdered tablets, uncoated
tablets and powdered uncoated tablets. Among the four calibration sets, prediction errors
in descending order were coated tablets, powdered coated tablets, uncoated tablets and
powdered uncoated tablets. Spectral interference from coating component decreased
model’s prediction performance. The Kennard Stone algorithm was also used to select a
set of representative samples from calibration set for developing a calibration transfer
method [134].
Principal Component Analysis (PCA) can also be used to select calibration samples based
on the variance information of individual sample [135]. Blanco et al. performed PCA on
a dataset containing laboratory and production samples spanning concentration as well as
physical variability [136]. Samples that showed large variability in the first two PCs,
were included into the calibration set to incorporate maximum spectral variance.
However, maximum spectral variance may not always indicate concentration variation. In
such scenario, PCA based selection should be performed on the PCs that primarily
explain concentration information. Some other physico-chemical parameters along with
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PCA analysis can also be used to select the calibration set. Alvarenga et al. prepared a
calibration set based on PCA and group statistics on API content, water content and tablet
hardness [59]. Samples having wider variability were included into the calibration set to
develop a robust calibration model. Shi et al. used PLS scores for selecting the process
samples to include into the calibration set during content uniformity analysis of tablets
[137]. This selection strategy was compared with a random selection process. The mean
difference between two sampling approaches was found insignificant. PLS score based
selection strategy was found to be cost and time effective. Selecting samples from PCA
or PLS scores space should be performed carefully, as this can exclude samples with
extreme concentrations and narrow the concentration range leading to undesired
extrapolation.
Feng et al. used a classification technique to select a calibration set during the
determination of roxithromycin and erythromycin in tablets from different manufacturers
[27]. The initial calibration set contained samples from random manufacturers. The
resulting calibration model failed to predict the concentration of APIs in tablets prepared
by manufacturers that were not included into the calibration set. A cluster analysis was
performed on average spectra of each batch based on wards algorithm. Samples from
different clusters were selected for the calibration set such that, uniform distribution of
API content and manufacturer was maintained. Calibration models were demonstrated to
be accurate, robust, specific, linear, and transferrable. However, the validity of this
method was challenged by Bleye et al. due to inappropriate prediction interval [138].
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A

Figure 1-3. Accuracy profiles obtained from the work of Feng and Hu [27] for the
quantification of Roxithromycin (A) and Erythromycin ethylsuccinate (B) using
different NIRS equipment. Dotted horizontal lines (black): ±5% acceptance limits;
dotted and dashed horizontal lines (green): ±15% acceptance limits; dashed lines
(blue): 95% prediction intervals; dots (black): relative predicted concentrations of
the corresponding NIRS methods [138]
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Although having low prediction errors, this method was demonstrated unfit for the
intended purpose, because the 95% prediction intervals were outside the acceptable range
as shown in Figure 1-3 for two different NIR instruments. The prediction interval should
be included in the list of figures of merit for assessing model performance.

1.3.2.3

Under dosing / over dosing (spiking) production samples

Calibration sets can also be prepared by spiking (under dosing / overdosing) production
samples. Spiking is performed to extend the concentration range of production samples
that are typically prepared at target concentration. Moes et al. used spiking strategy to
prepare two calibration sets for analyzing blend uniformity of powder and content
uniformity of tablet cores, respectively [139]. A high correlation between the API and
excipients concentrations was present in both calibration sets. Along with the high
correlation, calibration samples for content uniformity had uneven distribution of API
concentration levels and were compressed at different compaction pressures compared to
the validation samples. Poor prediction performance was observed during the prediction
of tablets compressed at compaction pressures that were not included into the calibration
set. Blanco et al. spiked production samples (64.5% amorphous miokamycin) with
amorphous/crystalline miokamycin and excipients to prepare a calibration set for
determining crystalline and total miokamycin content in tablets [140]. Different levels of
PSD were included into the calibration set to make the model robust against particle size
variations. Calibration design for determining one polymorph in presence of another
polymorph is challenging. High correlation between the concentrations of different
polymorphs can diminish calibration model specificity. In this study, the selectivity of the
32

calibration model was demonstrated qualitatively by using spectral correlation coefficient method.
A similar approach was undertaken to develop a calibration set for quantifying Caffeine
in tablets [141]. Due to the presence of high correlation in calibration set, model
specificity was assessed by band assignment for Caffeine and comparing spectral features
of Caffeine with first loading vector. A set of spiked samples was also used to prepare a
calibration set during ranitidine quantification at different steps of tablet manufacturing
process; in granules for compression, in tablet cores and in coated tablets [19]. The effect
of high correlation between ranitidine and excipients was minimized by selecting
appropriate wavelengths. Sarraguca et al. used spiked samples to prepare multiple
calibration sets for quantifying Acetaminophen, acetylsalicylic acid, folic acid and
neomycin in respective tablet formulation [142]. The correlation co-efficient between Net
Analyte Signal and pure API spectrum was used as a metric for model specificity.
Specificity was found to be low for all formulations due to the high correlation between
API and excipients concentrations. A high correlation between API and excipients
concentrations is usually found after spiking the production samples. The correlation can
be minimized by using multiple placebo mixtures and randomly select one at a time for
spiking production samples [135].
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B

Figure 1-4. Improvement in calibration performance as a function of the number of
production sample included into the calibration set with optimized latent variables
numbers (A) and fixed latent variable numbers (B). Each symbol represents a
different sequence of sample addition [62].
The inclusion of production samples in the calibration set can mitigate the difference
between calibration and routine samples in terms of physical properties. The calibration
set prepared by spiking the production samples was found to perform better than the
calibration set prepared from laboratory sample during quantification of commercial
tablets [143]. Spiking was performed with randomly selected placebo samples form a set
of placebo mixtures to reduce the correlation between API and excipients concentrations.
A set of production samples can also be combined with the laboratory samples into the
calibration set and improve calibration model performance [62, 144].
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Figure 1-4 shows the improvement in calibration performance as a function of the
number of production samples included into the calibration set while predicting otilonium
bromide in production tablets [62].
Production samples were also used to develop a calibration set for moisture content
determination of tablets [145]. The samples were stored in humidity chamber to vary the
moisture content. The samples were also varied in terms of different APIs, excipients,
and shapes to develop a global calibration model for moisture content determination.
Model developed from tablets of API I failed to predict moisture content of tablets
containing different APIs. The most robust model was found by including tablets from all
three APIs into the calibration set. However, the effect of uneven distribution of APIs,
moisture contents and tablet shapes was not investigated.
A combined strategy of using production and laboratory samples into the calibration set
can be helpful, because production samples introduce physical variances whereas
laboratory samples extend the calibration concentration range. Calibration sets containing
both laboratory and production samples was used for successful quantification of
tianeptine in coated tablets [146], Acetaminophen in production tablets [68],
hydrocortisone in pharmaceutical powders [147] and isoniazid and rifampicin in capsules
[86]. In the last study, production samples from several months were used to introduce
possible changes in sample composition, suppliers, process changes or variations in
storage conditions. Placebo samples were also used as calibration samples to deduce the
interference structure for respective APIs.
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A similar preparation method between laboratory and production samples can enhance
the performance of the calibration model developed from laboratory samples only.
During the determination of dexketoprofen in laboratory and production granules [148],
model developed from laboratory powder failed due to differences between granules and
powders in terms of physical properties. Although inclusion of production granules into
the calibration set improved the prediction performance, the most accurate model was
developed from laboratory granules that were prepared using similar process of
production granules. This was due to the wider concentration range of laboratory
granules compared to production granules. Preparation of laboratory samples
encompassing similar physical variability of production samples at wider concentration
range was found to be an effective strategy for developing calibration set with desired
predictive performance.
Cardenas et al. used process spectra instead of production sample spectra to introduce
physical variance into the calibration set during cetirizine quantification in different
stages of tablet manufacturing process; blending, compaction and coating [149]. The
calibration set was initially developed with powder samples for blend prediction and
optimized with process spectra at later stages for core and coated tablet prediction. The
process spectrum was calculated as the spectral difference between lab scale powder and
industrial samples (core and coated tablets) following the idea developed by Blanco et al
[41]. Although this approach offers some advantages for reducing the sample size for
calibration, some associated assumptions might have been violated during the calibration
development. The addition of a process spectrum assumes that the extent of the effect of
physical variation on the spectra remains consistent for all concentration ranges. It also
36

assumes that the physical effect and chemical effect on NIR spectra are orthogonal. These
assumptions are not often true as the physical properties of the samples can vary with
compositional variation. The process spectrum approach was compared with
conventional approaches for preparing calibration set with laboratory, production and
spiked samples [15]. Although similar model performance was achieved, the new
strategy was favored for its time and cost effectiveness and simplicity.
Blanco et al. compared different strategies for developing calibration set while predicting
nimesulide content in pharmaceutical granulate [75]. Laboratory samples, spiked samples
and production samples were used for developing the calibration sets. A calibration
model built from spiked samples predicted the production samples with acceptable
accuracy; however, model from lab samples failed in the prediction. Prediction
performances of both models were improved by including production samples into the
calibration sets.

The discussion on different strategies for calibration set development is summarized in
Table 1-1 in terms of advantages and disadvantages of each strategy.
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Strategies for
developing NIR
calibration set

Advantages

Disadvantages

Use of design of
experiment

• Generates
systematic
variance into the calibration set.
• Can be used to minimize
the effect of chance correlation.
• Can be optimized to meet
regulatory requirements in terms
of calibration range, levels.

• Usually
requires
large calibration set.
• Can introduce greater
than
nominal
variance
leading to reduced accuracy.
• Usually
employed
with laboratory samples
which
leads
to
poor
robustness against scale
variation.

Use of sample
selection techniques

• Can be employed with any
existing
dataset.
No
prior
requirements for designing data
generation.
• Constraints can be applied
to meet regulatory requirements.

• Model performance
is sensitive to the selection
techniques. It can be difficult
to select the appropriate
combination of selection
technique and constraints.
• Appropriate samples
can be missing in the dataset
leading to poor model
performance.

Under dosing/over
dosing (spiking)
production samples

• Similar
physical
properties of calibration samples
compared
to
the
routine
production samples, which leads
to improved model robustness.
• Calibration transfer is
comparatively easier due to
similarity
in
physical
characteristics across scales and
manufacturing plants.

• Can introduce chance
correlation in the calibration
set leading to poor model
specificity.
• Requires more time
and cost to implement in the
production floor due to the
requirements
of
sample
preparation
(production
samples
and
calibration
samples must be treated in
the same way).

Table 1-1. Advantages and disadvantages of different strategies for NIR calibration
set development
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1.3.3 Effects of calibration set on model performance
A calibration set has significant effects on NIR model performance. These effects can be
discussed from three perspectives as the effects of the calibration design structure, effects
of calibration factors and effects of calibration sample properties.

1.3.3.1

Effect of calibration design structure

The structure and parameters of the calibration design can significantly affect NIR model
performance. The effect of several parameters including distribution of design points,
absence of relevant information and simulation of natural population on NIR model
performance were investigated [39]. Although the study did not include pharmaceutical
samples, it investigated the general aspects of NIR calibration set, that were applicable
for pharmaceutical materials. Even span and all possible combinations of constituents
were shown to be necessary for successful model performance. Appropriate experimental
design was demonstrated to be a prerequisite for accurate estimation of regression coefficient and adequate predictability. Prediction in the center and corners of the design
depended on the sample distribution and overall variance of the design. More samples
near the center point gave better prediction performance in the center point compared to
evenly spread sample distribution; a finding similar to that of Araujo et al [28]. This trend
was opposite while predicting samples outside the center points.
Chance correlation of the calibration design has been pointed out as a limiting factor of
multivariate calibration by several researchers [150-154]. Chance correlation can be
presented in the calibration set due to inappropriate experimental design, sample
properties and the condition underlying the spectroscopic measurement. Xiang et al.
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assessed the effect of chance correlation on an NIR model performance [38]. The
correlation between API and excipients was set high and low in correlated and
randomized calibration set, respectively. The correlated design performed better than the
randomized design during calibration development. However, the former design failed
during cross-prediction of tablets with excipient and density variations. The randomized
design succeeded in cross-prediction indicating that the predictability achieved with the
correlated design was dependent on correlated signals not specific to the API. The effect
of chance correlation on model specificity is often overlooked due to the traditional
practice of univariate model development using HPLC where specificity is achieved by
the experimental technique itself.
The interference structure of a calibration set was demonstrated to be critical during NIR
calibration development [46]. A poor prediction performance was observed in the
validation set containing different interference structure. A priori information about the
component’s pure spectrum and/or interference structure helped to improve the
calibration model performance. Li et al. compared the performance between two
calibration sets having different levels of API but same levels of excipients [58]. Model
performances were similar between the two calibration sets. Quantifications of the minor
excipients were more accurate compared to the major excipients and API. It was
concluded that the variation of API and major excipients were used during the
quantification of the minor excipients leading to improved accuracy. During the
quantification of API and major excipients, variability of the minor excipients was not
usable due to low concentration leading to biased prediction. However, prediction using
other component’s concentration profile might have led to poor model specificity. A
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modification of the same scheme was used to predict Acetaminophen content in powder
blends [155]. Following the previous scheme a set of 625 design points was generated
and 50 most distant points in the PCA scores were selected for the calibration set.

Figure 1-5. Relative residuals (%) plots obtained from the prediction of four
external sample sets, using also four calibration models with different concentration
ranges (%, w/w, API). Vertical lines indicate the MDL/MQL for each model. Four
predictions are shown for calibration ranges: (a) 0–5.00%, (b) 0–2.00%, (c) 0–
0.25%, and (d) 0–0.10% (w/w) [156]
The concentration range of the calibration set can be critical to model’s predictive
performance in terms of multivariate detection limit (MDL) and quantification limit
(MQL) and should be selected based on the prediction set property [156]. The relative
prediction errors, MDLs and MQLs of four calibration models with different
concentration ranges are given in Figure 1-5.
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A narrow range of concentrations should be used for predicting low drug concentration
and the range should be updated according to the prediction range. Although no
explanation was provided, mathematically it can be explained from the equation used for
calculating MDL and MQL. As the concentration range decreased, calibration error
(SEC) decreased, which in turn decreased the MDL and MQL. Concentration range can
also affect the calibration structure. In a calibration set for Theophylline prediction,
Theophylline and Magnesium stearate were varied orthogonally and cellactose was
considered as filler [157]. However, variation in cellactose concentration had high
correlation (0.99) with variation in Theophylline concentration due to its larger range
compared to Magnesium stearate concentration. This undesired chance correlation might
have led to poor model specificity. Uniform distribution of concentration levels in the
calibration set is usually encouraged [50, 51]. However, a similar predictive performance
was observed between similar and random distribution of concentration levels [55].
Bondi et al. analyzed the effect of experimental design on the predictive performance of
NIR calibration model [9]. The five level full factorial and I-optimal models were
statistically similar and had the lowest errors, followed by the CCD, D-optimal and three
level full factorial models, respectively. The model generated from the I-optimal design
was superior considering the balance between performance and efficiency due to low
sample requirement. A more comprehensive assessment was reported by Scheibelhofer et
al [49]. Four types of experimental design each with two subtypes were used to develop
NIR calibration sets. Model performances in increasing order of prediction error were:
five level factorial < extended CCC < simplex centroid < simplex lattice < CCF < IOptimal with center < three level factorial < I-optimal < D-optimal. A calibration set with
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a regular spread between different concentration levels was preferred. It was also
concluded that, the similarity between calibration and test structure improves prediction
performance. However, as crude pre-processing techniques were used for all designs and
the same model was used for all three components, the results might not be the optimum.
Araujo et al. also analyzed the effect of experimental design on calibration model
performance as shown in Figure 1-6 and found that number of unique experimental run is
more important than the number of replicates, so that the calibration can span a wide
range of variance [28]. Lorber et al. assessed these effects in terms of a vector “hun”,
where “hun” is dependent on the orthogonality in the calibration space. In a poorly
designed calibration set, the reduced orthogonality decreases the net concentration signal
(orthogonal concentration), which in turns increases “hun” and prediction error [48].
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Figure 1-6. Prediction errors of five calibration designs (first column) predicting
three prediction sets (first row). The asterisks indicate experimental or predicted
areas [28]
1.3.3.2

Effect of calibration samples properties

Different properties of calibration samples can significantly affect NIR calibration model
performance. The effect of spectral collection state and scale of calibration set samples on
calibration model performance was assessed during blend monitoring [158]. A calibration
set was initially developed by collecting spectra at static state. Model performance was
improved by incorporating dynamic spectra into the calibration set. Dynamic data from
same scale as prediction set was found to improve model performance in a greater extent
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compared to the dynamic data from different scale. Sarraguca et al. demonstrated scale
and physical characteristics of the calibration set as critical to NIR quantitative method
[42]. Calibration set developed from the lab scale powder failed to predict API
concentration in the pilot scale powder and tablet due to the scale and physical state
difference. Variation in scales and physical attributes were also found to affect calibration
model performance during the determination of mirtazapine [135] and ibuprofen [91,
131]. A calibration set developed on one set of tablet thickness and shape, was found to
be spectrally different from other set of tablet thickness and shape for reflectance and
transmission NIR as shown in score plots in Figure 1-7. This effect was minimized by
extending the calibration design to include tablets of different thicknesses, shapes and
embossing. Although inclusion of physical variations into a calibration set increases
model robustness, it can also affect model accuracy. Model accuracy was found to be
decreased upon the inclusion of tablet thickness variations into a calibration set [26].
Accuracy of a model developed on pilot scale samples was affected upon the inclusion of
laboratory and production samples of different dosage units into the calibration set [159].
These findings demonstrate that, the current philosophy of including as much variation as
possible into the calibration set, can be detrimental to calibration performance. These
effects were minimized by bracketing where a local calibration set near the mean tablet
thickness [26] and calibration set specific to dosage units [159] were developed. Absence
of variation due to size, shape, thickness, as well as narrow concentration range in the
local calibration sets helped to improve prediction performances of the respective models.
Similar to bracketing, selection of an optimal subset from large calibration set was
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proposed by Lorber et al [48]. However, bracketing or subset selection techniques were
criticized for causing narrow concentration range and poor robustness of calibration [28].
A

B

Figure 1-7. Score plot from second derivative reflectance (A) and transmittance (B)
spectra by principal component analysis. Open symbols—calibration set: (○) flatfaced tablets with various content; closed symbols—prediction set: (●) flat-faced
tablets with various thickness, (∆) flat beveled edge tablet, (□) convex tablet. The
numbers by the data points correspond to the batch no [160]
Granules PSD and hardness of calibration tablets were found critical and recommended
to be included into the NIR calibration set [25]. However, effects of these factors were
not analyzed independently. In another study, the effect of PSD was found to be low
compared to that of hardness on calibration model performance [38]. Pan et al.
independently assessed the effect of variations in tablet hardness, granules PSD and
relative humidity on calibration model performance [161]. NIR predictions were found to
change up to 10% due to 16% variation in tablet hardness between calibration and
predictions sets. For a 20% increase in RH, the change was around 10-20%. No
correlation between PSD of granules and NIR predictions were found within the range
investigated. However, in another study, PSD of calibration samples was found to be
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critical to model performance due to its ability to cause variation in tablet hardness [162].
Reflectance NIR was found to be more sensitive to tablet hardness and packing density
compared to transmission NIR [69].
Pieters et al. assessed the effect of intra and inter batch variability of a calibration set on
calibration model performance [163]. The presence of these variations in the calibration
set helped to improve model performance. The performance was further improved by
augmenting the calibration set with noise matrix calculated from net analyte
preprocessing. The prediction performance for samples having moisture variation was
improved by updating the calibration set with samples having different moisture contents.
Mainali et al. assessed the effect of calibration set complexity during the prediction of
water content in tablets. The complexity was introduced by using multiple API and tablet
shapes into the calibration sets [145]. Slight increase in prediction error was observed
with increased complexity. The most complex calibration set (III) was preferred over
others due to its increased robustness against API and tablet shape variation. Effect of
nonhomogeneous distribution of different APIs and tablet shapes in the calibration set II
and III were not discussed.

1.3.3.3

Effect of calibration factors

Although it is recommended to include all factors into the calibration set for developing a
robust calibration model [51], this approach requires large sample set, which can be
inconvenient on particular instances [164]. Factors that do not affect NIR spectra should
be excluded to reduce the size of the calibration set. Factors such as processing
parameters, temperature, moisture content, raw material variations etc. can have a
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detrimental effect on NIR prediction performance. Tablet moisture content can vary
during different steps of the manufacturing process, storage and analysis [165] and
excipients variation can occur between batches [163]. All these relevant factors should be
included into the calibration set. A small prediction error can be obtained by including
relevant information in the calibration set [66]. However, it may not always be possible
for the calibration set to contain all relevant factors that can occur in the industrial scales
[166], making the models less robust and requiring frequent updates. Inclusion of nonrelative information into the calibration set can increase model complexity and affect
mode performance [163].
Roggo et al. demonstrated process changes as the critical factors for calibration set during
dissolution study [167]. Four types of process related changes were included into the
calibration. The changing parameters were time and temperature changes during melt
granulation, compaction pressure, coating formulation and coating times. Riley et al.
assessed the effect of number of varying components in the calibration set on calibration
model performance [168]. An increase in the number of varying components from 2 to 6
and 2 to 10, increased the error by approximately 50% and 340%, respectively. However,
a calibration set containing higher number of varying components could be useful for
predicting complex samples. El-Hagrasy et al. assessed the effect of environmental factor
such as blend storage time on calibration model performance [169]. The NIR spectra
were collected immediately after blend preparation and after storing for a week to
develop two calibration sets, respectively. The predicted blend profiles were significantly
different between two sets. As the environmental factor was found to be critical for
developing calibration set for blend monitoring, a D-optimal design was used to vary
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relative humidity along with concentrations to develop a calibration set in later studies
[170, 171]. The effects of NIR calibration set on model performance is summarized in
terms of affected validation characteristics and analytical figures of merit in Table 1-2.

Calibration set properties

Affected calibration metrics

Calibration design and structure

Accuracy, specificity, range, linearity,
robustness, detection limit and quantitation
limit.

Calibration samples properties

Accuracy, specificity, robustness and
linearity.

Calibration factors

Accuracy, specificity, robustness and
linearity.

Table 1-2. Advantages and disadvantages of different strategies for NIR calibration
set development
1.3.4

Conclusion

There are several strategies for developing NIR calibration sets for tablet analysis. The
selection of right strategy is critical to model performance, however, less emphasized
during calibration development. An in-depth understanding about the calibration set
requirements, interaction between calibration structure and model performance, and a
formulation and NIRS specific outlines can be helpful for developing an appropriate NIR
calibration set. Appropriate calibration set is a prerequisite for successful model
performance and must be designed carefully at the outset of calibration development to
ensure efficient and maximum utilization of NIRS capability in pharmaceutical analysis.
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2

Chapter 2: Method development of designing calibration set in spectral space

In this study, a method was developed to use the pure component spectra of a tablet to
identify the critical samples necessary for an efficient calibration set development. The
principal difference between current techniques and the proposed technique lies in the
space used for designing a calibration set. Calibration sets are typically designed in
concentration space where orthogonality between component concentrations is imposed
to minimize collinearity and maximize model specificity. In the proposed method, a
calibration set is designed in spectral space in order to create orthogonality of the spectral
response.
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Figure 2-1. Concentration space of a ternary system

2.1 Theory
Concentration space: Concentration space is a multi-dimensional space used to describe
the composition of a composite structure. The structure of the composite system is
described by relative positions and directions along each of the dimensions in
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concentration space coordinates. For example, Figure 2-1 illustrates a concentration space
describing two composite structures of a ternary system containing A, B and C
components at [0.2, 0.1, 0.7] and [0.6, 0.3, 0.1] concentration levels.
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Figure 2-2. Spectral data (direct spectral space (A)) presented in PCA score space
(factor space (B))
Spectral space: Spectral space is a multi-dimensional space to describe the spectral
response of a system. The spectral response at each wavelength/frequency is described
along each dimension of the spectral space coordinates. This space has higher order
dimensions, typically on the order of 100 to 10,000 depending on the analytical technique
of interest. Therefore, spectral space is often decomposed to a lower dimensional
orthogonal subspace using chemometric techniques such as orthonormalization, principal
component analysis (PCA), singular valued decomposition, eigen value decomposition
etc. Principal component analysis efficiently describes the spectral variance, revealing the
maximum variance in the first principal component (PC) and remaining orthogonal
variance in each succeeding PC in descending order [172]. The scores (projection of each
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spectrum) on the PCs are used to represent the high-dimensional spectral space into a
much lower dimensional score space. For example, a typical series of 45 NIR spectra
(4200 data points in each spectrum) representing 45 Acetaminophen tablets can be
represented in three dimensional score space instead of 4200 dimensional spectral space
without losing any significant spectral information as illustrated in
Figure 2-2 (99.18 % of total spectral variance is explained by 3 PCs).
The use of pure component spectra during calibration set development follows the
fundamental theory of spectroscopic multivariate calibration and experimental design. A
spectroscopic calibration model is developed to predict the chemical/physical properties
of a sample from its respective spectrum using regression equation. For a system with
“m” samples and “n” spectral variables (wavelengths), the regression equation is as
follows,
𝐲𝐲�𝐦𝐦∗𝟏𝟏 = 𝐗𝐗 𝐦𝐦∗𝐧𝐧 ∗ 𝐛𝐛𝐧𝐧∗𝟏𝟏

(2.1)

Where 𝐲𝐲� is the predicted chemical/physical properties, X is the spectral data matrix and b
is the regression vector. Concentration will be considered as an example of physicochemical property in rest of the chapter. The regression equation (2.1) can be expanded as
follows,
ŷ𝑖𝑖𝑖𝑖=1..𝑚𝑚 = 𝑏𝑏0 + 𝑥𝑥1𝑖𝑖 × 𝑏𝑏1 + 𝑥𝑥2𝑖𝑖 × 𝑏𝑏2 + ⋯ + 𝑥𝑥𝑛𝑛𝑖𝑖 × 𝑏𝑏𝑛𝑛

(2.2)

To approximate the relationship between concentrations (y) and spectral variables (x) by
estimating the regression coefficients bi, the theory of design of experiments indicates
that the spectral responses (x1..n) should vary orthogonally and the output concentrations
(y1…m) measured. Orthogonal variation in the independent variable (spectral response)
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would allow better estimation of regression coefficients with minimum number of
samples/ experiments.
Currently, there is no published technique available for orthogonally varying the spectral
responses. The conventional approach to multivariate calibration is to vary concentrations
orthogonally in the concentration space and assume that this orthogonality translates to
the spectral space. For a system with “k” components, “m” samples and “n” spectral
variables using C for the concentration of samples, P as the pure component spectra, and
X for the matrix of spectral responses, the current design follows the equation below,
(2.3)

𝐂𝐂𝐦𝐦∗𝐤𝐤 ∗ 𝐏𝐏𝐤𝐤∗𝐧𝐧 → 𝐗𝐗 𝐦𝐦∗𝐧𝐧
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Figure 2-3. Hypothetical pure component spectra (A) and respective spectral space
(B)
This does not necessarily create orthogonal variance in the spectral space due to external
factors other than concentrations affecting the spectral signals. Moreover, depending on
the pure component spectra and their relative contribution to the sample spectrum,
experimental design points created in a concentration space can result in highly redundant
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2.5

and/or inadequate spectral information. A hypothetical scenario is illustrated for a three
component system (A, B and C) analyzing with a spectroscopic technique of 3
wavelength channels (1000 nm, 1100 nm and 1200 nm).
Figure 2-3 represents the hypothetical pure component spectra of A, B and C and their
respective projections on the spectral space. The spectrum of any sample mixture
containing A, B and C should fall in the triangular plane (shaded region) formed by A, B
and C in the spectral space due to mixture constraint (sum of A, B and C is always 1).
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Figure 2-4. Hypothetical concentration space (left) and respective spectral space
(right)
Experimental design points created in the concentration space should retain its structure
and linearly mapped in this hypothetical plane. However, this does not occur
experimentally due to non-linearity between concentration and spectral response,
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3

different spectral contribution of each component into the mixture spectrum, physicochemical properties of the samples etc.
Figure 2-4 shows a hypothetical scenario where experimental design points in the
concentration space (Figure 2-4 (left)) fall outside the hypothetical plane (green) in the
spectral space (Figure 2-4 (right)). Thus, an orthogonal design in the concentration space
might lose its orthogonality in the spectral space, provide redundant information as well
as lack in critical information in the calibration design.
The proposed approach is an attempt to create the orthogonal variations in the spectral
space. Orthogonal variation in the spectral space helps to minimize the sample
requirement by identifying a set of critical samples necessary to develop a successful
calibration model. For instance, compositional variation in the spectrally similar
excipients will have unidirectional variation in the orthogonal spectral space. Designing
calibration samples in that direction by varying either of them would give sufficient
spectral variation to model against the concentration of API and reduce the calibration
sample size by a factor of two. Moreover, orthogonal spectral space helps to identify the
most spectrally dissimilar samples to be included into the calibration set to cover the
maximum possible spectral variation. Training a model against such variation is critical
to develop a robust calibration model at the outset of calibration development. The most
spectrally dissimilar samples are often different from the most compositionally dissimilar
samples. Building calibration set with compositionally different samples and training a
model against large compositional variation may not always be successful in developing
a calibration model that is robust against future spectral variation.
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However, in NIR spectroscopy, spectral responses at each wavelength cannot be varied
orthogonally due to highly correlated signals. Alternatively, the correlated spectral
responses can be decomposed into orthogonal directions using different techniques such
as Orthonormalization, Principal Component Analysis (PCA), Partial Least Square (PLS),
Singular Valued Decomposition (SVD) etc. In the proposed method, the pure component
spectra of a formulation are used to determine the spectral space for that formulation and
Orthonormalization technique is used to decompose the pure component spectral
response into orthogonal directions. The spectral projections onto the orthogonal
directions are termed as “scores”. The score is used as a metric of spectral variance in the
orthogonal spectral space of the formulation. Designing experiments by varying the
scores is considered equivalent to the design in orthogonal spectral space. In this study,
pure component spectra were acquired by compressing the pure components into tablets
and scanning with NIR instrument. When the pure component tablets are difficult to
prepare, pure component powders can be used (adjustments for spectral differences may
be necessary).
After defining the orthogonal spectral space of a formulation using pure component
spectra, a model tablet is compressed at the target formulation and an NIR spectrum is
acquired. The spectrum of the model tablet is projected onto the orthonormal basis
vectors of the pure component tablet spectra. The projections are termed as “model tablet
scores.” Scores of the ‘model tablet’ are calculated based on the following equation
𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏 𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜 𝐛𝐛𝐛𝐛𝐛𝐛𝐛𝐛𝐛𝐛

𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭
𝐌𝐌𝐌𝐌𝐌𝐌𝐌𝐌𝐌𝐌 𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭
𝐭𝐭 𝐌𝐌𝐌𝐌𝐌𝐌𝐌𝐌l
= 𝐱𝐱 𝟏𝟏∗𝐧𝐧
∗ 𝐖𝐖𝐧𝐧∗𝐫𝐫
𝟏𝟏∗𝐫𝐫
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(2.4)

Where, t is the scores of the “model tablet” for “r” factors, x is the spectrum of the
“model tablet” and W is the orthonormal basis of the pure component spectra.
The idea behind the model tablet score is to design a calibration set such that the scores
of the calibration samples are centered around the model tablet scores. This ensures the
calibration model to be centered at the target formulation. An in silico full factorial design
is created to achieve this objective. In the design, the numbers of factors are kept equal to
the number of chemical components. We assume that the signal from each component
contains orthogonal features with respect to other components. Thus, full chemical rank
is achieved by creating a design where the number of factors is equal to the number of
components. The numbers of levels in the design are selected to balance between
computational burden and simulation of spectral variance. Simulation of spectral variance
is required to select the calibration candidates from a large dataset. Addition of one level
can significantly increase the design points and subsequent simulation time. For
instances, five levels for each factor in a five-factor design will result in (55) = 3125
design points. An increase by one in the number of levels will result (65) = 7776 design
points. The effect of number of levels is minimal as long as it is kept equal for all the
factors to prevent any confounding effect and generate all the possible spectral variation
during simulation.
The center of the in-silico design is then set equivalent to the model tablet scores t and all
other design points are scaled from the center. The transformed design is defined as the
‘target score design’. Centering the design around model tablet scores ensures that the
target scores span the space around the model drug. The proposed approach centers the
regression model at the target composition (“model tablet”) and then creates balanced
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spectral variance around this center. The spectra corresponding these score values vary
orthogonally (or very nearly so), because the target score design is built from a full
factorial orthogonal structure. Figure 2-5 shows the procedure for designing scores
around the model tablet scores. Use of scores as the calibration design factors can also be
justified from chemometric point view. A mathematical description is given in Appendix
A.
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Figure 2-5. Procedure for designing scores around the model tablet scores in
spectral space
However, the challenge remains to find the compositional requirements for the sample
from which the spectrum is collected and scores are derived. Although the calibration
samples are designed in the spectral space, the design must be carried out in the
concentration space to prepare those samples.
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𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂

𝐂𝐂𝐦𝐦∗𝐤𝐤

𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏 𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬

∗ 𝐏𝐏𝐤𝐤∗𝐧𝐧

𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬

(2.5)

= 𝐗𝐗 𝐦𝐦∗𝐧𝐧

The relationship between the compositional points and the spectra can be expressed by
equation 2.5. However, this relationship is not always true due to different physical and
chemical contributions to the spectral features in the NIR region. A rotation matrix “R” is
introduced in the above expression to explain all other contributions on spectral features
except concentration. The rotation matrix rotates the estimated spectra towards the actual
spectra. “R” is calculated based on equation 2.7 (the detail derivation is given in
appendix B). Where, U is the left singular values, S is the singular values and V is the
right singular values for the concentration matrix, X is the spectral matrix containing the
pure component tablets and model tablet spectra and P is the pure component tablets
spectra.
𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂

𝐂𝐂𝐦𝐦∗𝐤𝐤

𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏 𝐜𝐜𝐜𝐜𝐜𝐜𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐩 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬

∗ 𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑
∗ 𝐏𝐏𝐤𝐤∗𝐧𝐧
𝐤𝐤∗𝐤𝐤

𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦
𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑
𝐤𝐤∗𝐤𝐤

𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬 ′

= 𝐕𝐕𝐤𝐤∗𝐤𝐤

𝐒𝐒𝐒𝐒𝐧𝐧𝐠𝐠𝐠𝐠𝐠𝐠𝐠𝐠𝐠𝐠

∗ �𝐒𝐒𝐤𝐤∗𝐦𝐦

′

𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒

∗ ��𝐒𝐒𝐤𝐤∗𝐦𝐦

𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏 𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜 ′

∗ �𝐏𝐏𝐧𝐧∗𝐤𝐤

�

𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏 𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜

∗ {�𝐏𝐏𝐤𝐤∗𝐧𝐧

𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒

� ∗ �𝐒𝐒𝐦𝐦∗𝐤𝐤

𝐋𝐋𝐋𝐋𝐋𝐋𝐋𝐋 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬

� ∗ �𝐔𝐔𝐦𝐦∗𝐦𝐦

′

𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬

= 𝐗𝐗 𝐦𝐦∗𝐧𝐧

′

𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏 𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜 ′ −𝟏𝟏

� ∗ �𝐏𝐏𝐧𝐧∗𝐤𝐤
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� ∗ 𝐗𝐗 𝐦𝐦∗𝐧𝐧
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(2.6)

(2.7)

The effect of rotation matrix in simulating spectral response is demonstrated in Figure
2-6.
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Figure 2-6. Effect of rotation matrix in spectral simulation

Equation 2.8 is solved for “C” to calculate the compositional requirements using a global
optimization technique, assuming that the variation in pure component spectra dictates
the primary spectral variation in the model, (the detail derivation is given in appendix C).
Where, C is the compositional matrix for the targeted score design having sample size
“u”, R is the rotational matrix, T is the target design in the score space, P is the pure
component spectra, W is the basis vector set and r = k (number of latent variables =
number of components). Two constraints are applied during the solution by the
optimization technique. The first one is, for all “u”, ∑ki=1 Ci = 1. This is a general

constraint for formulation, since the sum of the concentrations of all the components in
each design point must always be 1. The second constraint is set to each constituent
individually to meet the appropriate concentration range criteria for a feasible tablet
preparation and regulatory guidelines. For instances, API concentration ranges should
vary at a range around 70-130 % w/w of the label claim and the lubricant concentration
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must be limited to a very small range of concentration. Each row of the resultant matrix
“C” provides the compositional requirements (concentrations) of a sample that has been
designed in the orthogonal spectral space. This approach is referred to as spectral design
throughout the rest of this article.

𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂

𝐂𝐂𝐮𝐮∗𝐤𝐤

∗ 𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑n
𝐤𝐤∗𝐤𝐤

𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬

= 𝐓𝐓𝐮𝐮∗𝐫𝐫
∗

𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏 𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬
(𝐏𝐏𝐤𝐤∗𝐧𝐧

With the constraint: for all “u”, ∑ki=1 Ci = 1

∗

𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏 𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜 𝐛𝐛𝐛𝐛𝐛𝐛𝐛𝐛𝐛𝐛 −𝟏𝟏
𝐖𝐖𝐧𝐧∗𝐤𝐤
)

(2.8)

After determining the compositional requirements of the design points, a small
representative subset is selected from the design points as the calibration candidates.
Different selection strategies can be employed to select the calibration samples such as
the Kennard stone algorithm, orthogonal rotation, maximum distance in the score space
etc.
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2.2 Spectral calibration set for single API formulation
The spectral space strategy was used to design a NIR calibration set for quantitative
analysis of a model drug containing Acetaminophen as Active Pharmaceutical Ingredient
(API) and Microcrystalline cellulose (MCC), spray dried Lactose, Hypromellose and
Magnesium stearate as excipients. The spectral design was created based on the theory
discussed in section 2.1.
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Figure 2-7. Pure component spectra and respective basis vectors
The pure component powders were collected from different sources, Acetaminophen
(Mallinckrodt Inc., Raleigh, NC, USA), Hypromellose (HPMC; Pharmacoat 606, ShinEtsu Chemical Co. LTD, Tokyo, Japan), Lactose (modified spray-dried; Foremost Farms
USA, Rothschild, WI, USA), Microcrystalline cellulose (MCC; Avicel PH 200, FMC
Biopolymer, Mechanicsburg, PA, USA) and Magnesium stearate (MgSt; Fisher
Scientific, Waltham, MA, USA). The pure component powders were compressed using a
Carver Automatic Tablet Press (Model 3887.1SD0A00, Wabash, IN, USA) at 5000 lb
force using a 13 mm die and flat-faced punches. The target tablet weight was 700 mg.
The target formulation was set as Acetaminophen (27.3% w/w), MCC (34.15% w/w),
Lactose (34.15% w/w), HPMC (3.9% w/w) and MgSt (0.5% w/w). A model tablet was
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prepared at the target formulation. All these 6 tablets (5 pure component tablets and one
model tablet) were scanned using a bench top NIR instrument (XDS Rapid Content
Analyzer, FOSS NIRSystems, Inc) in reflectance mode. Spectral data were collected at
0.5 nm increment over a range of 400 nm – 2499.5 nm with 32 co-adds per spectrum.
Spectra from both faces of each compact were averaged to produce a single
representative spectrum.
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Figure 2-8. A full factorial design around the model tablet score in the orthogonal
spectral space
The pure component spectra were orthonormalized to determine the basis vector of the
pure components. Figure 2-7 shows the pure component spectra and basis vector. These
basis vectors are orthonormal (orthogonal and unit vector) to each other. The basis
vectors define the orthogonal spectral space of the pure component. Instead of the
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orthonormalization technique, PCA can be done on the unscaled pure component spectra
and the principal component of the PCA would give the exact same vector as the basis
vectors. The model tablet spectrum was projected on the basis vector set of the pure
components. The resulted scores are termed as target scores.
A 5-factor full factorial design with 5 levels per factor was calculated in the orthogonal
spectral space where the “model tablet” scores were set as the center of the design as
shown in Figure 2-8 for the first 3 basis vectors. This resulted in a 3125 (55) design
points. A rotation matrix was calculated from the pure component and model tablet
spectra. The rotation matrix, pure component spectra and orthonormal basis were used to
calculate the required composition for the 3125 design points based on equation (2.2.8).
A sample selection technique was employed to select a small representative subset of
maximum spectral variance within the full design. NIR spectra were simulated for all the
3125 design points using the concentrations, rotation matrix and pure component spectra
following equation (2.6) without adding additional noise. Principal component analysis
was performed and a 3-dimensional score space was created using scores on PC1, PC2
and PC3. A set of 3 PCs was able to explain all the variation in the spectra. Delaunay
triangulation was used to create a convex hull around the calculated score space. A
straight line through the center was rotated orthogonally and the two most distant samples
from center along the line were selected to capture maximum possible variance. Figure
2-9 shows the orthogonal rotation of the line in the PCA score space and selected design
points.
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Design
#

Acetaminophen

Hypromellose

Lactose

(% w/w)

(% w/w)

(% w/w)

1

32.02

4.42

2

20.67

3

Microcrystalline Magnesium
cellulose
Stearate
(% w/w)

(% w/w)

31.43

31.95

0.19

1.00

42.36

35.79

0.19

40.13

7.95

21.66

29.53

0.73

4

35.17

0.94

36.06

27.63

0.20

5

30.90

8.05

26.60

33.65

0.80

6

24.30

4.90

31.11

38.97

0.71

7

38.02

2.43

33.15

26.17

0.23

8

21.62

1.01

37.93

39.22

0.21

9

39.85

8.03

26.77

25.13

0.23

10

24.17

1.03

42.04

32.54

0.23

11

27.30

3.90

34.15

34.15

0.50

Table 2-1. Composition of the spectral calibration et for single API

A calibration set composed of 10 design points was selected using this technique. The
target composition along with the 10 design points provided 11 compositional points for
the spectral design as indicated in Table 2-1. This design was labeled as the ‘spectral
design’ and was used to develop a quantitative calibration method.
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PC3

PC3

Figure 2-9. Orthogonal rotation in spectral space to select calibration candidates

The spectral design samples were prepared by direct compression. All the components
(Acetaminophen, MCC, Lactose, HPMC and MgSt) for each design point were weighed
and placed in a 10 ml scintillation vial according to Table 2-1. The ingredients were
mixed by rotating the scintillation vial. Tablets were compressed on a Carver Automatic
Tablet Press (Model 3887.1SD0A00, Wabash, IN, USA) at 5000 lb force using a 13 mm
die and flat-faced punches. The target tablet weight was 700 mg. This tablet set was
defined as the ‘spectral calibration set’.
All the tablets were scanned using a bench top NIR instrument (XDS Rapid Content
Analyzer, FOSS NIRSystems, Inc) in reflectance mode. Spectral data were collected at
0.5 nm increment over a range of 400 nm – 2499.5 nm with 32 co-adds per spectrum.
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Spectra from both faces of each compact were averaged to produce a single
representative spectrum. Spectral calibration set and their respective spectra were used to
develop a quantitative NIR calibration model to quantify the amount of Acetaminophen
in tablets of interest.

2.3 Spectral calibration set for multiple API formulation
The spectral design strategy was also used to create a calibration set for quantitative
analysis of multiple API tablets. The multiple API tablets contained two APIs as
Acetaminophen (Acetaminophen; Mallinckrodt Inc., Raleigh, NC, USA) and Caffeine
anhydrous (Spectrum Chemical Mfg. Corp., New Brunswick, NJ, USA). The excipients
were

Microcrystalline

cellulose

(MCC; Avicel

PH

200,

FMC

Biopolymer,

Mechanicsburg, PA, USA), Lactose (modified spray-dried; Foremost Farms USA,
Rothschild, WI, USA), Crosscarmellose sodium (Crosscarmellose Na, Spectrum
Chemical Mfg. Corp., New Brunswick, NJ, USA) and Magnesium stearate (MgSt; Fisher
Scientific, Waltham, MA, USA). The target formulation was set as Acetaminophen
(31.25% w/w), Caffeine (4.05% w/w), MCC (37.32% w/w), Lactose (24.89% w/w),
Crosscarmellose Na (2% w/w) and MgSt (0.5% w/w). All the materials were stored in
room temperature and relative humidity. Anhydrous caffeine was reported to be stable
under 75% RH for 7 weeks [173]. No hydration and anhydrous caffeine was expected
considering lower room RH (~60%) and shorter storage time and analysis.
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The spectral design was created based on the theory discussed in section 2.1. Initially, the
pure component tablets (six tablets) and one model tablet at the target composition were
compressed at 5000 lb using a Carver Automatic Tablet Press. The tablets were stored for
two weeks for viscoelastic relaxation based on a previous study on similar formulation
[174]. After the viscoelastic relaxation, tablets were scanned using a bench top NIR
instrument (XDS Rapid Content Analyzer, FOSS NIRSystems, Inc) in reflectance mode.
Spectral data were collected at 0.5 nm increment over a range of 400 nm – 2499.5 nm
with 32 co-adds per spectrum. Spectra from both faces of each compact were averaged to
produce a single representative spectrum.
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Figure 2-10. Pure component spectra and respective basis vectors
The pure component spectra were orthonormalized to derive the basis vector of the
spectral space. Figure 2-10 shows the pure component spectra and basis vector. The
model tablet spectrum was projected on the basis vector to calculate model tablet scores
on the orthonormal basis of pure component spectra. A 6-factor full factorial design with
5 levels per factor was calculated in the orthogonal spectral space where the “model
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tablet” scores were set as the center of the design. This resulted a total of 15625 (56)
design points.
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Figure 2-11. PCA scores of the simulated spectra and selected calibration candidates
by KNN

A rotation matrix was calculated from the pure component and model tablet spectra to
help explaining spectral variance coming from sources other than the spectra of the pure
components. The rotation matrix, pure component spectra and orthonormal basis vectors
were used to calculate the compositional requirements for the 15625 target design points
based on eq. 2.8.
After determining the compositional requirements of the target design, the target design
spectra were simulated using the compositional requirements, the pure component spectra
and the rotation matrix using equation 2.6. A PCA analysis was performed on the
simulated spectra to determine the principal component scores.
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Acetaminophen
(% w/w)
34.25
19.17
43.75
30.93
27.88
39.60
24.39
36.59
34.31
24.52
40.49
28.34
35.11
32.39
43.62
24.59
41.67
28.03
41.42
29.53
29.99
33.22
31.08
26.15
43.75
36.55
34.56
41.38
35.95
21.71

Caffeine
(% w/w)
3.79
0.81
7.29
0.81
0.81
7.29
7.29
0.81
7.29
0.81
0.81
7.29
7.29
0.81
1.95
0.81
7.29
2.57
0.81
7.29
7.29
7.29
2.32
5.46
7.29
0.81
0.81
3.23
0.81
4.18

MCC
(% w/w)
36.77
38.31
30.17
27.89
51.96
23.23
32.90
24.85
38.61
51.96
24.38
47.58
23.23
39.48
35.83
32.54
34.25
41.25
41.58
27.82
42.93
29.42
46.37
47.05
24.29
31.15
30.85
31.13
43.29
35.95

Lactose
(% w/w)
21.99
37.40
15.64
38.97
15.49
28.89
31.13
35.74
15.49
21.41
30.62
15.49
33.07
24.52
15.49
37.75
15.49
27.45
15.49
33.43
15.49
26.37
15.93
19.03
23.96
27.79
32.48
23.56
16.25
33.86

Crosscarmellose
Na (% w/w)
2.40
3.50
2.95
1.20
3.08
0.80
3.50
1.81
3.50
0.50
3.50
0.50
0.50
2.60
2.32
3.50
0.50
0.50
0.50
1.73
3.50
3.50
3.50
1.51
0.51
3.50
0.50
0.50
3.50
3.50

Table 2-2. Composition of the spectral calibration set for multiple API
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MgSt
(% w/w)
0.80
0.80
0.20
0.20
0.78
0.20
0.80
0.20
0.80
0.80
0.20
0.80
0.80
0.20
0.80
0.80
0.80
0.20
0.20
0.20
0.80
0.20
0.80
0.80
0.20
0.20
0.80
0.20
0.20
0.80

The Kennard Stone algorithm was used to select 30 design points in the PCA score space
of the target design spectra (Spectral design). Kennard stone algorithm is a widely-used
technique for selecting a representative subset from a large dataset. The selection
algorithm provides uniform coverage over the dataset by selecting the most separated
samples at successive iteration. The details of the Kennard stone algorithm can be found
elsewhere [132]. Figure 2-11 shows the simulated scores of the 15625 points and selected
scores of 30 points by Kennard stone algorithm. The composition of the selected 30
points is given in Table 2-2.The target forumaltion was compressed at 3 different
compaction forces resulting in total 33 compositional points for the spectral design.
The 33 tablets of the spectral design were prepared by direct compression on a Carver
Automatic Tablet Press using a 13 mm die and flat-faced punches. The target tablet
weight was 700 mg. The compression forces range was 4000 lb to 6000 lb. The
compression force for each design point was selected such that the correlation between
compression force variation and concentration variation of each component is minimal
and variance in comapction force is maximal.
Table 2-3 provides the correlation co-efficient between compression force variation and
concentration variation. This tablet set was defined as the ‘spectral calibration set’. All
the tablets were scanned using a bench top NIR instrument (XDS Rapid Content
Analyzer, FOSS NIRSystems, Inc) in reflectance mode. Spectral data were collected at
0.5 nm increment over a range of 400 nm – 2499.5 nm with 32 co-adds per spectrum.
Spectra from both faces of each compact were averaged to produce a single
representative spectrum.
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Acetaminophen

Caffeine

MCC

Lactose

Cross
carmellose
Na

MgSt

Force

Acetamino-phen

1.00

0.13

-0.46

-0.35

-0.27

-0.48

0.00

Caffeine

0.13

1.00

-0.23

-0.22

-0.13

0.14

0.02

MCC

-0.46

-0.23

1.00

-0.60

0.10

0.45

0.00

Lactose

-0.35

-0.22

-0.60

1.00

0.01

-0.16

-0.01

Cross
carmellose
Na

-0.27

-0.13

0.10

0.01

1.00

0.12

0.00

MgSt

-0.48

0.14

0.45

-0.16

0.12

1.00

0.03

Force

0.00

0.02

0.00

-0.01

0.00

0.03

1.00

Table 2-3. Correlation co-efficient between composition and compression force

2.4 Conclusion
A method was developed to design calibration set in spectral space using pure component
spectra. Two calibration sets were designed in spectral space, one for a single API
formulation and the other for multiple API formulation. The spectral calibrations sets for
single API and multiple API were used to developed quantitative NIR methods for
respective APIs. The performances of the methods were compared with traditional
calibration strategies. The details of the method development and comparative results are
discussed in the following chapter.

Copyright ©: Part of this chapter has been reprinted from [175]. Copyright clearance is
provided at the end the dissertation.
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3

Chapter 3: Comparison between the model performance of spectral calibration
and traditional calibration sets

3.1 Introduction
The first step in developing NIR quantitative method for tablet analysis is to design the
calibration set. The performance of the NIR method depends on the suitability of the data
generated from the calibration set. Calibration sets are traditionally designed in
concentration space using experimental design plan. Traditional calibration sets are prone
to have redundant samples while simultaneously lacking necessary samples for a
successful calibration model. Traditional calibration sets are also developed based on
generic design. Similar calibration designs are followed for different spectroscopic
techniques and different formulations. Such a calibration strategy lacks the optimizing
capability to be technique and formulation specific. A new calibration strategy was
developed for designing an NIR calibration set for quantitative analysis of tablets.
Following this strategy, NIR calibration sets were designed in spectral space instead of
concentration space. The pure component NIR spectra of a tablet formulation were used
to define the spectral space of that formulation. The performance of this strategy was
compared with commonly employed experimental design approaches to calibration
development. The comparisons were conducted on single API (Active Pharmaceutical
Ingredient) and multiple API formulation to quantify model drugs using NIR
spectroscopy.
In the single API formulation, the comparison was based on a system to quantify a model
drug, Acetaminophen, in pharmaceutical compacts using NIRS. A 2-factor full factorial
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design (Acetaminophen with 5 levels and MCC:Lactose with 3 levels) was used for
calibration development as an example of traditional calibration design. Three replicates
at each design point resulted in a total of 45 tablets for the calibration set. Using the
newly developed spectral based method, 11 tablets were prepared for the calibration set.
Partial least squares (PLS) models were developed from respective calibration sets.
Model performance was comprehensively assessed based on the ability to predict
Acetaminophen concentrations in multiple prediction sets. One prediction set contained
similar information to calibration set while the other prediction sets contained different
information from calibration set in order to assess the model accuracy and robustness.
In multiple API formulation, NIRS was used to develop a quantitative method for a
model drug containing two APIs as Acetaminophen and Caffeine. The traditional
calibration design was developed in the concentration space using concentration-based
approach. A full factorial design of experiment was used to vary the APIs concentrations,
each at five levels and excipient concentration ratio at 3 levels. Each tablet was
compressed at three compaction pressures resulting in a total of 225 tablets in the
calibration set. Three other calibration sets were also developed using traditional optimal
experimental designs (central composite, D-Optimal and I-Optimal designs). A
calibration set of 33 design points was developed from each experimental design.
Another calibration set containing 33 samples was developed in the spectral space
following the spectral space based method. Partial Least Square (PLS) models were
developed from the respective calibration sets to predict APIs concentrations in an
independent test set. This chapter aims at comparing the performance of the spectral
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calibration sets with traditionally developed calibration sets. The experimental details and
results of these comparative studies are provided in the following sections.

3.2 Single API formulation
The single API formulation described in chapter 2 was used for this study. The single API
formulation contained a model drug Acetaminophen and four excipients such as
Microcrystalline cellulose (MCC), spray dried Lactose, Hypromellose and Magnesium
stearate. The target formulation was set as Acetaminophen (27.3% w/w), MCC (34.15%
w/w), Lactose (34.15% w/w), HPMC (3.9% w/w) and MgSt (0.5% w/w). A traditional
full factorial calibration design and a spectral calibration design were used to develop
quantitative NIR method for this formulation to predict Acetaminophen concentration in
pharmaceutical tablets. The prediction performances of the respective calibration models
were compared to evaluate the utility of the spectral design strategy.
3.2.1 Material and Methods
3.2.1.1

Full factorial Calibration

The traditional calibration design was a 5 by 3 level, 2-factor full factorial design.
Samples were prepared in the laboratory. The composition of these samples is provided in
Table 3-1. The factors were Acetaminophen concentration (% w/w) and MCC to Lactose
ratio. Each design point was replicated three times (45 samples total). The use of a full
factorial design of experiment for the calibration set provided orthogonality between the
active ingredient and the excipient ratios.
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Acetaminophen

Hyprome
-llose

Intragranular
Lactose

Microcrystalline
cellulose

Extragranular
Lactose

Magnesium
Stearate

1

19.11

2.73

5.46

51.77

20.43

0.50

2

23.21

3.32

6.63

48.65

17.70

0.50

3

27.30

3.90

7.80

45.53

14.97

0.50

4

31.40

4.49

8.97

42.41

12.24

0.50

5

35.49

5.07

10.14

39.29

9.51

0.50

6

19.11

2.73

5.46

38.83

33.37

0.50

7

23.21

3.32

6.63

36.49

29.86

0.50

8

27.30

3.90

7.80

34.15

26.35

0.50

9

31.40

4.49

8.97

31.81

22.84

0.50

10

35.49

5.07

10.14

29.47

19.33

0.50

11

19.11

2.73

5.46

25.89

46.31

0.50

12

23.21

3.32

6.63

24.33

42.02

0.50

13

27.30

3.90

7.80

22.77

37.73

0.50

14

31.40

4.49

8.97

21.21

33.44

0.50

15

35.49

5.07

10.14

19.65

29.15

0.50

Design
#

Table 3-1. Composition (% w/w) of the full factorial calibration set
Granules of Acetaminophen (Mallinckrodt Inc., Raleigh, NC, USA), Hypromellose
(HPMC; Pharmacoat 606, Shin-Etsu Chemical Co. LTD, Tokyo, Japan) and intragranular Lactose (modified spray-dried; Foremost Farms USA, Rothschild, WI, USA)
were manufactured using a fluid bed processor (model WSG 5, Glatt, Binzen, Germany).
Granules, Microcrystalline cellulose (MCC; Avicel PH 200, FMC Biopolymer,
Mechanicsburg, PA, USA) and Lactose (modified spray-dried; Foremost Farms USA,
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Rothschild, WI, USA) were mixed in a bin blender for 15 min. Magnesium stearate
(Fisher Scientific, Waltham, MA, USA) was added to this blend and blended for an
additional 2 min. Tablets were compressed at lab scale on a Carver Automatic Tablet
Press (Model 3887.1SD0A00, Wabash, IN, USA) at 5500 lb force using a 13 mm die and
flat-faced punches. The target tablet weight was 700 mg. The manufacturing steps were
tested to produce reliable tablets and reported in a previous study [174].
3.2.1.2

Spectral Design

The preparation method of the spectral design is described in section 2.2 in chapter 2. The
spectral calibration set contained 11 tablets. The composition of these 11 tablets is given
in Table 2-1 in chapter 2. The spectral design samples were prepared by direct
compression. All the components, Acetaminophen, MCC, Lactose, HPMC and Mg
stearate for each design point were weighed and placed in a 10 ml scintillation vial. The
ingredients were mixed by rotating the scintillation vial. The intra tablet homogeneity
was less of a concern due to the large spot size (~10 mm) of the NIR instrument. Tablets
were compressed on a Carver Automatic Tablet Press (Model 3887.1SD0A00, Wabash,
IN, USA) at 5000 lb force using a 13 mm die and flat-faced punches. The target tablet
weight was 700 mg.
3.2.1.3

Prediction sets

Multiple prediction sets (3 sets) were used to evaluate the performance of the traditional
calibration design and spectral calibration design. The first prediction set tablets were
prepared at lab scale whereas the other two prediction sets were prepared at the
manufacturing scale.
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3.2.1.4

Lab scale prediction

The first prediction set (prediction set 1) was developed using the same full factorial
design as used for the traditional calibration set; containing 45 samples at five levels of
Acetaminophen and 3 levels of MCC:Lactose ratio. These samples were prepared using
the same method as calibration set. Granules of Acetaminophen, Lactose and HPMC
were prepared and then compressed with MCC and MgSt at lab scale on a Carver
Automatic Tablet Press (Model 3887.1SD0A00, Wabash, IN, USA) at 5000 lb force using
a 13 mm die and flat-faced punches. The target tablet weight was 700 mg.
3.2.1.5

Manufacturing scale prediction

The second and third prediction sets were prepared at manufacturing scale. Prediction set
2 was prepared by varying the Acetaminophen concentration at 3 levels and keeping the
MCC:Lactose ratio constant. A set of 20 tablets was collected from each Acetaminophen
level, yielding 60 tablets for this set. Four batches of tablets were prepared using this
design, resulted in 240 tablets. A total of 239 samples were used in subsequent analysis,
after the accidental destruction of one tablet. Intentional variation resulting from
manufacturing scale was introduced in prediction set 2 to challenge the calibration set in
presence of unexpected variance. The target composition was used to create two
additional batches for the prediction set 3. Tablets were compressed on a weekly basis for
8 weeks at the target composition. A set of 20 tablets were collected each week yielding
160 tablets for prediction set 3. These tablets served as the real time prediction samples.
At the manufacturing scale, after the granulation and blending steps described in the full
factorial design section, tablets were compressed on a 38-station rotary tablet press
(Elizabeth-Hata International, Inc., North Huntingdon, PA, USA) using round beveled
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punches, 3/8 in. (9.5 mm) in diameter. The target tablet weight was 350 mg and the target
breaking force was 8 kp.
3.2.1.6

Spectral collection and reference measurements

NIR reflectance measurements for both sides of each compact were collected using a
bench top scanning monochromator instrument (XDS Rapid Content Analyzer, FOSS
NIR Systems, Inc., Laurel, MD, USA) after tablets reached stable dimensions
(viscoelastic relaxation). Spectra corresponding to each side of a compact were averaged
to give one spectrum per compact. Acetaminophen reference values for compacts from all
data sets except the spectral design were determined using High Pressure Liquid
Chromatography (Waters Alliance 2790, Milford, MA, USA), followed by UV detection
(Waters 2487). Gravimetric measurement was used as reference for the spectral design
compacts.
3.2.1.7

Modeling strategy

Two calibration models were developed, one from the 45 tablets of the full factorial
design and another from the 11 tablets of the spectral design. Both calibration models
were developed from the lab scale tablets only. To compare calibration model
performance between the full factorial set designed in concentration space and the set
designed in spectral space, model performance was assessed for lab (prediction set 1
containing similar information as calibration) and manufacturing scale predictions
(prediction sets 2 and 3 containing different information from calibration).
Principal Component Analysis (PCA) was used for spectral investigation and Partial
Least Squares (PLS) regression was used to develop the calibration models. The NIPALS
algorithm was employed. All calculations were performed with MATLAB 2011a (The
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Mathworks, Natick, MA, USA) equipped with the PLS_Toolbox v. 7.9.3 (Eigenvector
Research Inc., Wenatchee, WA, USA).
3.2.1.8

Model evaluation and design comparison parameters

Comparison of the performance of different calibration designs requires the evaluation of
the resulting models. The full factorial and spectral design were compared based on their
model predictive performance. Root mean squared error (RMSE) was used to evaluate
the model predictive performance in the calibration (RMSEC) and prediction sets
(RMSEP). The RMSEPs were separated into bias and Standard Error of Prediction (SEP).
The bias and SEPs of the two models (one from full factorial and the other from spectral
design) were compared using 95% t confidence interval around the bias difference and
ratio of SEPs respectively; following the method outlined by Fearn et al. and adapted by
Bondi et al [9, 176]. The 95% confidence interval was calculated based on the following
equation
𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵1 − 𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵2 ± 𝑡𝑡𝑛𝑛−1,0.025 ∗ 𝑆𝑆𝑒𝑒

(3.1)

Where, 𝑆𝑆𝑒𝑒 is the standard error of estimated difference and calculated based on the
following equation,

∑𝑛𝑛 (𝑑𝑑𝑖𝑖 − 𝑑𝑑̅ )2
𝑆𝑆𝑒𝑒 = � 𝑖𝑖=1
𝑛𝑛 ∗ (𝑛𝑛 − 1)

(3.2)

Here, 𝑑𝑑𝑖𝑖 represents the difference in residuals for sample “i” estimated by models being
compared and 𝑑𝑑̅ represents the mean difference in residuals for two models. The biases
between two models were considered significantly different only if the confidence
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interval for bias difference did not contain zero. The confidence interval for SEP ratio
was calculated based on equation (3.3) [9, 176],

Where,

and,

𝑆𝑆𝑆𝑆𝑆𝑆1 1
𝑆𝑆𝑆𝑆𝑆𝑆1
× 𝑎𝑎𝑎𝑎𝑎𝑎
× 𝐿𝐿
𝑆𝑆𝑆𝑆𝑆𝑆2 𝐿𝐿
𝑆𝑆𝑆𝑆𝑆𝑆2

𝐿𝐿 = �K + �(𝐾𝐾 2 − 1)
K=1+

2
2 (1 − 𝑟𝑟 2 ) ∗ 𝑡𝑡𝑛𝑛−2,0.025
𝑛𝑛 − 2

(3.3)

(3.4)

(3.5)

Here, r represents the correlation co-efficient between the residuals. The SEPs between
two models were considered significantly different only if the confidence interval of SEP
ratio did not contain one. The prediction performances between the two models were
considered significantly different if the bias, or SEPs, or both were significantly different
between the models being compared.
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Figure 3-1. Raw data for two calibration sets, solid line (-) represents the full
factorial design calibration samples and broken line (--represents the spectral design
calibration samples.

3.2.2 Results
3.2.2.1

Spectral investigations

Figure 3-1 illustrates the raw NIR spectra of the two calibration sets, traditional full
factorial and spectral design calibration set. Prediction sets prepared at the manufacturing
scale (prediction set 2 and 3) exhibited a baseline shift compared to the lab scale samples
(data not shown). The observed differences in baseline were attributed to shape, density
and hardness differences between the lab and manufacturing samples. Density differences
in the samples are known to cause baseline shift in NIR spectra [177, 178]. Figure 3-2
illustrates the score plots of PCA analysis of the preprocessed spectra from two
calibration sets and three prediction sets (total 500 spectra). Multiplicative scatter
correction (MSC) followed by Savitzky Golay 1st derivative in a second order polynomial
fit over a window size 19 was used as the spectral processing technique. Other
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preprocessing methods showed similar results in the PCA analysis. The 95% confidence
interval was dominated by the prediction set samples (444 out 500 tablets). Full factorial,
spectral design and prediction set 1 had similar variance explained by PC1 and PC2 and
were grouped together by PC scores except for the fact that the full factorial design and
prediction set 1 tablets had wider range of variance compared to the spectral design
tablets. The full factorial design and prediction set 1 tablets were prepared at the exact
same design points and showed similar projections in the PC space. Their wider spectral
variance was attributed to the wider range of the excipient concentrations and physical
variance compared to the spectral design tablets. The prediction sets prepared at the
manufacturing scale (prediction set 2 and 3) grouped separately in the scores plot due to
differences in the physical properties such as density, hardness, surface texture and mass.

Figure 3-2. Projection of the full factorial calibration, spectral calibration and three
prediction sets samples on the PC1 and PC2 of the combined PC space.
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The different ranges of score values between the two calibration designs and the separate
group of scores for manufacturing scale prediction sets were largely spanned in PC2
whereas all the samples had similar score values in PC1. It is critical for the calibration
and prediction samples to have similar score values in the principal components that
explain analyte concentration variation to achieve acceptable predictive performance. In
this study, PC1 primarily explained the concentration variation of Acetaminophen (the
absolute correlation co-efficient between Acetaminophen concentration and scores on
PC1 was 0.9125). The different projections on PC2 did not affect the prediction at a large
extent due to poor correlation with the Acetaminophen concentration (the absolute
correlation co-efficient between Acetaminophen concentration and scores on PC2 was
0.2525).
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Figure 3-3. Measured vs predicted plot of Acetaminophen concentration for full
factorial calibration and prediction set 1 (upper panel). Measured vs predicted plot
of Acetaminophen concentration for spectral calibration and prediction set 1 (lower
panel).
3.2.2.2

Model optimization

Models developed from each calibration design were independently optimized. The range
of the wavelength used was 1100-2500 nm for both calibration designs. The preprocessing and model optimization focused on maximizing the potential to predict
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samples manufactured at different scales. Multiplicative Scatter Correction (MSC)
followed by Savitzky-Golay first derivative (window size 19 and second polynomial
order) and mean centering was used as the optimized preprocessing technique. Other
preprocessing methods were also tried, but scatter correction followed by derivatives
provided better predictive performance for the calibration models. This preprocessing
technique minimized the baseline shift caused by scale variation in the tablet preparation
methods between calibration and prediction sets. However, the spectral difference could
not be completely removed as evident by the different projections of calibration and
predictions sets (after applying same preprocessing technique) on the PC score space in
Figure 3-2. Selection of the latent variables is critical for PLS model performance. A
minimum number of latent variables with acceptable prediction performance was
selected. The optimum numbers of latent variables for the spectral and full factorial
calibration design sets were two (spectral) and three (full factorial), respectively.
3.2.2.3

Prediction performance

The calibration models from the full factorial and spectral design were used to predict the
Acetaminophen concentrations in prediction sets. Prediction set 1 samples were prepared
at the lab scale; and samples for prediction sets 2 and 3 were prepared at the
manufacturing scale.
3.2.2.4

Lab scale prediction

Figure 3-3 shows the reference vs prediction plot for full factorial and spectral designs.
The model developed from the full factorial design predicted Acetaminophen in
prediction set 1 with RMSEC and RMSEP value of 1.13% and 1.34%, respectively.
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Figure 3-4. Measured vs predicted plot of Acetaminophen concentration for full
factorial calibration and prediction set 2 (upper panel). Measured vs predicted plot
of Acetaminophen concentration for spectral calibration and prediction set 2 (lower
panel).
The model developed from the spectral design had a lower RMSEC of 0.89% but higher
RMSEP of 2.70 %. The improved prediction performance for the full factorial design was
due to the chemical and physical similarity between prediction set 1 samples and the full
factorial design. The spectral design samples had compositional and physical
dissimilarities from prediction set 1 that include composition and preparation method.
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The full factorial design and prediction set 1 samples were prepared using wet
granulation method whereas the spectral design samples were prepared using dry mixing
method.
3.2.2.5

Manufacturing scale prediction

Robustness was tested for models developed from the full factorial and spectral designs.
Samples with new sources of variation (manufacturing scale) were predicted using the
models developed at the calibration step (lab scale) to test the robustness. Figure 3-4
shows the reference vs prediction plot of Acetaminophen concentrations in prediction set
2 for both models. The model developed from the full factorial design had a RMSEP of
4.68 % compared to the RMSEP of 2.21 % for the model developed from spectral design.
A bias is observed in the prediction of samples at the top figure of Figure 3-4 for the full
factorial design model. The bias was due to an interference introduced by the scale of the
sample preparation method. No significant bias was observed while predicting these
samples by the model developed from spectral design as shown at the bottom of Figure
3-4.
Figure 3-5 shows the reference vs prediction plots of prediction set 3, containing 160
tablets. This prediction set was prepared at the target concentration to mimic routine
production. Full factorial design model had a higher RMSEP of 5.05 % compared to the
RMSEP of 1.68 % of the spectral design model. Table 3-2 shows the prediction results
for both full factorial and spectral design.
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Figure 3-5. Measured vs predicted plot of Acetaminophen concentration for full
factorial calibration and prediction set 3 (upper panel). Measured vs predicted plot
of Acetaminophen concentration for spectral calibration and prediction set 3 (lower
panel).
3.2.2.6

Design comparison

The predictive performances of the optimized models from the traditional concentration
based full factorial design and the spectral design were compared. Figure 3-6 shows the
confidence intervals for bias and SEP comparison between the optimized models. The
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two models were significantly different in terms of both bias and SEP. Full factorial
design predictions had a lower bias for the lab scale samples (prediction set 1) and
higher

bias

for

the

manufacturing scale samples
(prediction set 2 and 3),
compared to the spectral
design
comparing

model.
SEPs,

While
full

factorial design had lower
SEP for prediction set 1 and
3 compared to the spectral
design. For prediction set 2,
the spectral design had a
lower SEP. Although full
factorial design had a lower
SEP, it had a higher RMSEP

Calibration Design

Spectral design

Full factorial design

No. of samples

11 samples

45 samples

No. of latent variable

2 LV

3 LV

RMSEC % (w/w):

0.889

1.133

RMSECV % (w/w):

1.625

1.288

RMSEP % (w/w):

2.701

1.342

Prediction Bias

1.270

0.071

SEP

2.384

1.340

RMSEP % (w/w):

2.212

4.682

Prediction Bias

-0.578

-3.938

SEP

2.135

2.531

RMSEP % (w/w):

1.676

5.046

Prediction Bias

-0.786

-4.882

SEP

1.480

1.274

Prediction Set 1

Prediction Set 2

Prediction Set 3

Table 3-2. Model performance comparison between
two methods of experimental design; spectral and full
factorial

due to the higher bias in the
prediction sets. For all the manufacturing scale predictions, full factorial design always
had a higher RMSEP compared to the spectral design. The spectral design approach was
found to be more robust than the traditional full factorial design in spite of having fewer
calibration samples.

90

Figure 3-6. Confidence interval for bias (A) and standard error of prediction (B)
comparison between full factorial design and spectral design for prediction sets
analysis.
3.2.2.7

Discussion

The main objective of this project was to develop and test a spectral design method and
compare it with a traditional full factorial design method for NIR spectroscopic
multivariate calibration. The use of a traditional design, such as full factorial, in
concentration space is a common practice for calibration sample preparation. However,
this practice is inefficient and includes redundant information in the calibration model.
The spectral design approach offers an efficient enhancement for NIR calibration
development by using pure component spectra. Information about the pure component
spectra was used to define an orthogonal spectral space for the formulation and identify a
set of critical samples necessary for successful calibration model development.
Designing a calibration sample set in this orthogonal spectral space was found to be an
efficient approach for developing an NIR calibration method for pharmaceutical tablets.
Fewer samples were required when this approach was used. A reduction of 75% in raw
material requirement was demonstrated (11 vs 45) while achieving similar (if not
improved) predictive performance compared to the traditional full factorial design.
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Considering the RMSEPs in manufacturing scale samples, the spectral design was found
to be more robust than the full factorial design. The full factorial design was very
sensitive to latent variable selection, scale variation and prone to biased prediction. The
sensitivity of this concentration based design was due to the information that is unique to
the calibration set and not always exists in the prediction sets. Fitting this information
into the model introduced biased predictions in the presence of new information (lack of
robustness). Biased corrected prediction performance (SEP) of the full factorial design
were found to be similar to the spectral design for manufacturing samples.
The spectral calibration set showed similar SEP to the full-factorial calibration set due to
similar span of Acetaminophen concentration between two calibration sets. The fullfactorial calibration set contained wider range of excipient variation compared to the
spectral calibration set, however, such information was redundant for calibration
performance. The limited excipient variation in the spectral calibration set was
representative of the additional excipient variation in the full factorial calibration set.
Prediction results at lab scale emphasized the similarity between the calibration and
prediction samples. For the full factorial design, calibration and lab samples came from
the same exact design points and were prepared using the same methodology. As
expected, the calibration model was very accurate in predicting this set of samples. In
spectral design method, errors from the lab scale predictions based on the spectral design
model were within errors observed in other prediction sets due to the inherent robustness
of the design.
Selection of the latent variables is critical to model performance. However, in practice,
this selection process occurs only during model development. Once the model is
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developed and optimized, further investigations of predictive performance are conducted
based on that optimized model only. The number of latent variable does not change
during the assessment of prediction performance. Following this practice, the
comparative analyses were performed between the optimized models with fixed latent
variables from respective designs.
3.2.3 Conclusion
A technique for designing a calibration set using pure component spectra for NIR
spectroscopic calibration method was described and tested for quantitative analysis of
pharmaceutical tablets. This technique was found to be efficient in terms of sample
requirements compared to the traditional (full factorial) concentration based technique. A
reduced number of calibration samples yielded a model with improved predictive
capabilities for this individual system. In particular, a calibration model developed in
spectral space demonstrated improved robustness in presence of variation introduced by a
change of manufacturing scale, with respect to a model developed using full factorial
design.
Calibration model performance can be highly system specific. The improved prediction
performance of the spectral calibration set is not expected for every formulation.
However, it is expected that the spectral calibration set will provide equivalent prediction
performance with fewer number of samples while comparing with traditional calibration
sets. It is also expected that the spectral calibration set will provide improved prediction
performance with an equal number of calibration samples while comparing with
traditional calibration sets. In general, spectral calibration is expected to be efficient in
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sample number compared to the traditional calibration sets. Such efficiency is more
critical for multiple API formulation, since the traditional calibration sets for multiple
API requires larger calibration sets compared to the single API. The following section
describes a comparative study conducted on multiple API system to assess the
performance of spectral calibration set and compare with traditional calibration sets.
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3.3 Multiple APIs formulation
The utility and performance of the spectral calibration technique was assessed for a multiple API
formulation. The performance of the spectral calibration set (33 calibration samples) was
compared with traditional full factorial calibration set of larger size (225 calibration samples) as
well as traditional optimal calibration sets of similar sizes (33 calibration samples) to further
investigate the applicability of the newly developed spectral calibration strategy. The multiple
API formulation described in section 2.3 in chapter 2 was used for this study. The multiple API
formulation contained two model drug Acetaminophen (Acetaminophen) and Caffeine and four
excipients such as Microcrystalline cellulose (MCC), spray dried Lactose, Crosscarmellose Na
and Magnesium stearate. A full factorial calibration design and three optimal calibration designs
were used as examples of traditional calibration set. A spectral calibration design was used to
develop another calibration set. All these calibration sets were used to develop quantitative NIR
methods for this formulation to predict Acetaminophen and caffeine concentration in
pharmaceutical tablets. The prediction performances of the respective calibration models were
compared to evaluate the utility of the spectral design strategy.
3.3.1 Material and Methods
3.3.1.1

Full factorial Calibration

The model drug product contained two APIs as Acetaminophen (Mallinckrodt Inc., Raleigh, NC,
USA) and anhydrous Caffeine (Spectrum Chemical Mfg. Corp., New Brunswick, NJ, USA), and
four excipients as Microcrystalline cellulose (MCC; Avicel PH 200, FMC Biopolymer,
Mechanicsburg, PA, USA), Lactose (modified spray-dried; Foremost Farms USA, Rothschild,
WI, USA), Crosscarmellose sodium (Crosscarmellose Na, Spectrum Chemical Mfg. Corp., New
Brunswick, NJ, USA) and Magnesium stearate (Fisher Scientific, Waltham, MA, USA). The
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target formulation was set as Acetaminophen (31.25% w/w), Caffeine (4.05% w/w), MCC
(37.32% w/w), Lactose (24.89% w/w), Crosscarmellose Na (2% w/w) and MgSt (0.5% w/w).
The traditional calibration design was developed using a 4-factor full factorial design. The
factors were Acetaminophen concentration, Caffeine concentration, MCC: Lactose ratio and
compaction force. Each of the APIs (Acetaminophen and Caffeine) concentrations was varied at
five levels and other two factors (MCC: Lactose ratio and compaction force) were varied at three
levels resulting in 225 design points in the traditional full factorial calibration set. A test set was
developed by varying all the factors except MCC: Lactose ratio, each at three levels resulting in
total 27 design points. Table 3-3 provides the details of the full factorial calibration and test
design.
Design Factors
Calibration Design
(5x5x3x3)
225
samples

Test Design
(3x3x3)
27
samples

Acetaminophen
(%)
Caffeine (%)

Design Levels
L.C.40%
L.C.80%

L.C.20%
L.C.40%

L.C.
L.C.

L.C.+20% L.C.+40%
L.C.
+40%

L.C.+80%

MCC/Lac

1

1.5

2

Force (lb)

4000

5000

6000

Acetaminophen
(%)

L.C.-35%

L.C.

L.C.+35%

Caffeine (%)

L.C.-70%

L.C.

L.C.+70%

Force (lb)

4000

5000

6000

MCC/Lac

1.5

Table 3-3. Full-factorial calibration design and test set
Tablets were individually prepared by direct compression. All the components for a single design
point were weighed using a digital weighing machine (Data Range, Model No. AX504DR,
Mettler Toledo) and placed in a 10 ml scintillation vial. The ingredients were mixed in a bin
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blender (L.B. Bohle LLC, Warminster, PA, USA) for 10 mins followed by a high shear mixing
using a vortex machine (Vortex-2 Genie, Model G-560, Scientific Industries, IN, USA). The final
mixing was done in the bin blender before compression. Additional blending steps were included
in the process to ensure well mixing of the low dose caffeine. Tablets were compressed on a
Carver Automatic Tablet Press (Model 3887.1SD0A00, Wabash, IN, USA) at respective
compression forces (4000/ 5000/ 6000 lb) using a 13 mm die and flat-faced punches. The target
tablet weight was 700 mg.
3.3.1.2

Optimal calibration designs

Three optimal calibration designs were developed in this study as examples of traditional
calibration designs. The factors of the designs were Acetaminophen concentration, Caffeine
concentration, MCC: Lactose ratio and compaction force. The CCD design was developed by
creating a CCD structure containing 11 design points in the concentration space and varying the
compaction force at three levels for each design point resulting a total of 33 design points in the
calibration set. The D-Optimal and I-Optimal designs were developed using JMP (v. 12, SAS,
Cary, NC, USA). A set of 33 design points was selected from a full factorial space such that the
determinant of the information matrix is maximized (D-Optimal) and average prediction
variance is minimized (I-Optimal). All the calibration design tablets were subsets of the fullfactorial design described earlier.
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Figure 3-7. Experimental procedures for designing a calibration set in spectral space
3.3.1.3

Spectral Design

The preparation method of the spectral design of multiple API is described in section 2.3 in
chapter 2. Figure 3-7 illustrates the procedure for designing a calibration set in the spectral space.
In summary, the pure component tablets (six tablets) and one tablet at the target composition
were compressed at the middle compression force (5000 lb) using a Carver Automatic Tablet
Press. A spectrum at the target composition was used for calculating model tablet scores (target
scores) on the orthonormal basis of pure component spectra. A 6-factor full factorial design with
5 levels per factor was calculated in the orthogonal spectral space where the “model tablet”
scores were set as the center of the design. The full factorial structure resulted a total of 15625
(56) design points. The compositional requirements for the target design were calculated using
eq. 3.6 (same as equation 2.8).
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𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂

𝐂𝐂𝐮𝐮∗𝐤𝐤

∗ 𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑n
𝐤𝐤∗𝐤𝐤

𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬

= 𝐓𝐓𝐮𝐮∗𝐫𝐫

𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏 𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬

∗ (𝐏𝐏𝐤𝐤∗𝐧𝐧

𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏 𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜 𝐛𝐛𝐛𝐛𝐛𝐛𝐛𝐛𝐛𝐛 −𝟏𝟏

∗ 𝐖𝐖𝐧𝐧∗𝐤𝐤

)

(3.6)

Here, C is the compositional matrix for the targeted score design having sample size “u”, R is the
rotational matrix, T is the target design in the score space, P is the pure component spectra, W is
the basis vector set and r = k (number of latent variables = number of components).
After determining the compositional requirements ‘C’ of the target design, the target design
spectra were simulated using the compositional requirements, the pure component spectra and
the rotation matrix. The Kennard Stone algorithm was used to select 30 design points in the PCA
score space of the target design spectra (Spectral Design) [132]. The composition of these 30
design points is provided in Table 2-2 in section 2.3 of chapter 2. The target formulation was
replicated 3 times resulting in 33 design points in the spectral design. The 33 tablets of the
spectral design were prepared by direct compression on Carver Automatic Tablet Press using a
13 mm die and flat-faced punches. The target tablet weight was 700 mg. The compression forces
were selected such that the correlation between compression force variation and concentration
variation of each component is minimal and variance in compaction force is maximal.
3.3.1.4

Experimental control

Intra homogeneity of the tablets can be critical in case the respective spectrum represents only a
portion of the tablet. The blending was performed in three steps in a bin blender followed by
high shear mixing and subsequent blending to avoid inhomogeneity of the tablet. The intra
homogeneity of the tablet was analyzed to test the appropriateness of the blending process. A set
of 15 tablets were selected from the 225 calibration samples. NIR images of these tablets were
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collect by NIR chemical imaging system (MatrixNIR, Malvern Inc., MD) with 0.5× objective
lens (field of view 1.72 cm × 2.15 cm). An integration time of 256 ms and a count of 16 co-adds
were utilized throughout the image collection of all 15 tablets. The wavelength range was from
1050 to 1620 nm with a 5 nm interval. A typical Classical Least Square approach was used to
develop a quantitative method for image analysis.
All the materials were stored in room temperature and relative humidity. Anhydrous caffeine was
reported to be stable at 75% RH for 7 weeks [173]. No hydration and anhydrous caffeine was
expected considering lower room RH (~60%) and shorter storage time and analysis. The tablets
were stored for 2 weeks to allow viscoelastic relaxation. Two weeks duration was set based on a
previous study [174].
Solid fraction of each of the 225 tablets was calculated based on the following equation
to test the appropriateness of the compaction force range. A wide range of solid fraction was
expected as a result of compaction force variation.
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 𝑜𝑜𝑜𝑜 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 =
3.3.1.5

𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑
�𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑

(3.7)

Spectral collection and reference measurements

NIR reflectance measurements for both sides of each compact were collected using the bench top
scanning monochromator instrument (XDS Rapid Content Analyzer, FOSS NIRSystems, Inc.,
Laurel, MD, USA) after tablets reached stable dimensions (viscoelastic relaxation). Spectra
corresponding to each side of a compact were averaged to give one spectrum per compact.
Gravimetric measurement was used as reference for all tablets.
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In the gravimetric method, all the weights of the individual chemical components at each design
point were recorded from digital weighing machine (Data Range, Model No. AX504DR, Mettler
Toledo). The tablet weights were recorded after compression using the same digital weighing
machine. The concentrations % (w/w) were calculated for APIs from the respective individual
weights and tablet weights, and used as reference values for model development.
3.3.1.6

Modeling strategy and optimization

Quantitative models were developed using Partial Least Squares (PLS) modeling technique in
MATLAB 2015a environment (The Mathworks, Natick, MA, USA) using PLS_Toolbox v. 7.9.3
(Eigenvector Research Inc., Wenatchee, WA, USA). Data independent spectral preprocessing
techniques were used to optimize model performance. Two calibration models were developed
for each API, one from the 225 tablets of the full factorial design and another from the 33 tablets
of the spectral design. Models developed from each calibration design were independently
optimized for each API. The processing techniques and loading vectors were selected
independently. Selection of the loading vector is critical for PLS model performance. Latent
variables were chosen based on a parsimonious approach. A minimum number of latent variables
with an acceptable performance level was selected. Model performance was assessed based on
the prediction of Acetaminophen and Caffeine concentration in calibration and test set tablets.
3.3.1.7

Model evaluation and design comparison parameters

Comparison of the performance of different calibration designs requires the evaluation of the
resulting models. Root mean squared error (RMSE) was used to evaluate the model predictive
performance in an independent test sets (RMSEP). A two-way analysis of variance (ANOVA)
test was performed to compare the prediction errors of the full factorial and spectral calibration
designs for each API [22]. The underlying model for the ANOVA analysis was following, where
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index ‘i’ refers to the calibration model and index ‘j’ refers to the sample number. The symbol 𝛼𝛼𝑖𝑖

and 𝛽𝛽𝑗𝑗 refer to the effect of model number i and sample number j on prediction error,

respectively.

(𝑦𝑦�𝑖𝑖𝑖𝑖 − 𝑦𝑦𝑖𝑖𝑖𝑖 )2 = 𝜇𝜇 + 𝛼𝛼𝑖𝑖 + 𝛽𝛽𝑗𝑗 + 𝑒𝑒𝑖𝑖𝑖𝑖

(3.8)

The calibration models are considered significantly different in terms of prediction performance,
if the calibration model parameter 𝛼𝛼 is found to be significant in the ANOVA analysis.

Robustness of the calibration models from respective calibration designs were tested based on
cross design prediction. During cross design prediction, calibration model was developed from
spectral calibration set and used to predict the API concentration in traditional calibration sets.
Subsequently, calibration models were developed traditional calibration sets and used to predict
the API concentration in spectral calibration set. The objective was to assess the prediction
performance of a calibration model in presence of new test structure. Robustness of the
calibration model was tested for both Acetaminophen and Caffeine PLS model.
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Figure 3-8. Quantitative predictions of NIR images of tablet at target formulation and
center compaction force.

3.3.2 Results and Discussion
3.3.2.1

Experimental control

Figure 3-8 shows the quantitative predictions of APAP and caffeine at both sides of the tablet
prepared at the target formulation and center compaction force. The quantitative results were
obtained from the NIR images of the tablet and CLS model of the pure component images. It was
shown that the APAP and caffeine were homogeneously distributed in the tablet. The red circle
shows the spot size (10 mm) of the NIR diffuse reflectance measurement. It was shown that the
NIR diffuse reflectance measurement reflects majority of the tablets due to large spot size. The
criticality of the intra tablet homogeneity was minimized by such large spot size.
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Figure 3-9. Solid fraction of tablets compressed at different compaction forces.
Figure 3-9 shows the solid fraction measurements of 75 tablets at each compaction force. The
compaction force range (4000 lb-6000 lb) results in a wide range of solid fraction (0.83-0.92).
This range of solid fraction was able to produce wide range of spectral variation related to tablet
density.
3.3.2.2

Calibration design comparison between full factorial and spectral calibration sets

Figure 3-10 shows the tablet compositions for the traditional full factorial calibration design,
spectral calibration design and test design. The resultant compositions from the spectral design
approach contained similar ranges of Acetaminophen and Caffeine concentrations. Spectral
design had wider range of excipient variation compared to the traditional full factorial design.
The wider excipient ranges were the result of distant design points in the target score space, that
could only be obtained by large variation in the excipient concentrations. Although wide
concentration range is considered to increase calibration model robustness, it can introduce nonlinearity and affect prediction performance. Good fit is almost guaranteed for a small set with
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narrow region. Moreover, a typical production batch is manufactured at the target composition
and large excipient variation is not expected. So, it is recommended to use two calibration sets,
one for coarse prediction of concentration (global calibration set) and the other for precise and
accurate prediction in the critical range (local calibration set). This technique is known as
bracketing [47]. However, maintaining two calibrations and selecting which one to use is
challenging. A single robust calibration capable of predicting at the critical range would be
advantageous over the bracketing technique. In this study, spectral calibration set containing
large excipient variation was tested for the critical range prediction around target composition.
Successful model performance from the spectral calibration set would offer a single calibration
set with sufficient robustness and accuracy.
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Figure 3-10. Tablet compositions of the traditional full factorial calibration, the spectral
calibration and the test set.
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3.3.2.2.1

Prediction performance

The calibration models from the full factorial and spectral design were used to predict the
Acetaminophen and Caffeine concentrations in the prediction set.
3.3.2.2.1.1 Acetaminophen prediction

Figure 3-11. Calibration model performance for traditional full factorial design during
Acetaminophen prediction
Figure 3-11 shows the calibration performance of the traditional full factorial design for
Acetaminophen prediction in the calibration and test set. Figure 3-11 (right) shows the projection
of the calibration and test samples on the first two loading vectors of the PLS model. The
calibration set and test set had similar spectral variance as indicated by their similar projections
on the first two loading vectors. The calibration set had wider range of scores on LV2 compared
to the test set. This effect was attributed to the wide excipient variation present in the calibration
set.
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Figure 3-12. Calibration model performance for spectral design during Acetaminophen
prediction
The RMSEP for the traditional Acetaminophen calibration was around 1% (w/w) and no
significant bias was observed during prediction. Figure 3-12 shows the calibration performance
of the spectral design for Acetaminophen prediction in the calibration and test set. The score plot
(Figure 3-12 (right)) shows similar projections of the calibration and test set on LV1 and
different projections on the LV2. However, this difference in the scores on LV2 did not affect the
prediction performance due to compensating effect of LV4 on the opposite direction (data not
shown). The information in LV2 and LV4 was majorly attributed to the wide range of excipient
variation in spectral calibration set. The RMSEP was 0.83% (w/w) and no significant bias was
observed. The prediction errors of the full factorial and spectral calibration design for
Acetaminophen prediction was found to be similar in the ANOVA analysis (p value 0.1968).
Table 3-4 provides the details of the calibration models developed from traditional full factorial
and spectral design.
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Traditional
(225 samples)

Spectral
(33 samples)

Preprocessing techniques
X block
Y block

MSC*, Auto scale
Auto scale

MSC*, SG (15,2,1)**, Auto scale
Auto scale

LV

6

4

RMSEC (% w/w)

0.829

1.092

RMSECV (% w/w)

0.867

1.336

RMSEP (% w/w)

0.982

0.832

Bias (% w/w)

0.221

0.115

R2 Calibration

0.991

0.973

R2 Prediction

0.989

0.991

p values (ANOVA)

0.1968

Table 3-4. Model performance comparison between full factorial and spectral
calibration design for quantitative analysis of Acetaminophen

3.3.2.2.1.2 Caffeine prediction

Figure 3-13 shows the calibration performance of the traditional full factorial design for Caffeine
prediction in the calibration and test set. The calibration set and test set had similar spectral
variance; indicated by their similar projections on the first two loading vectors as shown in
Figure 3-13 (right). The score ranges were similar in both latent variable directions as opposed to
the scenario in the Acetaminophen prediction model.
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Figure 3-13. Calibration model performance for traditional full factorial design during
Caffeine prediction
This effect was attributed to the similar ranges of APIs (Acetaminophen and Caffeine)
concentrations between the calibration and test set. The first two loading vectors primarily
explained the direction of variation in Caffeine concentrations even at low dose, due to
maximization of covariance between spectra and Caffeine concentrations. These loading vectors
also explained the direction of variation in Acetaminophen concentrations due to its unique
spectral feature and relatively large dose. The RMSEP for the traditional Caffeine calibration was
0.41% (w/w) and no significant bias was observed during prediction. Figure 3-14 shows the
calibration performance of the spectral design for Caffeine prediction in the calibration and test
set. Similar trend in the score plot Figure 3-14 (right)) was observed as compared to the
traditional calibration design. The first two loading vectors primarily explained the direction of
the variation in APIs concentrations. The RMSEP was 0.41% (w/w) and no significant bias was
observed. The prediction errors of the full factorial and spectral calibration design for Caffeine
prediction were found to be similar in the ANOVA analysis (p value 0.9527). Table 3-5 provides
the details of the calibration models developed from traditional full factorial and spectral design.
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Figure 3-14. Calibration model performance for spectral design during Caffeine prediction.
3.3.2.2.2

Discussion

The main objective of this project was to develop and test a spectral design method and compare
it with a traditional full factorial design method for NIR spectroscopic multivariate calibration
for multiple API system. The use of a traditional design such as full factorial in concentration
space is a common practice for calibration sample preparation. However, this practice is
inefficient and provides redundant information to the calibration model. This effect is
exacerbated for the tablets containing multiple API. The spectral design approach offers an
efficient enhancement for NIR calibration development by using pure component spectra.
Information about the pure component spectra defined an orthogonal spectral space for the
formulation and was used to identify a set of critical samples with necessary compositional
variation for successful calibration model development.
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Traditional
(225 samples)

Spectral
(33 samples)

Preprocessing techniques
X block
Y block

MSC*, Auto scale
Auto scale

MSC*, SG (15,2,1)**, Auto
scale
Auto scale

LV

6

6

RMSEC (% w/w)

0.394

0.261

RMSECV (% w/w)

0.410

0.473

RMSEP (% w/w)

0.406

0.411

Bias (% w/w)

0.087

0.232

R2 Calibration

0.971

0.991

R2 Prediction

0.976

0.979

p values (ANOVA)

0.9527

Table 3-5. Model performance comparison between full factorial and spectral
calibration design for quantitative analysis of Caffeine
Variation in the physico-chemical properties of the tablet (tablet density) was also added into this
study as a potential source of variation for NIR analysis of tablets. The objective was to test the
performance of the spectral calibration design technique in presence of physical variation.
Physical variation was added into the spectral design by minimizing correlation between
composition and compaction pressure to maximize design orthogonality. Physical variation can
also be added into the spectral space by compressing pure components using different
compaction forces. While this effort helps to build robustness against density variation, effect of
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tablet density variation on NIR spectra were also minimized by preprocessing techniques (scatter
correction and derivatives). Both spectral and traditional calibration models were found to be
robust against density variation. However, density variation was added more efficiently in the
spectral design technique (minimizing correlation) compared to the traditional full factorial
technique (replicating each design at different compaction forces).
Designing a calibration sample set in spectral space was found to be an efficient approach for
developing a NIR calibration method for tablets containing multiple API. Fewer samples were
required when this approach was used. A reduction of 85% in raw material requirement was
demonstrated (33 vs 225 samples) while achieving similar predictive performance compared to
the traditional full factorial design.
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Figure 3-15. Tablet compositions of the spectral and traditional calibration designs (filled
circles), and the test set (open circles)
3.3.2.3

Calibration design comparison between optimal and spectral calibration sets

Figure 3-15 shows the tablet compositions for the spectral and traditional designs along with the
test set compositions. The CCD design had maximum resemblance with the test set design. The
other designs have wider range of excipient variation compared to the CCD and test design. The
wide excipient range in the spectral design and traditional optimal designs (D-Optimal and IOptimal) were incorporated to maximize the spectral variance and concentration variance,
respectively.
3.3.2.3.1

Prediction performance

The calibration models from the optimal designs and spectral design were used to predict the
concentration of Acetaminophen and Caffeine in the prediction set.
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3.3.2.3.1.1 Acetaminophen prediction
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Figure 3-16. Calibration model performance of the spectral design and traditional designs
during Acetaminophen prediction.
Figure 3-16 shows the calibration performance of the traditional and spectral calibration designs
for Acetaminophen prediction in the calibration and test set. The traditional calibration sets
(CCD, D-Optimal and I-Optimal) and test set had similar spectral variance as indicated by their
similar projections on the first two loading vectors. For the spectral design, the score plot shows
similar projections of the calibration and test set on LV1 and different projections on the LV2.
Large excipient variation in the spectral design could contributed to the score differences.
However, this difference in the scores on LV2 did not affect the prediction performance due to
its small weight coefficients and minimal contribution to the regression vector and prediction.

114

The ascending order of the prediction error of Acetaminophen (RMSEP) was Spectral design <
CCD < D-Optimal < I-Optimal.
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Figure 3-17. Calibration model performance of the spectral design and traditional designs
during Caffeine prediction.
3.3.2.3.1.2 Caffeine prediction

Figure 3-17 shows the calibration performance of the traditional and spectral calibration designs
for Caffeine prediction in the calibration and test set. All the calibration sets and the test set had
similar spectral variance as indicated by their similar projections on the first two loading vectors.
The score ranges were similar in both latent variable directions as opposed to the scenario in the
Acetaminophen prediction model. This effect was attributed to the similar range of APIs
(Acetaminophen and Caffeine) concentrations between the calibration and test sets. The first two
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loading vectors primarily explained the direction of variation in Caffeine concentrations even at
low dose, due to maximizing the covariance between spectra and Caffeine concentrations. These
loading vectors also explained the direction of variation in Acetaminophen concentrations due to
its unique spectral feature and relatively large dose. The ascending order of the prediction error
of Caffeine (RMSEP) was CCD < Spectral design < D-Optimal < I-Optimal.
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Figure 3-18. Cross design performance of acetaminophen model (left) and caffeine model
(right)
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3.3.2.3.1.3 Assessment of model robustness

Model robustness was assessed by cross design prediction. The calibration model developed
from spectral calibration set was found to be more robust than the calibration models developed
from optimal calibration sets. The robustness between spectral and full factorial calibration set
was found to be similar. Figure 3-18 shows the results of the cross design prediction for both
Acetaminophen (left) and Caffeine (right). The blue bars indicate the prediction errors of the
spectral calibration model while predicting API in traditional calibration sets. The yellow bars
indicate the prediction errors of the traditional calibration model while predicting API in spectral
calibration. The spectral calibration model showed prediction errors similar to the full factorial
calibration model in spite of having fewer sample number (33 vs 225). The full factorial
calibration model was trained with larger sample size resulting in a robust calibration model. The
prediction error was relatively low when a different test structure (spectral calibration set) was
presented in front of the calibration model. The spectral calibration set was robust due to its wide
range of spectral variation built into the calibration set. The CCD and I-optimal calibration
models showed poor prediction performance for both Acetaminophen and Caffeine when a
different test structure (spectral calibration set) was presented. D-optimal calibration model
showed poor prediction performance while predicting Caffeine concentration in spectral
calibration set. The spectral calibration model showed reasonable prediction performance while
predicting Acetaminophen and Caffeine in all of the traditional calibration sets (Full factorial
(FFT), CCD, I-optimal and D-optimal) indicating model robustness against different types of test
set structure as shown in Figure 3-18.
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3.3.2.3.2

Discussion

The main objective of this project was to develop and test a spectral design method and compare
it with traditional calibration design methods for NIR spectroscopic multivariate calibration for
multiple API system. Table 3-6 provides the calibration performances of the spectral and
traditional designs for Acetaminophen and Caffeine. Spectral design and CCD were found to
outperform the optimal designs in terms of prediction performance. The use of a traditional
design in concentration space is a common practice for calibration sample preparation. However,
this practice is inefficient and provides redundant and deleterious information to the calibration
model as seen in the case of D-Optimal and I-Optimal design.

Acetaminophen prediction

Caffeine prediction

Spectral

CCD

DOpt

IOpt

Spectral

CCD

DOpt

IOpt

RMSEC

1.092

1.187

0.758

0.611

0.260

0.286

0.335

0.368

RMSECV

1.336

1.381

1.004

0.882

0.473

0.345

0.456

0.513

RMSEP

0.832

0.893

1.050

1.110

0.410

0.379

0.463

0.481

Bias

0.115

0.259

0.085

0.484

0.232

0.090

0.084

0.174

R2 Cal

0.973

0.967

0.993

0.995

0.991

0.971

0.977

0.974

R2 Pred

0.991

0.991

0.987

0.988

0.979

0.977

0.967

0.975

Table 3-6. Calibration performance of spectral and traditional calibration designs
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The optimality in the concentration space does not guarantee optimality in the spectral space.
This effect is exacerbated for the tablets containing multiple API. In multiple API formulation,
two individual APIs might have respective optimal design spaces that are very different from
each other. However, in the optimal concentration based design, the optimality is defined in a
single compositional space and same weightages are used for all chemical components including
APIs and excipients to generate the optimality criterion (e.g. levels 1,2,3… to calculate Doptimal or I-optimal criterion). The resultant design points of concentration based optimal design
are only indicative of optimal compositional structure but lack critical information specific to
APIs.
The improved performance of the CCD calibration set compared to the other optimal calibration
sets emphasizes the importance of similarity between calibration and prediction set structures.
The calibration model provides improved prediction performance when it encounters known
information in the prediction set. The CCD calibration model was trained on the information that
was available in the prediction set, resulting in improved performance. However, such similarity
is not always guaranteed. The calibration model from CCD calibration set showed poor
prediction performance when a different test structure (spectral calibration set) was presented
during cross design prediction for both Acetaminophen and Caffeine. Although the
recommendation is to include all anticipated variations into the calibration set, there is always a
possibility for the calibration set to encounter new information in the prediction set during model
life cycle. It is advantageous to practice robust modelling technique instead of anticipating
similarity between calibration and prediction set during calibration development.
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3.3.3 Conclusion
A technique for designing a calibration set for NIR spectroscopic calibration method for tablets
containing multiple API was described and tested. The pure component spectral information of
the tablet was used to develop a spectral design method to design the critical calibration samples
necessary for desired prediction performance. The spectral design strategy was found to be
efficient in terms of sample requirements compared to the traditional full factorial technique. A
reduced number of calibration samples yielded a model of similar predictive capabilities for both
APIs. The spectral design strategy was found to provide better performance compared to the
traditional optimal designs such as D-optimal and I-optimal designs. The spectral design strategy
was found to provide similar prediction performance compared to the CCD design. Overall, the
spectral design approach offers an efficient enhancement for the NIR calibration development for
pharmaceutical tablets.
This approach has the potential to be useful for other tablet formulations and spectroscopic
techniques. Infrared, Raman and THz spectroscopy have been used frequently to develop
quantitative method for pharmaceutical tablets. Spectral design strategy can be useful to
minimize the calibration sample requirements for such techniques.
PLS modeling technique was used in all comparatives studies. Selecting the appropriate number
of loading vector is a critical step during PLS model development. Appropriate number of
loading vector is critical to define the model variance space. The current strategies for selecting
the appropriate number of loading vector include cross-validation and total variance techniques.
However, these techniques were unable to select the appropriate number of loading vector for
traditional PLS model in section 3.2.1 for single API formulation. The poor model performance
was due to inappropriate number of loading vector in the PLS model. A new strategy was
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developed to select the appropriate number of loading vector based on weight co-efficient
technique. This strategy was tested on multiple NIR dataset. The details of the new method and
its performance are provided in the next chapter.
An improved prediction performance with lower RMSEPs was achieved from the traditional PLS
model for single API formulation following the new method of loading vector selection
(RMSEP2: 2.21 vs 4.68 and RMSEP3: 1.43 vs 5.05). The improved performance was found to
be similar to the spectral design calibration model (RMSEP2: 2.21 vs 2.21 and RMSEP3: 1.43 vs
1.68). Spectral design was considered to be efficient considering its fewer sample requirement
(11 vs 45) compared to the traditional calibration design.
Selecting the appropriate number of loading vector was critical to find the optimum calibration
models and compare the respective calibration strategies. The weight based co-efficient
technique was found to be an efficient alternative to the current loading vector selection
techniques. The following chapter discusses this technique in further details.

Copyright ©: Part of this chapter has been reprinted from [175]. Copyright clearance is provided
at the end the dissertation.
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Chapter 4: Selecting loading vector for PLS model during quantitative analysis of
tablets using NIRS

4.1 Introduction
NIR spectroscopy is a well-established analytical tool in the pharmaceutical industry for
quantitative analysis of tablets [1-3, 5]. It is fast, non-destructive and requires little or no sample
preparation. However, successful implementation of this technique requires analytical insight
and chemometric tools to analyze the complex dataset. The broad overtones and combination
vibrations in the NIR region are very difficult to assign to a specific chemical feature. Besides,
NIR spectra are very sensitive to both physical and chemical properties of the samples [47, 135,
178, 179]. A quantitative model developed to extract the chemical information from the tablet
spectrum is often affected by different sources of variations such as physical, chemical, scale,
instrumental and environmental variations during tablet analysis. Batch-to-batch variation in the
raw material properties such as particle size distribution of the granules and excipients, different
vendors of the same excipient leading lot to lot variation, polymorphic conversion of the API and
excipients during the manufacturing steps, all serve as potential sources of physico-chemical
variation in the samples affecting NIR model performance. Environmental variations such as
differences in relative humidity between different batches also affect NIR model performance.
Difference in the scales of tablet preparation is a very common source of variation in the NIR
spectra. It is quite possible for the analyst to develop a calibration model at one scale during the
product development phase and intent to predict samples throughout the product life cycles from
a different scale. A robust NIR model is critical to encounter such scale variations. In addition to
table manufacturing scale, relative tablet density of the tablet have significant impact on NIR
spectra [112]. Variation in the tablet density serves as a potential source of spectral variance. It is
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also possible for the API in tablets to undergo degradation and produce degradants during its
shelf life. The presence of a new chemical entity such as a degradant in the sample, can affect
NIR model performance. Similar spectral features of the API and degradant can have detrimental
effect on model selectivity. All these types of variation have the potentials to affect spectral
shapes and thereby NIR model performance. So, model robustness has long been discussed as a
critical merit during quantitative analysis using NIR spectroscopy [38, 54].
Special pre-processing techniques and multivariate calibration methods are often employed to
develop robust modeling technique and extract desired information from the NIR spectra [180182]. Besides, the analyst seeks to include as much variance as possible in the calibration step to
train the model against all possible variances within defined scopes of drug product, NIR
instrument and measurement environment that are forthcoming [183]. While, it is often
impossible to forecast all the possible variances at the outset of calibration development,
updating a calibration model with the newly encountered variance is a well-established practice
[184]. Calibration update is a slow process and requires re-validation. Moreover, it is often
difficult to get modification of an already approved method from the regulatory agencies [185].
So, it is desired to undertake the most robust modeling approach at the outset of calibration.
Partial Least Squares (PLS) is a widely used chemometric modeling technique used for
quantitative analysis. PLS is used to develop a quantitative model in the calibration step that can
be used to predict any future samples. A critical step during PLS model development is the
selection of optimum number of loading vectors (model components) [186]. A parsimonious
approach is frequently undertaken for this purpose. The minimum number of loading vector with
acceptable model performance is selected to mitigate the model complexity and prevent over
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fitting of the calibration model. Cross-validation technique is mainly employed to indicate the
model over fitting and select the optimum number of loading vectors for the model development
[187]. In addition to the cross-validation error, the amount of spectral and concentration variance
explained by each loading vector is also considered during the selection process.
There are various cross-validation techniques including random subset, venetian blinds,
contiguous blocks etc. However, all these techniques describe the error rate only in the
calibration subspace. These techniques cannot anticipate model predictive ability in any future
data set bringing new information to the calibration. The current techniques of cross-validation
may fail to indicate the optimum number of loading vector to develop the most robust model at
the outset of calibration development. In this study, a new method using the weight coefficient
of each loading vector is proposed during calibration development of a pharmaceutical tablet.
This method was tested to develop a calibration model robust against scale variation,
environmental variation, physico-chemical variation, chemical variation and raw material
variation. The robustness of the calibration model was compared with a traditionally built
calibration model using current cross-validation techniques. The new weight coefficient based
method was demonstrated to be more efficient than the current cross-validation techniques to
develop the most robust model at the outset of calibration development.

4.2 Theory
A quantitative spectroscopic calibration model is developed to quantify physico-chemical
properties of a sample from its respective spectrum using regression model. For a system with
“m” samples and “n” spectral variables (wavelengths), the regression model is as follows,
𝐲𝐲�𝐦𝐦∗𝟏𝟏 = 𝐗𝐗 𝐦𝐦∗𝐧𝐧 ∗ 𝐛𝐛𝐧𝐧∗𝟏𝟏
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(4.1)

�” is the predicted physico-chemical property, “X” is the spectral data matrix and “b” is
Here, “𝒚𝒚

the regression vector. Concentration will be considered as an example of physico-chemical
property in rest of the chapter.

In PLS, spectral data (X) and concentration data (y) are decomposed into scores and loading
vectors. The loading vectors describe the covariance structure between the spectra and
concentration. The scores serve as a metric for spectral variance of the individual sample in the
direction of the respective loading vectors. The details of the PLS theory is discussed elsewhere
[188].
′
𝐗𝐗 𝐦𝐦∗𝐧𝐧 = 𝐓𝐓𝐦𝐦∗𝐤𝐤 ∗ 𝐏𝐏𝐧𝐧∗𝐤𝐤

𝐘𝐘𝐦𝐦∗𝐮𝐮 = 𝐔𝐔𝐦𝐦∗𝐤𝐤 ∗ 𝐐𝐐′𝐮𝐮∗𝐤𝐤

(4.2)
(4.3)

Here, “T” and “U” are the scores of the spectral matrix “X” and concentration matrix “Y”
respectively and “k” is the number of loading vectors and weight vectors to be included into the
model. “P” and “Q” are the loading vectors for “X” and “Y” as well. For a single predictor, the
concentration matrix “Y” is a vector and does not need to be decomposed.
NIPALS is a widely used algorithm in PLS model development [189]. In NIPALS, the loadings
and scores are iteratively solved. The first loading “P” indicates the primary direction of
covariance between spectra and concentrations, and the first set of scores “T” indicates the
projections of samples into that “P” direction. The second loading vector indicates the direction
of maximum covariance between the residual spectra and residual concentration after spectral
reconstruction with the first loading vector. The third loading vector indicates the same after
spectral reconstruction with the first and second loading vector. Once the number of loading
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vector is fixed, the regression model of Eq (4.1) is developed by calculating the regression vector
as follows,[190]

′
′
′
𝐛𝐛𝐧𝐧∗𝟏𝟏 = 𝐖𝐖𝐧𝐧∗𝐤𝐤 ∗ (𝐏𝐏𝐤𝐤∗𝐧𝐧
∗ 𝐖𝐖𝐧𝐧∗𝐤𝐤 )−1 ∗ (𝐓𝐓𝐤𝐤∗𝐦𝐦
∗ 𝐓𝐓𝐦𝐦∗𝐤𝐤 )−1 ∗ 𝐓𝐓𝐤𝐤∗𝐦𝐦
∗ 𝐲𝐲𝐦𝐦∗𝟏𝟏

(4.4)

Here, “W” is the weight vectors expressing both the “positive correlation” between spectral
matrix “X” and concentration matrix “Y” and the “compensation correlation” needed to predict
“Y” from “X” clear from the secondary variation in “X” [191]. In the PLS toolbox from
Eigenvector Research Inc., the weight vector “W” is expressed as “W*”,
∗
′
𝐖𝐖𝐧𝐧∗𝐤𝐤
= 𝐖𝐖𝐧𝐧∗𝐤𝐤 ∗ (𝐏𝐏𝐤𝐤∗𝐧𝐧
∗ 𝐖𝐖𝐧𝐧∗𝐤𝐤 )−1

(4.5)

∗
′
′
𝐛𝐛𝐧𝐧∗𝟏𝟏 = 𝐖𝐖𝐧𝐧∗𝐤𝐤
∗ (𝐓𝐓𝐤𝐤∗𝐦𝐦
∗ 𝐓𝐓𝐦𝐦∗𝐤𝐤 )−1 ∗ 𝐓𝐓𝐤𝐤∗𝐦𝐦
∗ 𝐲𝐲𝐦𝐦∗𝟏𝟏

(4.6)

∗
𝐛𝐛𝐧𝐧∗𝟏𝟏 = 𝐖𝐖𝐧𝐧∗𝐤𝐤
∗ 𝐬𝐬𝐤𝐤∗𝟏𝟏

(4.7)

which provides the same information as “W”. So, Eq 4.5 can be written as,

Here, “s” is considered as the weight coefficients and “k” is the number of loading vector to be
included in the PLS model. The same weight coefficient is also used in the prediction equation as
follows (replacing “b” in Eq 4.1,
𝐲𝐲�𝐦𝐦∗𝟏𝟏 = 𝐓𝐓𝐦𝐦∗𝐤𝐤 ∗ 𝐬𝐬𝐤𝐤∗𝟏𝟏

(4.8)

In a PLS model, each weight vector, its associated loading vector and scores are associated with
a weight coefficient which can serve as a metric for its contribution in regression vector
calculation (Eq (4.7)), as well as in prediction equation (Eq (4.8)).
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Optimum selection of the loading vector number “k” is critical for model performance.
Traditional methods for selecting “k” involve either one of the two approaches or both:
1. Root Mean Squared Error of Calibration (RMSEC) and Root Mean Squared Error of
Cross Validation (RMSECV) at each loading vector and weight vector inclusion into
the model.
2. Variance explained by each loading vector during the model development.
However, these two techniques have the potential to fail in selecting the appropriate number of
loading vectors to develop a robust PLS model at the outset of calibration development. The new
method uses the weight coefficients “s” as the basis for selecting appropriate number of loading
vector “k” to be included into the model. It uses the weight coefficients ‘s’ for isolating loading
vectors that explain a small percent of the spectral and concentration variance while having high
influence (high weight coefficient) in the regression vector calculation and prediction equation.
Inclusion of such loading vectors can be detrimental to the model performance, because such
inclusion tends to over fit the model towards a direction that explains minimal spectral and
concentration variations. Overfitting model towards irrelevant information can affect model
specificity and prediction performance.
According to the new weight coefficient based method, any weight coefficient larger than the coefficient of the maximum variance explaining loading vector (often the first one) was considered
inappropriately high and PLS model was developed with the preceding loading vectors. If ‘nth’
weight co-efficient is higher than the co-efficient of the maximum variance explaining loading
vector, the optimum number of loading vectors was considered to be “n-1” according to the
weight coefficient based method.
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In the traditional method, PLS models were developed following the current two techniques for
selecting the optimum number of loading vector. In the new weight coefficient based method,
PLS model was developed using the weight coefficient along with the associated percent of
variance explained by each loading vector. The performances of the new and old methods were
compared in selecting the optimum number of loading vectors and developing the most robust
PLS model at the outset of calibration development.

4.3 Material and Methods
Five different datasets were used to test the NIR model robustness against different types of
critical variations including scale variation, environmental variation, physical variation, chemical
variation and raw material variation. The details of the dataset are given below
4.3.1

Scale Variation

The scale variation test was designed to analyze and compare model performance between the
traditional method and new weight coefficient based method while predicting Acetaminophen
concentrations in tablets prepared at different scales. The calibration set was prepared at
laboratory scale while the prediction set was prepared at manufacturing scale. The calibration
design was a 5 by 3 level, 2-factor full factorial design to make 45 tablets. The prediction set was
prepared over consecutive eight weeks at the label claim. 20 tablets collected from every week’s
run resulted in a total of 160 tablets in prediction set. These samples are the same samples as
traditional calibration set and prediction set 3 for single API. The details of the experimental
method are described in section 3.2.1.1 (calibration set) and 3.2.1.5 (prediction set).
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4.3.2

Environmental Variation

The environmental variation test was designed to analyze and compare model performance
between the traditional method and new weight coefficient based method while predicting
Acetaminophen concentrations in tablets prepared in different environmental conditions. The
calibration set was prepared in the winter (November, 2012) whereas the prediction set was
prepared in the summer in 3 consecutive months (May, June and July 2013).
The same calibration set mentioned in the scale variation test was used for calibration model
development. A 3 by 1 level full factorial design was used to generate the monthly prediction
sets. The factors of the design were kept same as in the calibration and the levels were inside the
calibration range. A set of 20 tablets at each design point resulted in a total of 60 tablets for each
month’s prediction set. The tablets were prepared at the manufacturing scale in the same fashion
described in the scale variation section in section 4.3.1.

4.3.3

Physical Variation (Density)

The density variation test was designed to analyze and compare model performance between the
traditional method and new weight coefficient based method while predicting Theophylline
concentrations in tablets of different densities. The capability of these two methods in selecting
the optimum number of loading vector were compared during calibration development and
calibration update. A previously published dataset was used for this purpose [112].
A fully balanced, quaternary mixture design comprising of Theophylline anhydrous, Lactose 316
Fast Flo Monohydrate, Microcrystalline cellulose and soluble starch was generated. A set of 29
design points was chosen to cover a wide range of all constituents. At each design point, five
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tablets were compressed at five compaction pressures (67.0, 117.3, 167.6, 217.8, and 268.1 MPa)
on a Carver Automatic Tablet Press (Model 3887.1SD0A00, Wabash, IN, USA) using a 13-mm
die and flat-faced punches. One additional tablet was also compressed at each design point, with
a compaction pressure chosen pseudo-randomly from the five levels resulted in a total of 174
tablets. This calibration set was divided into five groups (Cal 01 to Cal 05) based on the
compaction pressure levels. The first group contained samples compacted at 67.0 MPa, while the
second group contained samples compacted at both 67.0 and 117.3 MPa, and subsequently, the
fifth group contained samples compacted at all five compaction pressures. The primary
calibration was developed only using samples compacted at 67.0 MPa and then the calibration
set was updated by samples compacted at different compaction levels.
The same quaternary design was used to create a test set. At each design point, two tablets were
compressed at two randomly chosen compaction pressure out of five (67.0, 117.3, 167.6, 217.8,
and 268.1 MPa) using a Carver Automatic Tablet Press. A total of 58 samples were prepared in
the test set and used for assessing the prediction performance of all the models prepared in the
calibration step. Tablet density was measured for each compact and solid fraction was calculated.
A wide range of solid fraction (0.8 – 0.98) was reported along the range of the compaction forces
[112].
The performance of the traditional method and new weight coefficient based method were
compared in selecting the appropriate number of loading vectors for the models developed from
these five calibration sets (primary and updated sets).
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4.3.4

Chemical Variation (Degradant)

The chemical variation test was designed to analyze and compare the model performance
between the traditional method and new weight coefficient based method while predicting
Niacinamide concentration in tablets prepared with and without its degradant Niacin. The
calibration set was prepared using samples containing Niacinamide and excipients including
starch, Microcrystalline cellulose (MCC), Di-tab and Magnesium stearate. The prediction set was
prepared using samples containing Niacinamide, Niacin and excipients including starch,
Microcrystalline cellulose (MCC), Di-tab and Magnesium stearate.
The Niacinamide concentration was varied at 7 levels in the calibration set while keeping the
excipients ratios (starch:MCC:Di-tab) constant. The concentration of Magnesium stearate was
kept constant at 1%. The nominal target tablet weight was 500 mg.
At each design point, 5 gm samples mixture was prepared and placed in a 15 ml scintillation vial.
The samples were mixed by placing the vial in a bin blender and rotating for 15 minutes. At each
design point, three tablets were compressed from the same mixture on a Carver Automatic Tablet
Press (Model 3887.1SD0A00, Wabash, IN, USA) at 5000 lb. using a 13-mm die and flat-faced
punches.
A 3 by 3 levels, two-factor full factorial design was used to prepare the test set. The factors were
Niacinamide concentration and Niacin concentration. At each design point, 3 tablets were
compressed in the same fashion as mentioned earlier. Out of the total of 27 tablets, tablets from
one design point were damaged leaving 24 tablets in the test set. The test set was subdivided into
three sets based on the degradant (Niacin) concentration.
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4.3.5

Raw Material Variation

The raw material variation test was performed on a previously published dataset to analyze and
compared model performance between the traditional method and new weight coefficient based
method while predicting Theophylline concentration in tablets prepared with different raw
material properties [164]. The calibration set was prepared with a specific polymorph of API as
Theophylline anhydrous, a specific particle size distribution of Lactose as 100 microns and a
specific source of starch as EMD Chemicals. The prediction set was prepared using a different
polymorph of API as Theophylline monohydrate, different particle size distribution of Lactose as
50 micron and different vendor of starch as Acros Organics.
A fully balanced, quaternary mixture design comprising of Theophylline anhydrous, Lactose 316
Fast Flo Monohydrate, Microcrystalline cellulose and soluble starch was generated. A set of 29
design points were chosen to cover a wide range of all constituents. At each design point, 2
tablets were compressed at 2 randomly selected pressures out of five (67.0, 117.3, 167.6, 217.8
and 268.1 MPa) on a Carver Automatic Tablet Press (Model 3887.1SD0A00, Wabash, IN, USA)
using a 13-mm die and flat-faced punches. In total, 58 tablets were compressed for calibration set
with a target weight of 800 mg.
A 2 by 2 by 3 levels, three-factor full factorial design was used to prepare the test set at a single
composition inside the calibration range. The factors were selected as API polymorphs, sources
of starch and Lactose particle size distributions to ensure different types of raw material
variability in the test set. All the tablets were compressed at 167.6 MPa using the same setup as
calibration. At each design point, 3 tablets were compressed, resulted in a total of 36 tablets.
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The test set was subdivided into three sets based on the difference with calibration set in raw
material properties. The first set was comprised of all the samples containing Theophylline
monohydrate, second set comprised of all the samples containing Lactose of 50 microns particle
size distribution and third set comprised of all the samples containing starch from vendor 2
(Acron Organics).
4.3.6

Spectral collection

NIR reflectance measurements for both sides of each compact were collected using a bench top
scanning monochromator instrument (XDS Rapid Content Analyzer, FOSS NIRSystems, Inc.,
Laurel, MD, USA). Spectra were collected over the wavelength range of 400 – 2,500 nm at 0.5nm increments, averaging 32 co-adds per spectrum.

Spectra corresponding to each side of a

compact were averaged to give one representative spectrum per compact.
4.3.7

Modeling strategy

All calculations were performed with MATLAB 2015a (The Mathworks, Natick, MA, USA)
equipped with a PLS Toolbox v. 7.9.4 (Eigenvector Research Inc., Wenatchee, WA, USA).
4.3.8

Cross validation

PLS Toolbox was used to implement 3 different cross-validation techniques as random subset,
contiguous block and venetian blind. For each technique, the data set was divided into 3 different
ways to remove the aliasing effect between data subset and cross-validation error. The details of
the cross-validation technique using PLS toolbox can be found elsewhere [192].
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4.3.9

Model evaluation and design comparison parameters

The root mean squared error (RMSE) was used to evaluate model predictive performances in the
calibration (RMSEC), cross-validation (RMSECV) and prediction (RMSEP) sets.
∑𝑛𝑛1(ŷ − 𝑦𝑦)2
�
RMSE =
;
𝑛𝑛
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Figure 4-1. RMSECs and random subset (left), contiguous block (middle) and
venetian blind (right) RMSECVs during calibration development for scale
variations.

4.4 Results
4.4.1

Scale Variation

Figure 4-1 shows the RMSECs and RMSCEVs for loading vectors 1 to 10 calculated by different
cross-validation techniques such as random subset (left), contiguous block (middle) and venetian
blinds (right). The no. of splits was also changed as the optimization parameter as shown in the
figures. All the techniques (except contiguous block with 2 splits) showed a plateau between
RMSEC and RMSECV at fifth loading vector and there was no significant reduction in cross134

validation errors after that. A PLS model was developed using five loading vectors as per current
technique for selecting optimum number of loading vectors for model development.
Figure 4-2 shows the cumulative percent of variances explained after the addition of each
loading vector into the model. Besides RMSECV, this metric was also used for selecting
appropriate number of loading vectors. It was shown that, most of the variances in spectral
matrix (X) and concentration matrix (Y) were explained by five loading vectors, indicating five
as the optimum number of loading vectors for model development.
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Figure 4-2. Cumulative variances explained at each loading vector during calibration
development for scale variations.
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Figure 4-3. Weight co-efficient and percent of variances explained by each loading vector
during calibration development for scale variations.
Figure 4-3 shows the percent of variances explained by each loading vector and its respective
weight coefficient. It was found that, the third loading vector had a much higher weight
coefficient than first two loading vectors. High weight coefficient of the third loading vector
indicated its large influence on the regression vector calculation and prediction equation
compared to the first and second loading vector. However, only a small portion of the total
variances was explained by the third loading vector indicating that, inclusion of this loading
vector could over fit model using irrelevant information and affect model performance in the
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future samples. Two loading vectors were considered optimum according to the new weight
coefficient based method and a PLS model was developed using first and second loading vector.
Another PLS model was also developed with three loading vectors to analyze the effect of
including third loading vector into the model. These three PLS models were developed on lab
scale tablets and used to predict tablet set prepared at manufacturing scale for eight consecutive
weeks. The RMSEPs served as a metric for the model performance and robustness.
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Figure 4-4. RMSEPs of models predicting Acetaminophen in weekly runs prepared at
different scale.
Figure 4-4 shows the RMSEPs for models developed according to traditional method (5 LV
model), new weight coefficient based method (2 LV model) and model showing the effect of
third loading vector inclusion (3 LV model). The model developed using the new weight
coefficient based method was found to be more robust against scale variation and more accurate
through eight weeks compared to the traditional method. Inclusion of the third loading vector
affected the mode performance as anticipated during model development.
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Figure 4-5. RMSEPs of models predicting Acetaminophen in monthly runs prepared at
different environment.
4.4.2

Environmental Variation

The robustness of these calibration models were also tested against environmental variation. All
of the three models were developed in November, 2012 and used to predict the tablets prepared
in May, June and July 2013 at the manufacturing scale. Figure 4-5 shows the RMSEPs for all
three models predicting the tablets from different months. The model developed according to the
new weight coefficient based method (2 LV model) was found to be more robust and accurate
compared to other two models.
4.4.3

Physical Variation (Density)

Model robustness was tested against density variation as the physical source of variation in NIR
analysis. The primary calibration set contained samples made at a single compaction force and
then the calibration set was sequentially updated using samples made at four different
compaction forces.
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A total of 5 calibration sets were prepared. For each calibration set, two PLS models were
developed following the traditional and new weight coefficient based method, respectively. The
calibration models were used to predict the test set containing samples made at five different
compaction forces. This analysis compared the performance of the traditional method and new
weight coefficient based method in selecting optimum number of loading vectors during
calibration development and calibration update.
In the traditional method, the optimum number of loading vectors for each of the five models
was selected based on RMSEC and RMSECV plots and the percent of variances explained by
each loading vector. In the new weight coefficient based method, weight coefficient of each
loading vector was used to select the optimum number of loading vectors to be used during
model development.
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Figure 4-6. Weight co-efficient of each loading vector during calibration development for
density variations.
Figure 4-6 shows the weight coefficient of each loading vector for five calibration models. The
red arrows indicate the number of loading vectors used during model development following the
new weight coefficient based method. For “Cal 01”, four loading vectors were used, because the
fifth loading vector had higher weight coefficient than the previous four, indicating its large
influence on the regression vector calculation and prediction equation with very little information
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on the spectral and concentration variance. This approach was followed for the rest of the
calibration sets (Cal 02 to Cal 05).
Loading Vector
RMSEP % (w/w)
Sample Force
New
New
Calibration
Sample Included (MPa)
Weight
Weight
set
no.
in Calibration Traditional Coefficient Traditional Coefficient
Method
Method
Set
Based
Based
Method
Method
Cal 01
35
67.0
7
4
3.48
2.82
Cal 02
70
67.0, 117.3
8
4
3.31
2.37
67.0, 117.3,
Cal 03
105
9
4
2.94
2.26
167.6
67.0, 117.3,
Cal 04
139
5
6
2.39
2.26
167.6, 217.8
67.0, 117.3,
Cal 05
174
167.6, 217.8,
6
6
2.23
2.23
268.1
Table 4-1. Calibration for Density variation
Table 4-1 provides a summary of the calibration sets, the respective number of loading vectors
used by the traditional method and new weight coefficient based method and the RMSEPs of the
respective models. Figure 4-7 shows the RMSEPs of the calibration models developed by the
traditional method and new weight coefficient based method. The models developed by the new
weight coefficient based method were found to be more robust and accurate compared to the
models developed by the traditional method while predicting the same test set having density
variation. For the global set “Cal 05”, that contained samples prepared at all compaction forces,
both methods indicated the same optimum number of loading vector thereby providing equal
RMSEP. It was found that, with a fewer samples, the model developed using the new weight
coefficient based method was able to achieve similar prediction performance compared to the
global model (new method for Cal 03 (105 samples) vs traditional method for Cal 05 (174
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samples)). This indicated that, the new weight coefficient based method of model development
has the potential to reduce the burden of calibration update.
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Figure 4-7. RMSEPs of models predicting Theophylline in tablets with density variations.
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Figure 4-8. RMSECs and random subset (right), contiguous block (middle) and venetian
blinds (left) RMSECVs during calibration development for chemical variations.
4.4.4

Chemical Variation (Degradant)

Model robustness against chemical variation was tested by introducing a new chemical entity in
the prediction set. A degradant of the API was included in the prediction samples whereas the
calibration model was developed using samples without the degradant. shows the RMSEC and
RMSECVs of each loading vector calculated by different cross-validation techniques during
calibration development. For all these techniques, RMSEC and RMSECV reached a plateau at
second loading vector. A PLS model was developed using two loading vectors as per the
traditional method of model development.
Figure 4-9 shows the cumulative percent of variances explained after the addition of each
loading vector into the model. Five loading vectors explained most of the variances and no
significant variance was added after that. Another PLS model was developed using five loading
vectors as per the traditional method of model development.
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Figure 4-9. Cumulative variances explained at each loading vector during calibration
development for chemical variations
Figure 4-10 shows percent of variances explained by each loading vector and its respective
weight coefficient. It was found that, the second loading vector had higher weight coefficient
than the first loading vector indicating its higher influence on the regression vector calculation
and prediction equation. However, it explained a small portion of the X and Y variance
compared to the first loading vector. Inclusion of the second loading vector was expected to over
fit the model towards a direction that explained a small portion of the spectral and concentration
variances. A third PLS model was developed using only one loading vector as per the new
weight coefficient based method.
Two models developed by the traditional method and one model developed by the new weight
coefficient based method were used to predict Niacinamide concentration in test samples
containing different amount of Niacin. The RMSEPs served as a metric of the model
performance and robustness in presence of chemical variation coming from the Niacin as a
degradant of the API. Figure 4-11 shows the RMSEPs for all three models predicting
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Niacinamide concentration in samples containing 2%, 5% and 10% w/w of Niacin. It was found
that, for all concentrations of Niacin samples, the model developed by the new weight coefficient
based method was more robust and accurate in comparison to the other two models developed by
the traditional methods. As expected, all model performances deteriorated as the Niacin content
increased in the test samples.
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Figure 4-10. Weight co-efficient and percent of variances explained by each loading vector
during calibration development for chemical variation
4.4.5

Raw Material Variation

Model robustness was tested against raw material variation. The calibration models were
developed using the samples containing a specific polymorph of API as Theophylline anhydrous,
a specific particle size distribution of Lactose as 100 microns and a specific vendor of starch as
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EMD Chemicals. The models were used to predict the samples containing different polymorph
of API, different particle size distribution of one excipient and different vendor of the other
excipient.
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Figure 4-11. RMSEPs of models predicting Niacinamide in presence of chemical variations
(Niacin)
In this analysis, both the traditional method using RMSEC and RMSECV plot and the new
weight coefficient based method using weight coefficient indicated five loading vectors as the
optimal number for model development. Figure 4-12 shows the percent of variances explained
by each loading vector and its respective weight coefficient. Five loading vectors were selected
for model development because the sixth loading vector had higher weight coefficient than the
preceding loading vectors indicating its high influence on the regression vector calculation and
prediction equation. Inclusion of such loading vector would over fit the model towards a
direction that explained a very small portion of the spectral and concentration variance. Although
fourth and fifth loading vectors did not explain a significant portion of spectral or concentration
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variances individually, they were kept into the model due to their smaller weight coefficients
compared to the first loading vector.
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Figure 4-12. Weight co-efficient and percent of variances explained by each loading vector
during calibration development for raw material variation
Figure 4-13 shows the cumulative percent of variances explained at each successive loading
vector addition into the model. It was found that, after the third loading vector inclusion, no
significant variance was explained with the addition of a new loading vector. So, three loading
vectors were used for model development as per one of the traditional techniques.
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Figure 4-13. Cumulative variances explained at each loading vector during calibration
development for raw material variation
Figure 4-14 shows the RMSEPs of the two models developed by one of the traditional methods
(3 LV model) and the new weight coefficient based method (5 LV) for predicting Theophylline
concentration in test set containing new variances coming from different polymorph of API
(Theophylline monohydrate), different particle size distribution (Lactose 50 micron) and
different source (Starch vendor 2).

4.5 Discussion
In the above case studies, the new weight coefficient based method was found to be more
effective in selecting the optimum number of loading vectors and indicating the most robust PLS
model compared to the current techniques of cross-validation and variance calculation. Cross
validation provides the error rate at successive loading vectors, however, that error rate is
specific to the calibration space. Although cross-validation indicates model performance as a
function of loading vector and prevents over fitting of the model in the calibration space, it
provides little or no information about the model performance on any future data set containing
new information to the calibration. Thus, cross-validation often fails to aid in the development of
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the most robust PLS model at the outset of calibration. Upon such failure, it is usually assumed
that the working model is the best case in place and model update is necessary. This is often not
the case as shown in this paper. Moreover, it is also shown that, calibration update might not
even be necessary at some points (density variation) following the new weight coefficient based
method. This can be helpful in saving time and cost associated with calibration model update.
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Starch Vendor 2

Figure 4-14. RMSEPs of models predicting Theophylline in presence of raw material
variations.
During PLS model development, the goal is to maximize co-variance between the spectra and
the concentration. Being an iterative technique, the first iteration of PLS seeks to estimate the
direction of maximum co-variance between the spectra and the concentration, and the succeeding
steps seek to estimate the co-variance between the residual information of the spectra and the
concentration left from the preceding steps. Most often, the initial loading vectors explain
majority of the variance presented in the spectra and concentration assuming that appropriate
pre-processing has already been applied to mitigate other effects. While later loading vectors
explain a blend of information that is a small part of the total calibration variance, they still help
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to improve the model performance in the calibration space. However, outside the calibration
space, it is often possible that the new samples show different projections on the direction of the
later loading vectors for being different in terms of any of the blended information explained.
This might be detrimental, especially when the particular loading vector has high influence (high
weight co-efficient) in the regression vector calculation and the prediction equation. In that case,
the regression vector will be sensitive to the information that might not be related with the
concentration. The prediction can also be biased by the difference in sample scores on that
loading vector. Exclusion of these loading vectors is expected to prevent the model from poor
predictability for new samples and improve model robustness as demonstrated in this study. The
weight coefficient based method is mostly applicable when certain loading vector has high
weight coefficient but explains little spectral and concentration information. This method can
identify and eliminate such loading vector from model space. If no such latent variable exists in
the model space, the weight coefficient based method and current cross validation technique
would provide similar solution to the loading vector selection problem.

4.6 Conclusion
Model robustness is very critical for successful implementation of NIR method. Different
sources of variation can be present during product lifecycle and affect the NIR model
performance. It is best practice to develop the most robust model at the outset of calibration
development. Optimum number of loading vectors selection is necessary for indicating the most
robust model. A new method using the weight coefficient was found to be more effective in
selecting the optimum number of loading vectors and developing the most robust model
compared

to

the

current

techniques

variance calculation.
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Chapter 5: Method development for incorporating physico-chemical variation into the
spectral calibration set

5.1 Introduction
The NIR spectral response of a pharmaceutical tablet is affected by its physico-chemical
properties such as PSD of the API and excipients, tablet density, tablet hardness, moisture
content etc [26, 42, 159]. These physico-chemical properties are critical factors for calibration
design due to their effects on NIR spectra [25, 161, 162]. A calibration model typically shows
poor accuracy in quantifying tablets with new physico-chemical properties that were not built
into the calibration set. A calibration set should contain variation in the physico-chemical
properties of the tablets in order to develop a robust calibration model. In the previous chapters,
calibration sets were not controlled for certain critical factors such PSD of the API and raw
materials. Calibration sets were also used to predict samples with different physico-chemical
properties (lab scale vs manufacturing scale). The objective was to test and compare spectral
calibration strategy with traditional calibration strategy in presence of new information in the test
set. It was found that the presence of new information showed similar impacts on the spectral
calibration set and traditional calibration set. Thus, the spectral calibration strategy was
considered efficient due to its fewer sample requirements. However, the best practice for
calibration set development is to incorporate the critical physico-chemical information into the
calibration set. The current approach for incorporating physico-chemical variation into the
calibration set is to allow a systematic variation of the respective factors in the calibration design
[164]. This approach often leads to a large calibration set with redundant information; a
limitation observed during the incorporation of compositional variation as well. Designing
calibration set in the spectral space minimizes redundancy and offers an efficient strategy to
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incorporate compositional variation into the calibration set. However, it is also critical for the
spectral space calibration strategy to efficiently incorporate physico-chemical variation into the
calibration set to build a robust calibration model. Incorporation of physico-chemical variation
into the spectral calibration set requires the spectral space to contain physico-chemical
information. The NIR spectral signature of the physico-chemical properties of the samples can be
utilized to incorporate such information into the spectral space. A spectral space containing
physico-chemical information provides the basis for selecting a small set of calibration samples
with critical physico-chemical information. Such small calibration set would be efficient in
sample requirement to develop a robust calibration model for quantitative analysis of
pharmaceutical tablets.

Figure 5-1. Effects of tablet density and hardness on reflectance and transmission NIR
[193].
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In this study, a method was developed to incorporate physico-chemical variation into the spectral
calibration design strategy. Tablet density was selected as an example of critical physicochemical property of the tablet. Tablet density variation affects the NIR spectral signal due to the
changes in air-particle interfaces associated with density variation [11]. As the tablet density
increases, the number of air-particle interfaces inside the tablet decreases. Air-particle interface
acts as a scattering center for NIR light. As the number of air-particle interface decreases, the
extent of scattering also decreases, causing the NIR light to penetrate deeper into the sample and
resulting in an increased absorbance. The opposite effect is also observed when the tablet density
decreases. Reflectance NIR method was found to be affected more by the tablet density
compared to the transmission method [69]. Figure 5-1 shows the effect of tablet density and inter
particle interface on the reflectance and transmission NIR spectra.
It is critical for the calibration set to contain information regarding table density variation in
order to build a robust calibration model. Tablet density variation is usually incorporated into the
calibration set by compressing calibration samples at different compaction forces to prepare
tablets of different densities. In the spectral calibration design strategy, tablet density variation
was incorporated into the calibration set by selecting calibration samples from a spectral space
that contained information regarding tablet density variation. Tablet density variation was
incorporated into the spectral space by compressing pure component tablets at different
compaction forces. The pure components tablet spectra were used to simulate spectra of
compositionally varying tablets at different densities. The simulated tablet spectra of different
densities were decomposed to derive the spectral space for selecting calibration samples. The
covariance between spectra and API concentration was maximized prior to spectral
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decomposition in order to incorporate compositional variation besides the tablet density variation
into the spectral space.
Pure component
powders

Compaction
force 1
Pure component tablet
spectra

Compaction
force 2
Pure component tablet
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Compaction
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Pure component tablet
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Spectral
simulation

Spectral
simulation

Spectral
simulation

Compositionally varying
tablet spectra

Compositionally varying
tablet spectra

Compositionally varying
tablet spectra

Covariance maximization between API
concentration and spectral variation
Spectral decomposition
Spectral space
Sample selection
Calibration set
Figure 5-2. Spectral calibration strategy for incorporating tablet density variation into the
spectral space
The Kennard Stone algorithm was used to select a representative subset of samples as calibration
candidates from the spectral space. This strategy was tested to quantify API in tablets with
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different densities. This strategy was also compared with the current strategy for incorporating
density variation into the calibration set. The following diagram depicts the spectral calibration
strategy for incorporating tablet density variation into the spectral space.

5.2 Material and method
5.2.1

Incorporation of physico-chemical information
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Figure 5-3. Effect of compression force on the pure component tablet spectra
The multiple API formulation was selected for this study. The multiple API tablets contained
two APIs as Acetaminophen (Mallinckrodt Inc., Raleigh, NC, USA) and Caffeine anhydrous
(Spectrum Chemical Mfg. Corp., New Brunswick, NJ, USA). The excipients were
Microcrystalline cellulose (MCC; Avicel PH 200, FMC Biopolymer, Mechanicsburg, PA, USA),
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Lactose (modified spray-dried; Foremost Farms USA, Rothschild, WI, USA), Crosscarmellose
sodium (Crosscarmellose Na, Spectrum Chemical Mfg. Corp., New Brunswick, NJ, USA) and
Magnesium stearate (MgSt; Fisher Scientific, Waltham, MA, USA). The target formulation was
set as Acetaminophen (31.25% w/w), Caffeine (4.05% w/w), MCC (37.32% w/w), Lactose
(24.89% w/w), Crosscarmellose Na (2% w/w) and MgSt (0.5% w/w). The pure component
tablets and a tablet at target formulation were compressed at three different compaction forces
(2000, 4000 and 6000 lb) on a Carver Automatic Tablet Press using a 13 mm die and flat-faced
punches. The target tablet weight was 700 mg.
The experiments were controlled for tablet homogeneity and viscoelastic relaxation as described
in section 3.3.1.4 in chapter 3. All the materials were stored in room temperature and relative
humidity. Anhydrous caffeine was reported to be stable at 75% RH for 7 weeks [173]. No
hydration and anhydrous caffeine was expected considering lower room RH (~60%) and shorter
storage time and analysis. After a viscoelastic relaxation period of two weeks, tablets were
scanned using a bench top NIR instrument (XDS Rapid Content Analyzer, FOSS NIRSystems,
Inc) in reflectance mode. Spectral data were collected at 0.5 nm increment over a range of 400
nm – 2499.5 nm with 32 co-adds per spectrum. Spectra from both faces of each compact were
averaged to produce a single representative spectrum. Figure 5-3 shows the pure component
tablet spectra at different compaction forces. The pure component spectra showed consistent
increases in absorbance with increases in compaction pressure except the two cases of
Crosscarmellose Na and MgSt. Crosscarmellose Na and MgSt were very difficult to compress,
leading to some inconsistent behavior between compaction pressures and spectral responses.
However, this spectral effect was expected to be insignificant in the matrix tablet due to very
small concentration of Crosscarmellose Na and MgSt in the target formulation tablet.
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Figure 5-4. Effect of compression pressure on the tablet of target formulation
Figure 5-4 shows the target tablet spectra at three different compaction pressures. A consistent
increase in absorbance with the increase in compaction force was observed in the target tablet
formulation. A full-factorial experimental design was created to vary the concentration of
Acetaminophen, Caffeine and MCC:Lactose ratio. The Acetaminophen and Caffeine
concentrations were varied at 5 levels and MCC:Lactose ratio was varied at 3 levels resulting in
a total of 75 design points. The details of the design is given in Table 5-1

𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂

𝐂𝐂𝐦𝐦∗𝐤𝐤

𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏 𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬

∗ 𝐏𝐏𝐤𝐤∗𝐧𝐧

Design factors
Calibration
(5x5x3)
75 samples

𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬

= 𝐗𝐗 𝐦𝐦∗𝐧𝐧

(5.1)

Factor levels

Acetaminophen (%)

L.C.-40%

L.C.-20%

L.C.

L.C.+20%

L.C.+40%

Caffeine (%)

L.C.-80%

L.C.-40%

L.C.

L.C. +40%

L.C.+80%

MCC/Lac

1

Table 5-1. Full factorial calibration design
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Figure 5-5. Effect of residual spectra on the simulation of spectral response
The spectra of these 75 design points were simulated using equation 5.1. The pure component
spectra of each compression force were used during the simulation, resulting in 3 sets of
simulated spectra for 3 compression forces (2000, 4000 and 6000 lb).
Significant differences were observed between the simulated spectral response and actual
spectral response of the target tablet formulation at all three compaction forces. The spectral
difference was calculated between the actual and simulated spectral response of the target
formulation for each compaction force. These residual spectra (3 residual spectra from 3
compaction forces) were added to the respective simulated spectral responses. Figure 5-5 shows
the actual and simulated spectral responses of the compaction pressure 2000 lb with and without
the contribution from the residual spectrum. The actual spectral response were obtained by
preparing 75 actual tablets at the compositional points and collecting NIR spectra following the
method described in section 2.3 in chapter 2. In total, there were 225 simulated spectra (5 levels
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of Acetaminophen, 5 levels of Caffeine, 3 Levels of MCC : Lactose, and 3 levels of compaction
forces). Figure 5-6 shows the simulated spectra of 225 design points.

Figure 5-6. Simulated spectral response of 225 design points
The spectral data was truncated from 1100-2499.5 nm. A Principal component analysis was
performed on the simulated data using MATLAB 2015a (The Mathworks, Natick, MA, USA)
equipped with the PLS_Toolbox v. 7.9.3 (Eigenvector Research Inc., Wenatchee, WA, USA).

Figure 5-7 shows the score plot of first two principal components. In the PCA score space (left),
the in-silico samples are separated based on the compaction forces indicating that the majority of
the simulated spectral variation was generating from different compaction forces.
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Figure 5-7. Principal component analysis of the simulated spectra of 225 design points.
Left: Color coded based on compaction forces (2000, 4000 and 6000 lb), Right: Color coded
based on Acetaminophen concentration levels (18.75%, 25%, 31.25%, 37.5% and 43.75%
w/w)
The later principal components also explained variation related to composition as shown in
Figure 5-7 (right) (Acetaminophen), Figure 5-8 (left) (Caffeine) and Figure 5-8 (right)
(MCC:Lactose ratio). However, the spectral variation was dominated by compaction force
variation. The PC1 that explained 97.60% of the total spectral variation, clearly separated the insilico samples based on the compaction forces. The objective of this study was to incorporate
physico-chemical information into the calibration design by selecting the calibration candidates
from a score space (aka spectral space) that contained information related to physico-chemical
properties. In this score space, such selection would be dominated by compaction force
information only. The selected calibration design points would represent insufficient information
related to compositional variation. However, the compositional variation is also critical to
calibration set, since the primary objective of the calibration set development is to build a
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quantitative calibration model for compositional analysis. A balance between compositional and
physico-chemical variation is desired to develop a robust calibration model.
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Figure 5-8. Principal component analysis of the simulated spectra of 225 design points.
Left: Color coded based on Caffeine concentration, Right: Color coded based on MCC to
Lactose ratio
Signal preprocessing technique can be utilized to minimize the spectral effect due to compaction
force and offer a balance between physico-chemical and compositional variation. Multiple
scattering corrections were applied to minimize the baseline variation caused by the compaction
force variation. A PCA analysis was performed on the preprocessed spectra. The PCA analysis
showed that the information related to compaction force variation was minimized after
preprocessing.
Figure 5-9 shows the PCA score plots after applying MSC correction on the spectral data. No
dominance of a single source of spectral variation was observed (no separation in the first two
PCs). However, it was also critical for the relevant information to be present in the spectral space
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for guiding the calibration candidate selection. A comprehensive PCA analysis was performed.
Figure 5-10 shows the PCA score plots generated from subsequent PCs.
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Figure 5-9. Principal component analysis of the MSC corrected simulated spectra of 225
design points. Left: Color coded based on compaction forces, Right: Color coded based on
Acetaminophen concentration
Figure 5-10 (left) and Figure 5-10 (right) show that the spectral data set contained information
related to compaction force and Acetaminophen concentration variation. Figure 5-11 shows that
the spectral response also contained information related to the MCC to Lactose ratio of the insilico samples. The simulated spectra of in-silico samples were found to contain both physical
and chemical variation and it was possible to incorporate a balance between these two sources of
spectral variation by implementing an appropriate preprocessing technique.
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Figure 5-10. Principal component analysis of the MSC corrected simulated spectra of 225
design points. Left: Color coded based on compaction forces, Right: Color coded based on
Acetaminophen concentration
5.2.2

Selection of calibration candidates

The next step was to find the calibration candidates for developing quantitative methods for
Acetaminophen and Caffeine. It was assumed that the optimum calibration sets are different for
different APIs. In other words, the optimum calibration set for Acetaminophen is different from
the optimum calibration set for Caffeine (this assumption was tested and the result is shown in
the next chapter). However, selecting the calibration candidates in the PCA score space would
result the same calibration design points for Acetaminophen and Caffeine. It was also observed
that the PCA score space contained little/no information regarding the variation of Caffeine
concentration. Selecting the calibration candidates in the PCA score space would result a
calibration set without appropriate variation in Caffeine concentration. It is critical to select the
calibration candidates from a score space that contains information regarding the variation in the
respective API concentration. In PLS, the covariance between respective API (Acetaminophen /
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Caffeine) and spectral response is maximized to generate the score space. Therefore, PLS
technique was used to generate separate score spaces that are specific to Acetaminophen and
Caffeine.

0.2

1.0
1.5
2.0

0.15

95% Confidence Level

0.1

Scores on PC 4 (2.32%)

0.05

0

-0.05

-0.1

-0.15

-0.2
-0.5

-0.4

-0.3

-0.2

-0.1

0

0.1

Scores on PC 2 (11.46%)

0.2

0.3

0.4

Class Set: MCC:Lactose

Figure 5-11. Principal component analysis of the MSC corrected simulated spectra of 225
design points. Figure is color coded based on MCC to Lactose ratio

5.2.2.1 Calibration candidates for Acetaminophen
PLS model was developed from the in-silico samples to maximize the covariance between
Acetaminophen concentration and simulated spectral variation. MSC and mean centering were
used as the preprocessing techniques for spectral data as indicated by the PCA analysis. Auto
scaling was used to preprocess the concentration data. The resultant score space from PLS model
is shown in Figure 5-12. It was observed that, the first set of LVs explained spectral variation
related to Acetaminophen concentration due to the maximization of covariance between
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Acetaminophen concentration and spectral response. The spectral variation related to compaction
force and excipient variation was also explained by other LVs (LV 3 and LV5) as shown in
Figure 5-13.
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Figure 5-12. Score plot from the PLS model. The figure is color coded based on
Acetaminophen concentration level
From this score space, a set of 60 design points was selected as the calibration candidates for
Acetaminophen calibration model using the Kennard Stone algorithm. Kennard Stone algorithm
selected a representative sub set of in-silico samples from the large dataset based on Euclidian
distances. The details of the Kennard stone algorithm can be found elsewhere [132]. Figure 5-14
shows the selected points using Kennard stone algorithm in the score space. It was shown in the
score plot that, calibration candidates were selected from all potential sources of variation during
the selection process. All levels of Acetaminophen concentrations, MCC:Lactose ratios and
compaction forces were included into the selected calibration candidates. It is critical to include
all sources of variation into the calibration set to make a robust calibration model against all
potential sources of variation. The current strategy to incorporate such variation is to create a
wide range of systematic variation in all sources of variation during calibration design.
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Following such strategy, the traditional method of incorporating compaction force variation
would be to prepare tablets at 3 compaction forces for each of the 75 compositional design
points, resulting in a total of 225 calibration points in the calibration set. This traditional
calibration set will be referred as ‘global calibration set’ throughout the rest of the chapter. The
global calibration set may contain redundant information since tablets of all three compaction
forces at each compositional design point might not be necessary to incorporate sufficient
amount of spectral variation into the calibration set. The selection of calibration candidates in the
simulated score space would allow the incorporation of compaction force variation into the
calibration set using limited number of samples.
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Figure 5-13. Score plot from the PLS model. Left: Color coded based on compaction force.
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The set of 60 calibration candidates had critical sources of spectral variation including
Acetaminophen concentration variation, Caffeine concentration variation, MCC:Lactose ratio
and compaction force. In the traditional calibration design approach, the variation of such critical
factors is not guided by a priori information and largely depends on user choice (e.g. no of levels
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for each factor). However, in the spectral design strategy, such variations in the calibration set
were guided by the spectral information from each individual factor and their interaction.
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The selection of the calibration candidates was also guided by maximizing the covariance
between Acetaminophen concentration and spectral variation. The effect of this guided selection
strategy was investigated by analyzing the distribution of different critical factors such as
Acetaminophen concentration, Caffeine concentration, MCC:Lactose ratio and compaction force
variation in the selected calibration candidates.
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Figure 5-15. Distribution of Acetaminophen in global calibration set and spectrally selected
calibration set
Figure 5-15-17 shows the distribution of the critical factors in the global calibration set (225
samples) and in the selected calibration set (60 samples). In the global calibration set (225 design
points), all five concentration levels were presented at 45 occurrences (5x45=225) as shown in
Figure 5-15 in red bars. In the spectral calibration set, a set of 60 design points was selected in
which all the concentration levels were homogeneously distributed and occurred around 12 times
for each concentration level as shown in Figure 5-15 in blue bars.
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Figure 5-16. Distribution of Caffeine in global calibration set and spectrally selected
calibration set
The Caffeine concentrations in the selected design points were mostly distributed at the extreme
levels to make the calibration model robust against Caffeine concentration variation as shown in
Figure 5-16. Mid-level concentration points were mostly excluded as the sensitivity to Caffeine
concentration was not critical for the calibration performance during Acetaminophen prediction.
Also, the low dose of Caffeine was not able to contribute a significant portion of the spectral
variation after the preprocessing and maximization of covariance between spectra and
Acetaminophen concentration. The extreme design points were sufficient to cover such small
spectral contribution from the Caffeine concentration. The excipient concentrations (MCC and
Lactose) were widely distributed in the selected design points as shown in Figure 5-17. Excipient
variation contributed to a significant portion of spectral variation as shown in the score plots.
Excipient variation also causes variation in the physical properties such as density, porosity,
hardness, moisture content of the tablets. An even distribution of excipient variation in the design
points is critical to cover such variation in the calibration set.
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The objective of this study was to incorporate physico-chemical information such as variation in
tablet density into the calibration set. The compaction force is usually varied to introduce
variation in the tablet density into the calibration set. Traditionally, compaction force is varied
comprehensively without any prior direction or optimization in the calibration set. In this study,
the spectral effect of the compression force was analyzed and a small representative subset was
selected based on the spectral effect of the compression force.

The distribution of the

compaction forces in the traditional global calibration set and in the spectrally selected
calibration set is shown in Figure 5-18. A large number of design points were selected in the low
compaction force region compared to the high compaction force region. A lower compaction
force causes wider distribution of solid fractions in the tablet set compared to the high
compaction force. As the solid fraction affects the NIR spectral response, it was assumed that,
more design points were required / selected at the low compaction force region to cover wider
distribution of solid fractions and associated spectral responses.
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Figure 5-18. Distribution of compaction forces in global calibration set and spectrally
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5.2.2.2 Calibration candidates for Caffeine
A similar strategy was used to select calibration candidates for developing a quantitative method
for Caffeine. A PLS model was developed from the simulated spectral response of the in-silico
tablets and respective Caffeine concentration. A set of 60 design points was selected from the
PLS score space using the Kennard stone algorithm. The distribution of critical factors such as
Caffeine concentration and Acetaminophen concentration in the global calibration set (225
samples) and selected calibration set (60 samples) are shown in
Figure 5-19. In this calibration set, a homogeneous distribution of Caffeine concentration was
observed; contrary to the calibration set of Acetaminophen. A homogeneous distribution of
Caffeine concentration was selected from the latent variable score space due to maximization of
covariance between Caffeine concentration and spectral variance. Such distribution of Caffeine
concentration was critical to make the model sensitive to Caffeine concentration.
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Figure 5-19. Distribution of Acetaminophen (left) and Caffeine (right) concentration in
global calibration set and spectrally selected calibration set
Similar distributions of MCC and Lactose concentration were observed in the calibration set of
Caffeine compared to the calibration set of Acetaminophen. The distribution of MCC and
Lactose concentrations in the global (225 design points) and selected calibration set (60 design
points) are shown in Figure 5-20. A wide distribution of excipients was critical to ensure
calibration model robustness against excipient variation. Figure 5-21 shows the distribution of
compaction forces in the selected calibration set for Caffeine. This calibration set also contained
more design points at low compaction force compared to the high compaction force.
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Justification of low compaction force
It was assumed that more design points were selected at the low compaction force due to wide
range of spectral variation and solid fraction. These tablet design points were in-silico tablets and
its spectra were simulated from actual pure component and target tablets at different compression
forces. It was assumed that, tablets prepared at low compaction forces had wider spectral
variation compared to the tablets prepared at high compaction forces. And the wide spectral
variation was caused by wide range of solid fraction usually seen at low compaction forces.
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Figure 5-21. Distribution of compaction forces in global calibration set and spectrally
selected calibration set
Actual tablets were prepared at different compression forces to test this assumption. The solid
fraction of each tablet was measured by the following equation 5.2. Figure 5 22 (left) shows the
tablet solid fractions at each compaction force. At low compaction force, a wider range of solid
fraction was present as expected. The spectral variances were calculated at each wavelength in
the simulated spectral set of each compaction force. Figure 5 22 (right) shows the spectral
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variance at each wavelength for all three compaction forces of in-silico tablets. In contrast to the
initial assumption, it was found that the wide distribution of solid fractions did not cause wide
range of spectral variation.

𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 𝑜𝑜𝑜𝑜 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 =

𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑
�𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑

(5.2)

The spectral variation was minimum at the low compaction force in-silico tablets. The spectral
variation was maximum at the high compaction force in-silico tablets. It was further investigated
to understand the cause behind the selection of more design points from low compaction force
in-silico tablets associated with smaller amount of spectral variation.
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Figure 5-22. Solid fraction of tablets at different compaction forces (A). Spectral variation
of the tablet sets prepared at different compaction forces (B).
It was expected to have more design points at high compaction force in the selected calibration
set due to the large spectral variance observed at high compaction force. However, after the MSC
correction of the spectral data during PLS model development, more spectral variance was
observed at low compaction force as shown in Figure 5-23. It might be due to the greater extent
of non-linearity caused by the wider distribution of solid fractions at the low compaction force.
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MSC preprocessing technique corrects for linear scattering effect. The non-linear scattering
effect could not be corrected by MSC preprocessing, resulting in wide range of spectral variation
in the preprocess data at low compaction force. Such wide range of spectral variation resulted in
wide distribution of scores in the PLS score plots as shown in Figure 5-24.
Force 2K

0.05

Force 2K

0.02

Force 4K

Force 4K
Force 6K

Force 6K

0.04

0.015

StdDev

StdDev

0.03

0.02

0.01

0.005

0.01

0

0
500

1000

1500

2000

Variables

500

2500

1000

1500

2000

2500

Variables

Class Set: Force

Figure 5-23. Spectral variation before (A) and after MSC correction of the spectral data.
The area inside the box represents the range of score distribution for each respective compression
force. The distribution of scores was wider for low compaction force tablets compared to the
high compaction force tablets. This wider distribution of scores of low compaction force tablets
resulted in higher k-nearest neighbor (KNN) distance scores. Since, the Kennard stone algorithm
selects samples based on inter sample distances and the highly distant samples are included in
the selected subset, more samples were selected from the low compaction force during the
selection of calibration candidates.
Figure 5-25 shows the KNN distance scores of tablets at three different compaction forces for
both Acetaminophen and Caffeine. For both APIs, the higher KNN distances of low compaction
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force tablets resulted in large number of low compaction design points in the selected calibration
candidates.
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Figure 5-24. PLS scores of first two loading vectors at three different compaction forces

5.2.3

Spectral calibration set for Acetaminophen

A set of 60 design points was selected to develop the calibration set for Acetaminophen
prediction. Actual tablets at the selected design points were prepared by direct compression. The
required amounts of Acetaminophen, Caffeine, MCC, Lactose, Crosscarmellose Na and MgSt at
each design point were weighed and placed in a 10 ml scintillation vial. The ingredients were
mixed by rotating the scintillation vial. Tablets were compressed on a Carver Automatic Tablet
Press (Model 3887.1SD0A00, Wabash, IN, USA) at respective compaction force using a 13 mm
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die and flat-faced punches. The target tablet weight was 700 mg. This tablet set was defined as
the ‘spectral calibration set’ for Acetaminophen.
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Figure 5-25. KNN distance scores of samples at three different compaction forces for PLS
models of Acetaminophen (A) and Caffeine (B)
All the tablets were scanned using a bench top NIR instrument (XDS Rapid Content Analyzer,
FOSS NIRSystems, Inc) in reflectance mode. Spectral data were collected at 0.5 nm increment
over a range of 400 nm – 2499.5 nm with 32 co-adds per spectrum. Spectra from both faces of
each compact were averaged to produce a single representative spectrum. Spectral calibration set
and their respective spectra were used to develop a quantitative NIR calibration model to
quantify the amount of Acetaminophen in tablets of interest.
5.2.4

Traditional calibration set for Acetaminophen

The traditional calibration set was developed using the 4-factor full factorial design previously
used to simulate the spectral response. The factors were Acetaminophen concentration, Caffeine
concentration, MCC: Lactose ratio and compaction force. Each of the APIs (Acetaminophen and
Caffeine) concentrations was varied at five levels and other two factors (MCC: Lactose ratio and

177

compaction force) were varied at three levels resulting in 225 (5x5x3x3) design points in the
traditional full factorial calibration set. The calibration design is different from the design in
chapter 3 in that, the levels of compaction forces are 2000, 4000 and 6000 lb in the current
design contrary to 4000, 5000 and 6000 lb in the earlier design.
Each of the 225 tablets was individually prepared by direct compression. All the components for
a single design point were weighed using a digital weighing machine (Data Range, Model No.
AX504DR, Mettler Toledo) and placed in a 10 ml scintillation vial. The ingredients were mixed
in a bin blender (L.B. Bohle LLC, Warminster, PA, USA) for 10 mins followed by a high shear
mixing using a vortex machine (Vortex-2 Genie, Model G-560, Scientific Industries, IN, USA).
The final mixing was performed in the bin blender before compression. Tablets were compressed
on a Carver Automatic Tablet Press (Model 3887.1SD0A00, Wabash, IN, USA) at respective
compression forces using a 13 mm die and flat-faced punches. The target tablet weight was 700
mg.
All the tablets were scanned using a bench top NIR instrument (XDS Rapid Content Analyzer,
FOSS NIRSystems, Inc) in reflectance mode. Spectral data were collected at 0.5 nm increment
over a range of 400 nm – 2499.5 nm with 32 co-adds per spectrum. Spectra from both faces of
each compact were averaged to produce a single representative spectrum. Traditional calibration
set and their respective spectra were used to develop a quantitative NIR calibration model to
quantify the amount of APPA in tablets of interest.
5.2.5

Spectral calibration set for Caffeine

The spectral calibration set for Caffeine was developed using the similar strategy as used for
spectral calibration set for Acetaminophen. A set of 60 design points was selected as the
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calibration candidates from the PLS scores of Caffeine calibration model of in-silico samples.
Only 29 design points were found to be common between the selected design points of
Acetaminophen and Caffeine. Actual tablets at these design points were prepared by the direct
compression technique described earlier. The NIR spectra of these tablets were collected using
the same instrument and method described earlier. This calibration set was described as ‘spectral
calibration set’ for Caffeine. Spectral calibration set and their respective spectra were used to
develop a quantitative NIR calibration model to quantify the amount of Caffeine in tablets of
interest.
Design Factors
Test 1

Design levels

Acetaminophen (%) L.C.-40% L.C.-20%

(5x5x3x1)

Caffeine (%)

L.C.-80% L.C.-40%

75 samples

MCC/Lac

1

L.C.

L.C. +20%

L.C. +40%

L.C.

L.C. +40%

L.C. +80%

1.5

Force (lb)

Test 2
(3x3x1x4)
36 samples

2

5000

Acetaminophen (%)

L.C.-35%

L.C.

L.C.+35%

Caffeine (%)

L.C.-70%

L.C.

L.C.+70%

MCC/Lac
Force (lb)

1.5
2000

4000

Table 5-2. Design of the two test sets
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5000

6000

Figure 5-26. Selection and preparation method of spectral calibration set and test set for
Acetaminophen and Caffeine
5.2.6

Traditional calibration set for Caffeine

The same full factorial calibration set for Acetaminophen (225 samples) was used to develop a
traditional calibration method for Caffeine prediction.
5.2.7

Test sets to evaluate model performance

Two test sets were used to evaluate the performance of the calibration designs. The first test was
developed by varying Acetaminophen and Caffeine concentration at five levels and MCC to
Lactose ratio at 3 levels resulting in 75 design points. In the first test set, the compaction force
was kept constant. The second test set was developed by varying Acetaminophen and Caffeine
concentration at three levels and compaction force at four levels resulting in total 36 design
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points. In the second test set, the excipient ratio was kept constant. Table 5-2 describes the
structure of the two test sets. The method for preparing calibration and test set is depicted in
Figure 5-26.
5.2.8

Quantitative model development

Quantitative models were developed using Partial Least Squares (PLS) modeling technique in
MATLAB 2015a environment (The Mathworks, Natick, MA, USA) using PLS_Toolbox v. 7.9.3
(Eigenvector Research Inc., Wenatchee, WA, USA). Data independent spectral preprocessing
techniques were used to optimize model performance. Two calibration models were developed
for each API (Acetaminophen and Caffeine), one calibration model from the 225 actual tablets of
the full factorial design and another calibration model from the 60 actual tablets of the spectral
design. Models developed from each calibration design were independently optimized for each
API. The preprocessing techniques and loading vectors were selected independently. Selection of
the loading vector is critical for PLS model performance. Latent variables were chosen based on
a parsimonious approach. A minimum number of latent variables with acceptable performance
were selected. Model performance was assessed based on the prediction of Acetaminophen and
Caffeine concentration in calibration and test set tablets.
The effect of the incorporation of physico-chemical information into the spectral calibration sets
was analyzed by evaluating calibration model performance and comparing it with the global
calibration model performance. Root mean squared error (RMSE) was used to evaluate the
model predictive performance in the two independent test sets (RMSEP). A two-way analysis of
variance (ANOVA) test was performed to compare the prediction errors of the full factorial and
spectral calibration sets for each API [22]. The underlying model for the ANOVA analysis is
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described in equation 5.3, where index ‘i’ refers to the calibration model and index ‘j’ refers to
the sample number. The symbol 𝛼𝛼𝑖𝑖 and 𝛽𝛽𝑗𝑗 refer to the effect of calibration model ‘i’ and sample
number ‘j’ on prediction error, respectively.

�𝑖𝑖𝑖𝑖 − 𝑦𝑦𝑖𝑖𝑖𝑖 )2 = 𝜇𝜇 + 𝛼𝛼𝑖𝑖 + 𝛽𝛽𝑗𝑗 + 𝑒𝑒𝑖𝑖𝑖𝑖
(𝑦𝑦

(5.3)

The calibration models are considered significantly different in terms of prediction performance,
if the calibration model parameter 𝛼𝛼 is found to be significant in the ANOVA analysis.

5.3 Results and discussion
5.3.1

Prediction of Acetaminophen

A PLS model was developed from the traditional calibration set (225 samples). The
preprocessing techniques were selected as MSC and mean centering for spectral data and auto
scaling for concentration data. A set of 6 loading vectors was selected for model development.
Figure 5-27 shows the performance of the traditional calibration set for predicting
Acetaminophen in the first test set (75 samples). The score plot shows that the spectral variation
in the test set was covered by the calibration set. The calibration, cross validation and prediction
errors were found to be similar (~1% w/w). A reasonable prediction performance was achieved
due to similar spectral variation between calibration and test set samples.
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Figure 5-27. PLS model performance of the global calibration set predicting
Acetaminophen in test set 1

Another PLS model was developed from the spectral calibration set for Acetaminophen
prediction. Same preprocessing techniques (MSC and mean centering for spectral data and auto
scaling for concentration data) were found to be optimum for this model. A set of 6 loading
vector was selected for model development. Figure 5-28 shows the performance of the spectral
calibration set for predicting Acetaminophen in the first test set. The calibration samples had
similar and wider spectral variation compared to the test set samples. Similar prediction
performance (RMSEP ~ 1% w/w) was achieved by the spectral calibration set compared to the
traditional calibration set in spite of having fewer samples (60 vs 225).
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Figure 5-28. PLS model performance of the spectral calibration set predicting
Acetaminophen in test set 1
The same calibration models of traditional calibration set and spectral calibration set were used
to predict the concentration of Acetaminophen in the second test set. In the second test set (36
samples), the prediction errors of the two models were slightly higher compared to the first test
set (RMSEPs ~ 1.2 % w/w). The higher error was caused by the compaction force variation in
the test set samples. The prediction performances between the two calibration models were found
to be equivalent. Figure 5-29 shows the score plot and reference vs prediction plot for two
calibration models predicting Acetaminophen in the second test set.
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Figure 5-29. PLS model performance of the traditional (A) and spectral calibration sets (B)
predicting Acetaminophen in test set 2
5.3.2

Prediction of Caffeine

A PLS model was developed from the traditional calibration set (225 samples) to predict
Caffeine concentration in the first test set (75 samples). The preprocessing techniques were
MSC, Savitzky-Golay derivative (window size 15, second order polynomial, first derivative) and
mean centering for spectral data and auto scaling for the concentration data. A set of 5 loading
vectors was selected for model development. Figure 5-30 shows the score plot and reference vs
prediction plot for the calibration model. Similar ranges of spectral variation were observed
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between traditional calibration and first prediction set. The RMSEC and RMSEP were 0.35%
w/w and 0.46% w/w, respectively.
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Figure 5-30. PLS model performance of the traditional calibration set predicting Caffeine
in test set 1

Another PLS model was developed from the spectral calibration set (60 samples) of Caffeine.
The preprocessing techniques were MSC, Savitzky-Golay derivative (window size 15, second
order polynomial, first derivative) and mean centering for spectral data and auto scaling for the
concentration data. A set of 5 loading vectors was selected for model development. Figure 5-31
shows the score plot and reference vs prediction plot for the calibration model. Similar ranges of
spectral variation were observed between the calibration and prediction sets. The prediction
performance of the spectral calibration set (RMSEP 0.46% w/w) was found to be similar to the
traditional calibration set in spite of having fewer calibration samples (60 vs 225).
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Figure 5-31. PLS model performance of the spectral calibration set predicting Caffeine in
test set 1
The same calibration models of the traditional and spectral calibration sets were used to predict
the concentration of Caffeine in the second test set (36 samples). The prediction performances
for both calibration models were improved in the second calibration set. The extents of
improvement were similar between the traditional and spectral calibration sets. The RMSEPs for
both calibration models were ~ 0.35% w/w. Figure 5-32 shows the score plot and reference vs
prediction plots for the two calibration models of traditional and spectral calibration sets.
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Figure 5-32. PLS model performance of the traditional (A) and spectral calibration sets (B)
predicting Caffeine in test set 2

5.4 Conclusion
The spectral calibration sets (60 samples) were found to provide equivalent prediction
performances compared to the traditional calibration set (225 samples) for both Acetaminophen
and Caffeine. Equivalent prediction performances were observed in both test sets containing
compositional and physico-chemical variation. The summary of the prediction performances is
given in Table 5-3. The spectral calibration sets were designed by using prior information about
the spectral effect of physico-chemical information. This information was utilized to efficiently
design a small calibration set to incorporate wide range of information. Such incorporation was
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successful in building a robust calibration model against compositional and physico-chemical
variation.
Acetaminophen model

Caffeine model

Full factorial
design

Spectral design

Full factorial
design

Spectral design

No. of Samples

225

60

225

60

RMSEC (% w/w)

0.983

0.907

0.351

0.271

RMSECV (% w/w)

1.032

1.148

0.365

0.309

R2 Calibration

0.988

0.990

0.977

0.987

RMSEP1 (% w/w)

1.001

0.996

0.457

0.459

Prediction Bias 1
(% w/w)

-0.472

-0.338

0.087

0.062

R2 Prediction 1

0.990

0.989

0.963

0.962

RMSEP2 (% w/w)

1.171

1.202

0.351

0.347

Prediction Bias 2
(% w/w)

-0.101

-0.014

-0.069

-0.084

R2 Prediction 2

0.984

0.983

0.982

0.982

Table 5-3. Summary of the calibration model performance of the traditional and spectral
calibration set

189

6

Chapter 6: Optimum calibration structure for pharmaceutical formulation and
spectroscopic techniques

6.1 Introduction
Calibration structure is a critical factor for ensuring desired performance of the spectroscopic
method for quantitative analysis of pharmaceutical formulation. The optimum calibration
structure depends on the sample formulation and spectroscopic technique. An optimum
calibration structure for an NIR method can be sub-optimum for a different spectroscopic method
such as Raman or THz spectroscopy due to inherent differences in spectral responses. An
optimum calibration structure for one formulation can also be sub-optimum for another
formulation. This is the fundamental concept leading to the development of spectral design
strategy for calibration development. In the traditional strategy, same set of samples designed in
the concentration space is usually used for both NIR and Raman calibration method
development. These samples are designed to allow wide concentration and physical variation to
follow the traditional concept of incorporating as much variance as possible into the calibration
set. However, all the variance information in the calibration set may not be relevant to the
particular technique of interest. For instance, a NIR method can be sensitive to a particular type
of physical variation that needs to be incorporated into the calibration set to develop a robust
quantitative model, whereas the same physical variation may not affect Raman spectra and be
unnecessary to incorporate into the Raman calibration set.
Spectral design strategy allows optimization of the calibration structure depending on the
formulation and technique. Since the strategy utilizes pure component spectral information, the
resultant calibration structure depends on the interaction between formulation and spectroscopic
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technique. A unique calibration set is developed for each formulation and spectroscopic
technique. However, the criticality of having unique calibration structure to ensure optimum
calibration performance has not been investigated. In this study the optimum calibration structure
between NIR and Raman were compared. The optimum calibration structures between two APIs
(Acetaminophen and Caffeine) were also compared. This study also provided the basis for
utilizing spectral design strategy to design a formulation and technique specific calibration set.

6.2 Material and Method:
6.2.1 Calibration and test set
The multiple API formulation was selected for this study. The multiple API tablets contained two
APIs as Acetaminophen (Acetaminophen; Mallinckrodt Inc., Raleigh, NC, USA) and Caffeine
anhydrous (Spectrum Chemical Mfg. Corp., New Brunswick, NJ, USA). The excipients were
Microcrystalline cellulose (MCC; Avicel PH 200, FMC Biopolymer, Mechanicsburg, PA, USA),
Lactose (modified spray-dried; Foremost Farms USA, Rothschild, WI, USA), Crosscarmellose
sodium (Crosscarmellose Na, Spectrum Chemical Mfg. Corp., New Brunswick, NJ, USA) and
Magnesium stearate (MgSt; Fisher Scientific, Waltham, MA, USA). The target formulation was
set as Acetaminophen (31.25% w/w), Caffeine (4.05% w/w), MCC (37.32% w/w), Lactose
(24.89% w/w), Crosscarmellose Na (2% w/w) and MgSt (0.5% w/w).
A full-factorial experimental design was created to vary the concentration of Acetaminophen,
Caffeine, MCC:Lactose ratio and compaction force of the tablets. The Acetaminophen and
Caffeine concentration was varied at 5 levels and MCC : Lactose ratio and compaction force
were varied at 3 levels resulting in a total of 225 design points. A test set was developed by
varying all the calibration factors except MCC: Lactose ratio, each at three levels resulting in a
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total of 27 design points. Table 6-1 provides the details of the full factorial calibration and test
design.

Design Factors

Calibration Design
(5x5x3x3)
225
samples

Test Design
(3x3x3)
27
samples

Acetaminophen
(%)
Caffeine (%)

Design Levels
L.C.40%
L.C.80%

L.C.20%
L.C.40%

L.C.

L.C.+20%

L.C.

L.C.
+40%

L.C.+40%
L.C.+80%

MCC/Lac

1

1.5

2

Force (lb)

4000

5000

6000

Acetaminophen
(%)

L.C.-35%

L.C.

Caffeine (%)

L.C.-70%

L.C.

L.C.+70%

Force (lb)

4000

5000

6000

MCC/Lac

L.C.+35%

1.5

Table 6-1. Calibration and test design
Each tablet of the calibration and test design points was individually prepared by direct
compression. All the components for a single design point were weighed using a digital weighing
machine (Data Range, Model No. AX504DR, Mettler Toledo) and placed in a 10 ml scintillation
vial. The ingredients were mixed in a bin blender (L.B. Bohle LLC, Warminster, PA, USA) for
10 mins followed by a high shear mixing using a vortex machine (Vortex-2 Genie, Model G-560,
Scientific Industries, IN, USA). The final mixing was performed in the bin blender before
compression. Tablets were compressed on a Carver Automatic Tablet Press (Model
3887.1SD0A00, Wabash, IN, USA) at respective compression forces using a 13 mm die and flatfaced punches. The target tablet weight was 700 mg.
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NIR reflectance measurements for both sides of each compact were collected using a bench top
scanning monochromator instrument (XDS Rapid Content Analyzer, FOSS NIRSystems, Inc.,
Laurel, MD, USA) after tablets reached stable dimensions (viscoelastic relaxation). Spectra
corresponding to each side of a compact were averaged to give one spectrum per compact.
Gravimetric measurement was used as reference for all tablets.

A

B

Figure 6-1. NIR (A) and Raman (B) spectra of the calibration sets
Raman measurements for both sides of each compact were collected using a PhAT System
spectrometer coupled with a probe head (HoloGRAMS version 4.0, Kaiser Optical Systems, Inc,
Ann Arbor, MI). The laser excitation wavelength was 785 nm. The PhAT System samples a spot
size of ~6 mm. The integration time and co-adds were 15 seconds and 3, respectively. Spectra
corresponding to each side of a compact were averaged to give one spectrum per compact over
the range of 150 to 1890 cm–1 at a 0.2 cm–1 increment. The NIR and Raman spectra of the
tablet are given in Figure 6-1.
All the analyses were performed in MATLAB 2015a environment (The Mathworks, Natick, MA,
USA). Quantitative models were developed using Partial Least Squares (PLS) modeling
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technique using PLS_Toolbox v. 7.9.3 (Eigenvector Research Inc., Wenatchee, WA, USA). Data
independent spectral preprocessing techniques were used to optimize the model performance.
2

0.8
Calibration

Calibration

0.6

95% Confidence Level

1

0.4

0.5

0.2

Scores on LV 4 (0.91%)

Scores on LV 2 (2.95%)

Test

Test

1.5

0

-0.5

0

-0.2

-0.4

-1

-1.5

95% Confidence Level

-0.6
-6

-4

-2

0

2

Scores on LV 1 (88.51%)

4

6

-2

Class Set: Cal/Test Samples

-1.5

-1

-0.5

0

Scores on LV 3 (4.84%)

1

0.5

1.5

Class Set: Cal/Test Samples

Figure 6-2. NIR PLS model for Acetaminophen from traditional calibration set

6.2.2 Quantitative model development
6.2.2.1
6.2.2.1.1

NIR infrared spectroscopy
Acetaminophen prediction

A PLS model was developed for predicting Acetaminophen concentration in calibration and test
set tablets. During PLS model development, the optimum preprocessing techniques were found
to be SNV and mean centering for the spectral data and auto scaling for the concentration data.
The optimum number of loading vector (6) was selected from a routine cross validation step. The
projected scores of the calibration and test samples on the first four loading vectors are given in
Figure 6-2. Similar projections were found between calibration and test set tablets indicating
similar types of spectral variations on the loading vectors direction. A lower prediction error in
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both calibration (0.97% w/w) and test (1.04% w/w) set ensured reasonable model performance.
The reference vs prediction plot is given in Figure 6-3.
This calibration structure was designed from a full factorial template without any prior
information. The calibration structure was neither optimized for Acetaminophen, nor for NIR
spectroscopy. The optimality of the calibration structure and calibration performance was
unknown. Although the NIR method provided reasonable prediction performance, the best
possible prediction performance with available resources was unknown. A mathematical search
was performed to find the optimum calibration set that provided the best prediction performance
(lowest prediction error) for the test set. It must be noted that the optimum calibration structure
depends on the test set structure. A different calibration set could provide the best performance
for a different test set. The search for the optimum calibration set followed the steps provided
below:
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Figure 6-3. Reference vs prediction plot of Acetaminophen from traditional calibration set
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Figure 6-4. Search for optimum calibration set
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Figure 6-5. Prediction performance of randomly selected calibration sets and optimally
selected calibration set
Initially a PLS calibration model was developed using all the calibration samples (global
calibration set) and used for predicting Acetaminophen concentration in the test set. The
calibration set was set as ‘Optimum calibration set’ and resultant RMSEP was set as
‘RMSEP_TARGET’. Then a second PLS model was developed using randomly selected 3
calibration samples (initial calibration set) and used for predicting Acetaminophen concentration
in the same test set. The resultant RMSEP was set as ‘RMSEP_INITIAL’. Then another
randomly selected calibration sample was added to the initial calibration set, a PLS model was
developed using the updated calibration set and used to predict Acetaminophen concentration in
the test set. The resultant RMSEP was set as ‘RMSEP_MODEL’. If RMSEP_MODEL was
found to be lower than ‘RMSEP_INITIAL’, the newly added sample was kept in the updated
calibration set, otherwise discarded from the updated calibration set. The RMSEP of the updated
calibration set was set as ‘RMSEP_INITIAL’ (for sample inclusion it would change (lowered),
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for sample exclusion it would remain same). Then another randomly selected calibration sample
was added to the updated calibration set and effect of its inclusion on the prediction performance
of the test set was calculated. It was kept in case it helped to improve the prediction performance,
otherwise discarded. This process was iterated until all the calibration samples were tested for
their effects on the prediction performance. A subset of calibration samples was found after the
iteration. The RMSEP of the calibration subset (RMSEP_MODEL) was compared with RMSEP
of the global calibration set (RMSEP_TARGET). If the RMSEP_MODEL was found to be lower
than RMSEP_TARGET, a set of better calibration candidates was found by sample inclusion
strategy. The algorithm then went to the next phase to analyze the effect of sample exclusion on
the

prediction

performance.

If

RMSEP_MODEL

was

found

to

be

higher

than

RMSEP_TARGET, the algorithm started from the beginning by randomly selecting a different
initial set and calibration candidates.
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Figure 6-6. NIR PLS model for Acetaminophen from optimum calibration set
In the next phase, a randomly selected sample was excluded from the updated calibration set, a
PLS model was developed and used to predict Acetaminophen concentration in the test set. The
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sample was excluded in case the exclusion lowered the RMSEP, otherwise it was kept in the
updated calibration set. In the next step, another randomly selected sample was tested for
exclusion criteria. This process was iterated until all the samples were individually tested to
analyze the effect of their exclusion on the prediction performance. A calibration subset
containing better calibration candidates was found at the end. All these calibration samples were
tested for both inclusion and exclusion criteria and found to improve the prediction performance.
The RMSEP of the updated calibration set (RMSEP_MODEL) was calculated and compared
with the RMSEP_TARGET. If RMSEP_MODEL was found to be lower than the
RMSEP_TARGET, the RMSEP_MODEL was set as the new RMSEP_TARGET. The updated
calibration set was stored and set as the ‘Optimum calibration set’. If RMSEP_MODEL was
found to be higher than the RMSEP_TARGET, the RMSEP_TARGET and ‘Optimum
calibration set’ remained same. This whole process was repeated iteratively, until
RMSEP_TARGET (lowest RMSEP at hand) was found to be lower than the RMSEP_MODEL
for five consecutive iterations. It indicated that the search algorithm found the ‘Optimum
calibration set’ that provided the best calibration performance (lowest RMSEP). The
performance of this guided search algorithm was compared with multiple randomized search
algorithms. The resultant RMSEPs of the search algorithms are shown in Figure 6-5 with the
calibration sample number. The guided search algorithm was able to find the calibration set that
provided the best model performance. Following the guided search, the optimum calibration set
for Acetaminophen was found to contain 35 calibration samples.
A PLS model was developed from this optimum calibration set. The preprocessing techniques
were SNV and mean centering for the spectral data and auto scaling for the concentration data,
respectively. A set of 6 loading vectors was selected for model development. The scores of the
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calibration and test samples on the first four loading vectors are given in Figure 6-6. It was found
that, the small optimum calibration set was able to explain similar spectral variation as the test
set. An improved prediction performance (RMSEC 0.49 % w/w and RMSEP 0.69% w/w) was
observed from the optimum calibration set as compared to the global calibration set. The
reference vs predicted concentration for calibration and test sample is given in Figure 6-7.
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Figure 6-7. Reference vs prediction plot of Acetaminophen from optimum calibration set
6.2.2.1.2

Caffeine prediction

A PLS model was developed from all the 225 samples to predict the concentration of Caffeine in
the test set. The optimal preprocessing techniques were SNV and mean centering for spectral
data and auto scaling for concentration data. A set of 6 latent variables was selected for model
development. The scores of the calibration and test samples on the first four loading vectors are
given in Figure 6-8. The calibration and test samples were found to span similar spectral
variation on the loading vector directions.
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Figure 6-8. NIR PLS model for Caffeine from traditional calibration set
Similar projections of calibration and test samples ensured reasonable prediction performance of
the calibration model. The resultant RMSEC and RMSEP were 0.40% w/w and 0.43% w/w,
respectively. The reference vs predicted concentration for calibration and test sample is given in
Figure 6-9.
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Figure 6-9. Reference vs prediction plot of Caffeine from traditional calibration set
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Figure 6-10. NIR PLS model for Caffeine from optimal calibration set
A guided search was performed following the previously described algorithm to find the
optimum calibration set for Caffeine prediction. The optimum calibration set of Caffeine was
selected based on the prediction performance on the test set. The resultant optimized calibration
set contained 37 samples. A PLS model was developed from the optimum calibration set. The
preprocessing techniques were SNV and mean centering for the spectral data and auto scaling for
the concentration data. A set of 6 loading vectors was selected.
Figure 6-10 shows the calibration and test sample scores on the first four loading vectors. It was
found that, the small optimum calibration set spanned the entire range of spectral variation of the
test set samples. Such spectral coverage ensured improved model performance compared to the
global calibration set in spite of having fewer sample number. The resultant RMSEC and
RMSEP were 0.19% w/w and 0.28% w/w, respectively. The reference vs prediction plot is given
in Figure 6-11. A small optimum calibration set was able to provide better model performance
compared to the global calibration for both Acetaminophen and Caffeine. These optimum
calibrations sets were found by the search algorithm. The optimum calibration sets between
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Acetaminophen and Caffeine were different. Only 8 samples were found to be common between
the optimum calibration set for Acetaminophen (35 samples) and Caffeine (37).
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Figure 6-11. Reference vs prediction plot of Caffeine from traditional calibration set
6.2.2.2

Raman spectroscopy

The same dataset was scanned with Raman spectroscopy. Quantitative PLS models were
developed from Raman spectra to predict the concentrations of Acetaminophen and Caffeine in
the test set.
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Figure 6-12. Raman PLS model for Caffeine from traditional calibration set
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6.2.2.2.1

Acetaminophen prediction

A PLS model was developed to predict the concentration of Acetaminophen in the test set using
Raman spectra. The optimum preprocessing techniques were SNV, normalization and mean
centering for the spectral data and auto scaling for the concentration data. A set of 4 latent
variables were selected for the model development. Figure 6-12 shows the projection of the
calibration and test samples on the first four loading vectors. The first two loading vectors
grouped the calibration (5 groups) and test samples (3 groups) based on the Acetaminophen
concentration. It was also observed that the calibration and test samples spanned similar ranges
of spectral variation. A reasonable prediction performance was achieved. The RMSEC and
RMSEP were 1.02 % w/w and 1.09 % w/w, respectively.

Figure 6-13. Reference vs prediction plot of Acetaminophen from traditional calibration set
The reference vs prediction plot is shown in Figure 6-13. An optimum subset was selected from
225 samples using the search algorithm described earlier. The resultant optimum calibration set
contained 71 samples. A PLS model was developed from the selected 71 samples. The
preprocessing techniques were SNV, normalization and mean centering for the spectral data and
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auto scaling for the concentration data. A set of 4 latent variables was selected for model
development.
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Figure 6-14. Raman PLS model for Acetaminophen from optimal calibration set

Figure 6-14 shows the projections of the calibration and test samples on the first four loading
vectors. Similar to the global calibration set (225 samples), calibration and test samples were
grouped based on the Acetaminophen concentration on the first two loading vectors. The extents
of variation explained by the first two loading vectors were also similar to that of global
calibration set. The calibration and test samples had similar projection on the loading vector. An
improvement in the prediction performance was observed from the optimum calibration set
compared to the global calibration set. The RMSEC and RMSEP were 1.05 % w/w and 0.79 %
w/w, respectively. The reference vs prediction plot is shown in Figure 6-15.
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Figure 6-15. Reference vs prediction plot of Acetaminophen from optimum calibration set
6.2.2.2.2

Caffeine prediction

A PLS model was also developed to predict the concentration of Caffeine in the test set using
Raman spectra. The optimum preprocessing techniques were SNV and mean centering for the
spectral data and auto scaling for the concentration data. A set of 4 latent variables was selected
for model development. Figure 6-16 shows the projections of the calibration and test samples on
the first four loading vectors. No clear grouping based on the Caffeine concentrations was
observed in the score plot. The first four loading vectors explained convoluted information from
Caffeine concentrations and other sources of spectral variation. The Caffeine concentration was
not a dominant factor due to low concentration in the tablets.
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The calibration and test samples had similar ranges of spectral variation. A reasonable prediction
performance was achieved from the global calibration set. The RMSEC and RMSEP were 0.59
% w/w and 0.55 % w/w, respectively. The reference vs prediction plot is shown in Figure 6-17.
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Figure 6-16. Raman PLS model for Caffeine from traditional calibration set
An optimum subset was selected from 225 samples using the search algorithm described earlier.
The resultant optimum calibration set contained 58 samples. A PLS model was developed from
this optimum calibration set. The preprocessing techniques were SNV and mean centering for the
spectral data and auto scaling for the concentration data. A set of 4 latent variables was selected
for model development.
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Figure 6-17. Reference vs prediction plot of Caffeine from traditional calibration set.
Figure 6-18 shows the calibration and test scores on the first four loading vectors. No grouping
based on Caffeine concentration was observed in the score plot. The calibration and test set had
similar ranges of spectral variation as shown in the score plot. An improved prediction
performance was observed from the optimum calibration set as compared to the global
calibration set. The RMSEC and RMSEP were 0.38 % w/w and 0.46 % w/w, respectively. The
reference vs prediction plot is shown in Figure 6-19.
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Figure 6-18. Raman PLS model for Caffeine from optimum calibration set
The optimum calibration sets with fewer sample numbers were able to provide better model
performances compared to the global calibration sets with higher sample numbers for both
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Acetaminophen and Caffeine. The optimum calibration sets between Acetaminophen and
Caffeine were found to be different. Only 24 samples were found common between the optimum
calibration sets for Acetaminophen (71 samples) and Caffeine (58 samples). This scenario was
similar to the scenario in NIR spectroscopy.
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Figure 6-19. Reference vs prediction plot of Caffeine from optimum calibration set.

6.3 Results and discussion
6.3.1 Comparison between optimum calibration sets of NIR and Raman spectroscopy
The optimum calibration sets between NIR and Raman spectroscopy were different for both
Acetaminophen and Caffeine. The comparison of the optimum calibration sets are discussed in
the following sections.
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6.3.1.1

Optimum calibration sets of Acetaminophen

The optimum calibration set of NIR spectroscopy required fewer samples compared to the
optimum calibration set of Raman spectroscopy (35 vs 71) during the prediction of
Acetaminophen in the test set. The optimum structures of the calibration sets were different from
each other. Only 14 samples were common between the two calibration sets.
Figure 6-20 shows the compositional points between full global calibration set, optimum NIR
and Raman calibration sets. The optimum NIR calibration set had lower prediction error
compared to that of optimum Raman calibration set (RMSEP 0.69% w/w vs 0.79% w/w) in spite
of having fewer sample number. However, a significant test was performed following the
method described in section 5.2.8 in chapter 5 and no significant difference were found between
their prediction performances.
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Figure 6-20. Compositional points between full global, NIR optimized and Raman
optimized calibration sets for Acetaminophen.

The distribution of Acetaminophen concentration in optimum calibration sets of NIR and Raman
is provided in Figure 6-21. The NIR calibration set required fewer samples compared to the
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0.55

Raman set, especially at low concentration of Acetaminophen. These samples were selected from
traditional full factorial calibration set. The traditional full factorial calibration structure was not
fully orthogonal. In the calibration structure, there was a correlation between Acetaminophen
concentration and MCC concentration as shown in Figure 6-22. At low Acetaminophen
concentration, the MCC concentration was usually high. MCC has a strong background features
on Raman spectra due to fluorescence. Due to such strong spectral features of MCC, Raman
calibration set required more samples at high MCC concentration to make the calibration set
robust against fluorescence.
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Figure 6-21. Acetaminophen distribution between NIR and Raman optimized calibration
sets
MCC does not have any strong fluorescence like unique features on NIR spectra. So, high
concentration of MCC at the low level of Acetaminophen did not direct the optimum calibration
set to select higher number of samples.
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Figure 6-22. Concentrations of Acetaminophen and MCC in full traditional, NIR optimized
and Raman optimized calibration sets
These two optimum calibration sets were also different in terms of excipient concentration. The
distribution of MCC and Lactose between Optimum NIR and Raman calibration sets are shown
in Figure 6-23. The optimum calibration for NIR required narrower distribution of excipients,
especially for Lactose.
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Figure 6-23. MCC (left) and Lactose (right) distribution between NIR and Raman
optimized calibration sets for Acetaminophen
The overall required spectral variation from excipient was also small for NIR calibration set
compared to that of Raman calibration set. This was due to the similarity of the spectral
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responses between MCC and Lactose in NIR spectroscopy. MCC and Lactose has very similar
NIRS response as shown in Figure 6-24. Due to such similarity, the excipients were not required
to be varied simultaneously. Variance in MCC would provide necessary spectral variation in the
calibration structure. As a result, the optimum calibration set provided good prediction
performance without significant variation in the Lactose concentration. However, in the Raman
spectroscopy MCC and Lactose have very different spectral responses as shown in Figure 6-24.
The optimum Raman calibration set required variation in both MCC and Lactose concentration
due to their unique information. This resulted in higher number of calibration samples in the
optimum Raman calibration set compared to that of NIR spectroscopy.
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Figure 6-24. NIR (left) and Raman (right) spectra of MCC and Lactose
6.3.1.2

Optimum calibration sets of Caffeine

The optimum calibration structures of Caffeine were found to be different between NIR and
Raman spectroscopy. The optimum calibration set of NIR spectroscopy required fewer samples
compared to the optimum calibration set of Raman spectroscopy (37 vs 58) during the prediction

213

of Caffeine; a scenario similar to the Acetaminophen calibration set. Only 10 samples were
common between the two calibration sets.
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Figure 6-25. Compositional points between full global, NIR optimized and Raman
optimized calibration sets for Caffeine.

Figure 6-25 shows the compositional points between global calibration set, optimum NIR and
Raman calibration sets for Caffeine. The prediction performance of the optimum NIR calibration
set was significantly better than the prediction performance of the optimum Raman calibration
set (RMSEP 0.28% w/w vs 0.46% w/w). The significance test was performed following the
method described in section 5.2.8 in chapter 5.
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Figure 6-26. Caffeine distribution between NIR and Raman optimized calibration sets
The distribution of Caffeine concentrations between the NIR and Raman calibration sets is
shown in Figure 6-26. Similar distributions were observed between NIR and Raman spectra. The
NIR calibration set did not require fewer calibration samples at low Caffeine concentration as it
did for the optimum calibration set of Acetaminophen. No correlation between Caffeine and
MCC concentration was found as shown in Figure 6-27. MCC concentrations were relatively
similar at all levels of Caffeine concentration resulting in similar distribution of Caffeine
between optimum calibration sets of NIR and Raman spectroscopy.
The excipient distributions (MCC and Lactose) between two calibration sets are given in Figure
6-28. The optimum NIR calibration set required fewer calibration samples due to similarity
between the spectral response of MCC and Lactose. However, the optimum Raman calibration
set required higher number of calibration samples due to unique information from both
excipients.
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Figure 6-27. Concentrations of Caffeine and MCC in full traditional, NIR optimized and
Raman optimized calibration sets
The optimum calibration sets of NIR and Raman spectroscopy were found to be significantly
different from each other for both APIs due to inherent differences in the analytical techniques.
However, the current practice of calibration design does not account for such variations in the
analytical techniques. A similar strategy is followed for both techniques resulting in sub-optimal
calibration performance. A study was performed to analyze the criticality of the calibration sets
to be technique specific.
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Figure 6-28. MCC (left) and Lactose (right) distribution between NIR and Raman
optimized calibration sets for Caffeine
In this study, a Raman calibration method was developed from the optimal calibration structure
of NIR spectroscopy for both Acetaminophen and Caffeine. Similarly, an NIR calibration
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Raman
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Raman
Optimum

Global

Raman
Optimum

NIR
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225
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6

6

6

4

4

4

RMSEC
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0.49
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1.02

1.05

0.78

RMSECV

1.03
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1.11

1.27

1.01

RMSEP

1.04
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0.79

1.13
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0.08
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0.15

0.39

0.14

0.4

SEP

1.04

0.13

1.12

1.02

0.77

1.05

Table 6-2. Model statistics for global, optimum and cross calibration sets NIR and Raman
during the prediction of Acetaminophen
method was developed from the optimal calibration structure of Raman spectroscopy. For
instance, during the prediction of Acetaminophen, the optimal calibration sets for NIR and
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Raman spectroscopy contained 35 and 71 calibration samples, respectively. A Raman method
was developed from the optimal NIR calibration set that contained 35 samples and an NIR
method was developed from the optimal Raman calibration set that contained 71 samples. This
study was conducted for both Acetaminophen and Caffeine. PLS models were developed from
the respective calibration sets. Model performances were compared with the optimal and global
calibration performance. The results for Acetaminophen prediction are provided in Table 6-2.
It was shown that, the prediction performance of the calibration set deteriorated when the
optimal structure of a different spectroscopic technique was used. The RMSEP of the optimal
NIR calibration set (35 samples) was 0.69 % w/w. The prediction performance was affected

NIRS

Raman

NIR
Raman
Optimum Optimum

Global

Raman
NIR
Optimum Optimum

Calibration set

Global

Sample no.

225

37

58

225

58

37

LV

6

6

6

4

4

4

RMSEC

0.4

0.19

0.4

0.59

0.38

0.48

RMSECV

0.42

0.27

0.52

0.63

0.49

0.62

RMSEP

0.43

0.28

0.48

0.55

0.46

0.6

Bias

0.15

0.02

0.14

0.09

0.02

0.05

SEP

0.41

0.28

0.45

0.54

0.46

0.6

Table 6-3. Model statistics for global, optimum and cross calibration sets NIR and Raman
during the prediction of Caffeine
significantly (RMSEP 1.13% w/w) when the optimal structure of Raman calibration set (71
samples) was used to develop a NIR calibration model to quantify the same API. The
performance of this same calibration set was significantly better when it was used for Raman
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spectroscopy (RMSEP 0.79% w/w). And the prediction performance of the optimal NIR
calibration set deteriorated significantly when it was used to develop a Raman calibration
method (RMSEP 0.69% w/w vs 1.13% w/w).
Similar results were obtained during the calibration model development for Caffeine prediction
as shown in Table 6-3. When the optimum calibration set of Raman (58 samples) was used to
develop an NIR method, the prediction error was significantly high (RMSEP 0.48% w/w)
compared to the prediction error (RMSEP 0.28% w/w) of optimum calibration set of NIR (37
samples). This optimum set of 37 samples was suitable specifically for NIR spectroscopy. When
this optimum NIR set of 37 samples was used to develop a Raman calibration model, the
prediction error was significantly high (RMSEP 0.6% w/w).

14

8

NIR
Acetaminophen
(35)

Raman
Acetaminophen
(71)

NIR Caffeine
(37)

Raman
Caffeine (58)

24

10
Table 6-4. Number of common samples between the optimum calibration sets of
different techniques and different APIs
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6.4 Conclusion
The optimum calibration sets for NIR and Raman spectroscopy were found to be different from
each other. Only a few common samples were found between two APIs and two spectroscopic
techniques. Table 6-4 summarizes the results. These results indicated that the optimum
calibration structure depends on the interaction between spectral responses and physico-chemical
properties of the tablets. An optimum calibration set for one formulation and/or technique can be
sub-optimum for another formulation and/or technique. A formulation and technique specific
calibration set should be designed to maximize calibration performance of a spectroscopic
system for quantitative analysis of pharmaceutical tablets.
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7

Chapter 7: Summary

The theory of experimental design is well established and NIR calibration have been widely used
for wide range of applications, however there is a gap between the theory and practical
implementation of experimental design during NIR calibration set development. Direct
application of classical theory of experimental design is still missing in the problem of
multivariate spectroscopic calibration [76, 194]. Bridging this gap can lead towards better
understanding of the interaction between calibration structure and NIRS model performance.
This understanding can be helpful to identify the necessary information for a calibration set and
challenge the current philosophy of incorporating all possible variances into the calibration set.
All possible variances may not always be necessary for desired model performance. Moreover, it
requires a large calibration set to span all possible variances, which may not be an efficient
approach in terms of time and available resources. Besides, it is almost impossible to anticipate
and span all possible variances, especially at the early stage of product and process development.
The current all-inclusive calibration strategy can be replaced by an efficient strategy for
developing NIR calibration set using spectral space.
It was demonstrated that, the pure component spectral response of a formulation can be utilized
to define the spectral space of that formulation. The use of pure component spectral information
results in a formulation and technique specific spectral space. Such specificity leads towards the
development of a formulation and technique specific calibration set. The current strategies for
designing NIR calibration sets do not account for such specificity towards formulations and
analytical technique. Regulatory guidelines and general rules of thumb are usually followed for
all types of formulations resulting in similar concentration ranges, levels and number of samples
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for all types of calibration sets. However, an optimal calibration design for one formulation can
be sub-optimal for a different formulation. Different NIR responses produced by different
formulations should be considered during the selection of calibration structure, range, size,
concentration levels and variance information. It was also demonstrated that the spectral space
can be used to identify the critical calibration samples. Information regarding the critical sample
requirement helps to design and prepare a small and efficient calibration set. This strategy was
defined as the spectral space design strategy for calibration set development during NIR
quantitative analysis of tablets.
The spectral space design strategy was compared with the current calibration strategies of
designing calibration sets. The current strategy is prone to have redundant information. It was
demonstrated that, a traditionally designed calibration set contained redundant information
whereas a spectrally designed calibration set identified and eliminated redundant information,
thus requiring fewer calibration samples to provide similar calibration performance. Multiple
comparative studies were conducted between commonly employed experimental design
approaches to calibration development and the newly developed spectral space based technique.
The comparisons were conducted on single API (Active Pharmaceutical Ingredient) and multiple
API formulations to quantify drug tablet API using NIR spectroscopy. Partial least squares (PLS)
models were developed from respective calibration designs. Model performance was
comprehensively assessed based on the ability to predict API concentrations in independent
prediction/validation sets. Similar prediction performance was achieved using the smaller
calibration set designed in spectral space (11 for single API and 33 for multiple API tablets),
compared to the traditionally designed large calibration sets (45 for single API and 225 for
multiple API tablets). An improved prediction performance was observed for the spectrally
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designed calibration sets (33 tablets for spectral design) compared to the traditionally designed
calibration sets of equal sizes (33 tablets for D-Optimal, CCD and I-Optimal designs). It was
demonstrated that a calibration set designed in spectral space provided an efficient means of
developing spectroscopic multivariate calibration for tablet analysis. Such strategy provides
opportunity to design formulation and technique specific calibration sets to optimize calibration
capability.
The spectral design strategy was built on the spectral space of a formulation. The spectral space
was defined the by pure component spectral information. Initially the spectral space was used to
identify only compositional design points that are critical to calibration performance. However, it
is also critical for a calibration set to contain physico-chemical variation besides the
compositional information to build a robust calibration model. The current strategy for
incorporating physico-chemical variation into the calibration requires large calibration set. It was
demonstrated that, spectral space can be used to develop an efficient strategy to incorporate
physico-chemical information into the calibration set. The density of the tablet was identified as
a critical physico-chemical information for the NIR calibration set. The pure component tablet
spectra at different densities were utilized to define a latent variable spectral space containing
both concentration and density information at different directions. A small set of critical samples
was selected from the latent variable spectral space. These samples were designed to prepare a
small calibration set containing both concentration and density information. The performance of
this small calibration set was compared with the traditionally designed large calibration set
during quantitative analysis of Acetaminophen and caffeine using NIR. The small calibration set
provided similar prediction performance compared to the large calibration sets indicating the
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efficiency of the spectral design strategy to incorporate physico-chemical information into the
calibration set.
The spectral design strategy can be generalized to develop efficient calibration sets for other
formulations. However, it is critical to have pure component spectral information to define the
spectral space of that formulation. In this study, pure component spectral information was
collected from pure component tablets. Pure component powder can also be used to collect pure
component spectra for uncompressible/less compressible powders. The spectral design strategy
can also be generalized to incorporate other types of physico-chemical information such as
moisture content, particle size distribution etc. However, it is critical to consider the effects of
physico-chemical information in the pure component spectra and tablet spectra during such
analysis.
The spectral design strategy identifies the critical samples from spectral information whereas the
current calibration design strategy assumes certain samples to be critical for the calibration set
development from their compositional information. For instance, the full factorial design
assumes the orthogonal compositional samples are most critical to calibration set, the D-optimal
design assumes that the compositionally distant samples are most critical to calibration set. The
advantage of having large sample set is that, it provides useful and critical information even
when these assumptions are violated. Such information from a large calibration set can be used
to develop a successful quantitative NIR method. The advantage of spectral calibration set is
that, it provides similar performance with a smaller calibration set. It is very critical to consider
that spectral design is expected to be ‘efficient’ not ‘better / more accurate’ compared to the
current calibration approaches.
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It is also critical to consider that the spectral design strategy utilizes a selection technique to
identify critical calibration samples in the spectral space. Different selection techniques can
result in slightly different calibration sets in the spectral space. In this study, multiple selection
techniques (Kennard stone, orthogonal rotation, Euclidian distance) were used to identify critical
samples and all of these sets gave similar prediction results due to similar spanning of spectral
variation. Different spectral variation from different selection algorithm would have resulted
differences in prediction performances. It is critical that the selection technique maximizes the
variation in spectral space to find the calibration set with optimum performance. Such optimum
performance can be obtained with the current calibration strategy in case the same samples
maximize variation in the concentration space. Such case would require linear mapping between
spectral and compositional spaces.
In this study, it was also demonstrated that the optimal calibration structure depends on the
formulation and spectroscopic technique. An optimal calibration set for one formulation can be
sub-optimal for another formulation. An optimal calibration set for one spectroscopic technique
can be suboptimal for another spectroscopic technique. The current calibration strategies do not
allow optimization of calibration set based on formulation variation and specific spectral
response. The same calibration design is used for different formulations and different techniques.
This strategy does not provide optimum performance of the calibration efforts. The optimum
calibration structures between NIR and Raman spectroscopy were compared during the
quantitative analysis of Acetaminophen and Caffeine. The optimum NIR calibration set was
found to be different from the optimum Raman calibration set for both APIs. The optimum
calibration set for Acetaminophen was found to be different from the optimum calibration set for
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Caffeine for both spectroscopic techniques. The common calibration designs between different
formulations and different techniques do not provide optimal calibration performance.
In the spectral design strategy, the use of pure component spectral information allows the
calibration set to be formulation and technique specific. Such specificity would provide
additional information to establish method suitability during method validation. However, it
would not ease the validation steps or make it more difficult. The current validation steps require
the calibration model to demonstrate accuracy, linearity, specificity, precision, range and
robustness. The same requirements should be applied to the spectrally design calibration set. It is
expected that, the spectrally design calibration set should pass the validation steps with fewer
samples.
In this study, Partial Least Square (PLS) was used as the modeling technique. It was
demonstrated that robustness of the PLS calibration model is critical for successful
implementation of an NIR quantitative method in the pharmaceutical industry. Different sources
of variations such as scale variations, physical variations and chemical variations can affect the
PLS model performance during product life cycle. A robust PLS model is required to be
developed at the outset of calibration to encounter such variations and provide desired predictive
performance thus avoiding the needs for recurrent model updates. Selecting the optimum number
of model components (loading vectors) is critical to build a robust model with the available
dataset. Cross-validation error along with the amount of model variance captured by each model
component is currently used to select the optimum number of model components. A new method
was developed to select the optimum number of model components based on weight co-efficient
of each model component. The new weight coefficient based method was found to be more
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effective in selecting the optimum number of model components and improving model
robustness compared to the current selection technique. Several datasets possessing different
types of critical variations to NIR PLS model were used in this study to demonstrate the
efficiency of the new weight coefficient based method in selecting the optimum number of
model components.
PLS is the most frequently used modeling technique for calibration development. However, there
are other modeling techniques such as Principal Component Regression, Multiple Linear
Regression, Support Vector Machine, Artificial Neural Network etc. that can be used for
calibration model development. The spectral design strategy was tested for PLS modeling
technique considering its wide applicability. However, for other modeling techniques, the
efficiency of the spectral design strategy is yet to be tested. This can be a direction of the future
studies exploring spectral design strategy as an efficient alternative.
In future, the strategy demonstrated in this dissertation can also be used for other spectroscopic
techniques including Raman and terahertz spectroscopy to develop an efficient calibration
strategy. Pure spectrum of each component should be used during the design/selection of the
calibration set. Comprehensive studies in this direction can lead towards formulation specific
calibration development and ensure optimal performance of each calibration set. Comparative
studies are suggested to distinguish the interactions between calibration structures and different
spectroscopic techniques.
One of the challenges of the spectral design strategy is to calculate the compositional
requirements of the spectrally designed samples. In this study, pure component and target tablet
information was used to define the rotation matrix and calculate the compositional requirements
227

for spectrally designed samples. The rotation matrix was defined using target tablet since the
calibration set was intended to center around target formulation. In other instances, when
calibration sets are not intended to center around target formulation, the target tablet and pure
component tablets might not be sufficient to calculate the rotation matrix. Additional sets of
actual tablets might be necessary to calculate the rotation matrix and compositional requirements
of the spectrally designed samples. Other challenge of the spectral design strategy is that, it
utilizes optimization algorithm during the solution of compositional requirement calculations.
All the optimization algorithms have the potentials to provide local minima solution. Multiple
iterations are required to ensure global minima and expected solution.
There is no best calibration design that works for all purpose. A great deal depends on the
method requirements [28]. The traditional practices for developing calibration sets are too
generalized. Spectral design approach offers an efficient and formulation specific alternative
strategy to the current practices of NIR calibration design for quantitative analysis of
pharmaceutical tablets.
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Appendices
Appendix A (Motivation for using scores as design factors for calibration)
The motivation for using scores as calibration design factors comes from the multivariate
regression equation itself. The regression equation 2.1 can be transformed into a linear model
equation with the concentrations as a response and PLS scores (projection on the orthogonal
spectral space of the PLS model) as input variables shown in equation 2.9 for the same system
with “m” samples, “n” spectral variables and “r” eigen vectors/(selected latent variables in PLS)
using y for the concentrations of samples, T for the score matrix of “r” latent variables and u for
the regression vector between scores and concentrations
𝐲𝐲�𝐦𝐦∗𝟏𝟏 = 𝐗𝐗 𝐦𝐦∗𝐧𝐧 ∗ 𝐛𝐛𝐧𝐧∗𝟏𝟏

′
′
𝐲𝐲�𝐦𝐦∗𝟏𝟏 = 𝐗𝐗 𝐦𝐦∗𝐧𝐧 ∗ 𝐖𝐖𝐧𝐧∗𝐫𝐫 ∗ (𝐓𝐓𝐫𝐫∗𝐦𝐦
∗ 𝐓𝐓𝐦𝐦∗𝐫𝐫 )−𝟏𝟏 ∗ (𝐓𝐓𝐫𝐫∗𝐦𝐦
∗ 𝐲𝐲𝐦𝐦∗𝟏𝟏 ) [Here y� is the predicted

concentration for new samples, y is reference concentration of the calibration samples. Please

note that, the sample numbers do not have to be equal]

(2.9)

𝐲𝐲�𝐦𝐦∗𝟏𝟏 = 𝐓𝐓𝐦𝐦∗𝐫𝐫 ∗ 𝐮𝐮𝐫𝐫∗𝟏𝟏

(2.10)

ŷ𝑖𝑖𝑖𝑖=1..𝑚𝑚 = 𝑡𝑡1𝑖𝑖 ∗ 𝑢𝑢1 + 𝑡𝑡2𝑖𝑖 ∗ 𝑢𝑢2 + ⋯ + 𝑡𝑡𝑟𝑟𝑖𝑖 ∗ 𝑢𝑢𝑟𝑟

′
′
𝐲𝐲�𝐦𝐦∗𝟏𝟏 = 𝐓𝐓𝐦𝐦∗𝐫𝐫 ∗ (𝐓𝐓𝐫𝐫∗𝐦𝐦
∗ 𝐓𝐓𝐦𝐦∗𝐫𝐫 )−𝟏𝟏 ∗ (𝐓𝐓𝐫𝐫∗𝐦𝐦
∗ 𝐲𝐲𝐦𝐦∗𝟏𝟏 )

Thus, the classical idea of design of experiments is best embodied by orthogonally varying the
PLS scores and measuring the concentrations as response according to equation 2.10. These
experiments are then used to approximate a linear model between concentrations (y) and scores
(t) with a limited number of factors. The challenge for designing orthogonal PLS scores is not
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trivial. The designed scores need to be derived from a set of real pharmaceutical samples. The
pure component spectra of the samples can be used to define the orthogonal spectral space of the
PLS model assuming that, the primary model variance is dictated by the formulation variation
after appropriate preprocessing technique has been applied.

Appendix B (Derivation of equation 2.7)
𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂

𝐂𝐂𝐦𝐦∗𝐤𝐤

𝐋𝐋𝐋𝐋𝐋𝐋𝐋𝐋 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬

𝐔𝐔𝐦𝐦∗𝐦𝐦

𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏 𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬

∗ 𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑
∗ 𝐏𝐏𝐤𝐤∗𝐧𝐧
𝐤𝐤∗𝐤𝐤
𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒

∗ 𝐒𝐒𝐦𝐦∗𝐤𝐤

𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦
𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑
𝐤𝐤∗𝐤𝐤

𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑 𝐬𝐬𝐬𝐬𝐬𝐬𝐠𝐠𝐮𝐮𝐮𝐮𝐮𝐮𝐮𝐮

∗ 𝐕𝐕𝐤𝐤∗𝐤𝐤

𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬 ′

= 𝐕𝐕𝐤𝐤∗𝐤𝐤

𝐋𝐋𝐋𝐋𝐋𝐋𝐋𝐋 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬

∗ �𝐔𝐔𝐦𝐦∗𝐦𝐦

𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒

′

𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒

� ∗ �𝐒𝐒𝐦𝐦∗𝐤𝐤

𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬

� ∗ 𝐗𝐗 𝐦𝐦∗𝐧𝐧

𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏 𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜

∗ {�𝐏𝐏𝐤𝐤∗𝐧𝐧

𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏 𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬

∗ 𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑
∗ 𝐏𝐏𝐤𝐤∗𝐧𝐧
𝐤𝐤∗𝐤𝐤

∗ ��𝐒𝐒𝐤𝐤∗𝐦𝐦

′

𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬

= 𝐗𝐗 𝐦𝐦∗𝐧𝐧

−𝟏𝟏

�∗�

𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏 𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜 ′

∗ �𝐏𝐏𝐧𝐧∗𝐤𝐤

𝐏𝐏𝐮𝐮𝐫𝐫𝐫𝐫 𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜 ′ −𝟏𝟏

� ∗ �𝐏𝐏𝐧𝐧∗𝐤𝐤

𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒

∗ �𝐒𝐒𝐤𝐤∗𝐦𝐦

�}

�

𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬

= 𝐗𝐗 𝐦𝐦∗𝐧𝐧
′

�

Since, the “S” is a diagonal matrix, a simpler solution can be performed by taking the diagonal
values and making an inverse of the diagonal elements. However, it would give the exact same
solution. The readers are encouraged to use either of the solutions.
Appendix C (Derivation of equation 2.8)
Using the assumption that the variation in pure component spectra dictates the primary spectral
variation in the model and resembles the weight factors in the PLS,
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𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬

𝐗𝐗 𝐮𝐮∗𝐧𝐧

𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂

𝐂𝐂𝐮𝐮∗𝐤𝐤

𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂

𝐂𝐂𝐮𝐮∗𝐤𝐤

𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏 𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜 𝐛𝐛𝐛𝐛𝐛𝐛𝐛𝐛𝐛𝐛

∗ 𝐖𝐖𝐧𝐧∗𝐤𝐤

𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬

= 𝐓𝐓𝐮𝐮∗𝐫𝐫

𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏 𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬

∗ 𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑
∗ 𝐏𝐏𝐤𝐤∗𝐧𝐧
𝐤𝐤∗𝐤𝐤

𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬

∗ 𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑𝐑
= 𝐓𝐓𝐮𝐮∗𝐤𝐤
𝐤𝐤∗𝐤𝐤

𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏 𝐜𝐜𝐜𝐜𝐦𝐦𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐩 𝐛𝐛𝐛𝐛𝐛𝐛𝐛𝐛𝐛𝐛

∗ 𝐖𝐖𝐧𝐧∗𝐤𝐤

𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏 𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬

∗ (𝐏𝐏𝐤𝐤∗𝐧𝐧
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= 𝐓𝐓𝐮𝐮∗𝐤𝐤
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∗ 𝐖𝐖𝐧𝐧∗𝐤𝐤
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